Document:

EX-4.2

 Exhibit 4.2 

UNITEDHEALTH GROUP INCORPORATED 

$725,000,000 4.250% Notes due April 15, 2047 

Officers’ Certificate and Company Order 

Pursuant to the Indenture, dated as of February 4, 2008 (the “Indenture”), between UnitedHealth Group Incorporated, a Delaware
corporation (the “Company”), and U.S. Bank National Association, as trustee (the “Trustee”), and resolutions adopted by the Company’s Board of Directors on November 8, 2016, this Officers’ Certificate and Company
Order is being delivered to the Trustee to establish the terms of a series of Securities in accordance with Section 301 of the Indenture, to establish the form of the Securities of such series in accordance with Section 201 of the
Indenture, to request the authentication and delivery of the Securities of such series pursuant to Section 303 of the Indenture and to comply with the provisions of Section 102 of the Indenture. This Officers’ Certificate and Company
Order shall be treated for all purposes under the Indenture as a supplemental indenture thereto. 
 All conditions precedent provided for in
the Indenture relating to (i) the establishment of a series of Securities, (ii) the establishment of the form of Securities of such series and (iii) the procedures for authentication and delivery of such series of Securities have been
complied with. 
 Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to them in the Indenture.

  

	A.	Establishment of a Series of Securities pursuant to Section 301 of the Indenture. 

There is hereby established pursuant to Section 301 of the Indenture a series of Securities which shall have the following terms: 

 

	 	(1)	The Securities shall bear the title “4.250% Notes due April 15, 2047” (referred to herein as the “Notes”). 

  

	 	(2)	The aggregate principal amount of the Notes to be issued pursuant to this Officers’ Certificate and Company Order shall be limited to $725,000,000 except for (a) Notes authenticated and delivered upon
registration of, transfer of, or in exchange for, or in lieu of, other Notes pursuant to Section 304, 305, 306, or 1007 of the Indenture, (b) Notes which, pursuant to Section 303 of the Indenture, are deemed never to have been
authenticated and delivered thereunder and (c) any Securities of this series which are issued in the manner contemplated by paragraph 19(a) hereof. 

  

	 	(3)	Interest will be payable to the Person in whose name a Note (or any Predecessor Security) is registered at the close of business on the Regular Record Date (as defined below) immediately preceding each Interest Payment
Date (as defined below). In the event that a payment of principal or interest is due on a date that is not a Business Day (as defined below), the related payment of principal or interest shall be made on the next succeeding Business Day with the
same force and effect as if made on the date such payment was due, and no interest shall accrue on the amount so payable for the period from and after such Interest Payment Date or date of maturity, as the case may be. “Business Day” shall
mean any day other than a Saturday, a Sunday or a day on which banking institutions in New York, New York or Minneapolis, Minnesota are authorized or required by law, regulation or executive order to close. 

 

	 	(4)	The Stated Maturity of the Notes shall be April 15, 2047. 

  

	 	(5)	 The Notes shall bear interest at the rate of 4.250% per annum (based upon a
360-day year of twelve 30-day months), from March 13, 2017 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, as
the case may be, payable semi-annually in 

	 	
arrears on April 15 and October 15 in each year, commencing October 15, 2017, until the principal thereof is paid or made available for payment. Each such April 15 and
October 15 shall be an “Interest Payment Date” for the Notes, and each April 1 and October 1 (whether or not a Business Day), as the case may be, immediately preceding an Interest Payment Date for the Notes shall be the
“Regular Record Date” for the interest payable on such Interest Payment Date. 

 The provision related to interest on
overdue principal in Section 501 of the Indenture shall not be applicable to the Notes. 
  

	 	(6)	Principal of (and premium, if any) and interest on the Notes will be payable, and, except as provided in Section 305 of the Indenture with respect to a Global Security (as defined below), the transfer of the Notes
will be registrable and Notes will be exchangeable for notes bearing identical terms and provisions at the corporate trust office of U.S. Bank National Association, in St. Paul, Minnesota. The method of such payment shall be by wire transfer for
Notes held in book-entry form or at the option of the Company by check mailed to the Person entitled thereto as shown on the Security Register. 

  

	 	(7)	The Notes will be subject to redemption, in whole or in part, at any time before October 15, 2046 (six months prior to their Stated Maturity), at the option of the Company at a Redemption Price equal to the greater
of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (excluding the portion of any such interest accrued
to the Redemption Date) that would be due if such Notes matured on October 15, 2046, discounted to the Redemption Date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Yield (as defined below), plus 20 basis points, plus, in each case, accrued and unpaid interest thereon to, but not including, the Redemption Date. 

At any time on or after October 15, 2046 (six months prior to their Stated Maturity), the Notes will be redeemable, in whole or in part at
any time and from time to time, at the option of the Company, on not less than 30 nor more than 60 days’ notice by mail, at a Redemption Price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest
thereon to, but not including, the Redemption Date. 
 For this purpose, the following terms have the following meanings: 

 

	 	•	 	“Treasury Yield” means, with respect to any Redemption Date, the rate per year equal to the semi-annual equivalent yield to maturity or interpolated (on a day-count
basis) yield to maturity of the applicable Comparable Treasury Issue, assuming a price for such Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the applicable Comparable Treasury Price for such Redemption Date.

  

	 	•	 	“Comparable Treasury Issue” means the United States Treasury security selected by an Independent Investment Banker appointed by the Trustee after consultation with the Company as having an actual or
interpolated maturity comparable to the remaining term of the Notes being redeemed (assuming that the Notes matured on October 15, 2046), or such other maturity that would be utilized at the time of selection and in accordance with customary
financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Notes being redeemed. 

  
 2 

  

	 	•	 	“Comparable Treasury Price” means, with respect to any Redemption Date, (i) the average of the Reference Treasury Dealer Quotations for such Redemption Date, after excluding the highest and lowest such
Reference Treasury Dealer Quotations for such Redemption Date, or (ii) if the Trustee obtains fewer than four such Reference Treasury Dealer Quotations, the average of all such Reference Treasury Dealer Quotations. 

 

	 	•	 	“Independent Investment Banker” means any of J.P. Morgan Securities LLC, Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated or Morgan Stanley & Co. LLC or their
respective successors or, if such firms are unwilling or unable to select the Comparable Treasury Issue, one of the remaining Reference Treasury Dealers appointed by the Trustee after consultation with the Company. 

 

	 	•	 	“Reference Treasury Dealer” means each of (i) J.P. Morgan Securities LLC, Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Morgan Stanley & Co. LLC or
their affiliates and any other primary U.S. Government securities dealer in the United States (a “Primary Treasury Dealer”) designated by, and not affiliated with, any of J.P. Morgan Securities LLC, Goldman, Sachs & Co., Merrill
Lynch, Pierce, Fenner & Smith Incorporated or Morgan Stanley & Co. LLC; provided, however, that if J.P. Morgan Securities LLC, Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated or Morgan
Stanley & Co. LLC or any of their respective affiliates shall cease to be a Primary Treasury Dealer, the Company will appoint another Primary Treasury Dealer as a substitute for such entity; and (ii) any other Primary Treasury Dealer
selected by the Trustee. 

  

	 	•	 	“Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any Redemption Date, the average, as determined by the Trustee, of the bid and asked prices for the applicable
Comparable Treasury Issue (expressed, in each case, as a percentage of its principal amount) quoted in writing to the Trustee by such Reference Treasury Dealer at 5:00 p.m. on the third Business Day preceding such Redemption Date. 

A notice of redemption may provide that it is subject to certain conditions that will be specified in the notice. If those conditions are not
met, the redemption notice will be of no effect and the Company will not be obligated to redeem the Notes. 
 A partial redemption of the
Notes may be effected on a pro rata basis (and in such manner as complies with applicable legal and stock exchange requirements, if any) or in such method as the Trustee, in the exercise of its reasonable discretion, deems fair and appropriate. The
Trustee may provide for the selection for redemption of portions in amounts of $1,000 or whole multiples of $1,000; except that if all of the Notes of a Holder are to be redeemed, the entire outstanding amount of Notes held by such Holder, even if
not a multiple of $1,000, shall be redeemed. 
 Notice of any redemption will be mailed at least 30 days but not more than 60 days before the
Redemption Date to each Holder of the Notes to be redeemed. 
 Unless any Note called for redemption shall not be paid upon surrender thereof
for redemption, on and after the Redemption Date interest will cease to accrue on the Notes or portions thereof called for redemption. 

  
 3 

	 	(8)	The Company shall not be obligated to redeem or purchase any Notes pursuant to any sinking fund or analogous provisions. 

  

	 	(9)	If a Change of Control Triggering Event (as defined below) occurs, unless the Company has exercised its option to redeem all the Notes of this series, the Company shall be required to make an offer (a “Change of
Control Offer”) to each Holder of the Notes of this series to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of that Holder’s Notes on the terms set forth herein. In a Change of Control
Offer, the Company shall be required to offer payment in cash equal to 101% of the aggregate principal amount of Notes of this series repurchased, plus accrued and unpaid interest, if any, on the Notes of this series repurchased to, but not
including, the date of repurchase (a “Change of Control Payment”). Within 30 days following any Change of Control Triggering Event or, at the Company’s option, prior to any Change of Control, but after public announcement of the
transaction that constitutes or may constitute the Change of Control, a notice shall be transmitted to Holders of the Notes of this series describing the transaction that constitutes or may constitute the Change of Control Triggering Event and
offering to repurchase such Notes on the date specified in the notice, which date shall be no earlier than 30 days and no later than 60 days from the date such notice is transmitted (a “Change of Control Payment Date”). The notice shall,
if transmitted prior to the date of consummation of the Change of Control, state that the Change of Control Offer is conditioned on the Change of Control Triggering Event occurring on or prior to the Change of Control Payment Date.

 In order to accept the Change of Control Offer, the Holder must deliver to the Paying Agent, at least five Business Days
prior to the Change of Control Payment Date, the Holder’s Note together with the form entitled “Election Form” (which form is annexed to the Note) duly completed, or a telegram, telex, facsimile transmission or a letter from a member
of a national securities exchange, or the Financial Industry Regulatory Authority or a commercial bank or trust company in the United States setting forth: 
  

	 	(i)	the name of the Holder of the Note; 

  

	 	(ii)	the principal amount of the Note; 

  

	 	(iii)	the principal amount of the Note to be repurchased; 

  

	 	(iv)	the certificate number or a description of the tenor and terms of the Note; 

  

	 	(v)	a statement that the Holder is accepting the Change of Control Offer; and 

  

	 	(vi)	a guarantee that the Note, together with the form entitled “Election Form” duly completed, will be received by the Paying Agent at least five Business Days prior to the Change of Control Payment Date.

 Any exercise by a Holder of its election to accept the Change of Control Offer shall be irrevocable. The Change of Control
Offer may be accepted for less than the entire principal amount of the Note, but in that event the principal amount of the Note remaining outstanding after repurchase must be equal to $2,000 or an integral multiple of $1,000 in excess thereof. 

On the Change of Control Payment Date, the Company shall, to the extent lawful: 

 

	 	(i)	accept for payment all Notes of this series or portions of such Notes properly tendered pursuant to the Change of Control Offer; 

  
 4 

	 	(ii)	deposit with the Paying Agent an amount equal to the Change of Control Payment in respect of all Notes of this series or portions of such Notes properly tendered; and 

 

	 	(iii)	deliver or cause to be delivered to the Trustee the Notes of this series properly accepted together with an Officers’ Certificate stating the aggregate principal amount of Notes of this series or portions of such
Notes being repurchased. 

 The Company shall not be required to make a Change of Control Offer upon the occurrence of a Change
of Control Triggering Event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for an offer made by the Company and the third party purchases all Notes of this series properly tendered
and not withdrawn under its offer. In addition, the Company shall not repurchase any Notes of this series if there has occurred and is continuing on the Change of Control Payment Date an Event of Default under the Indenture, other than a default in
the payment of the Change of Control Payment upon a Change of Control Triggering Event. 
 The Company shall comply with the requirements of
Rule 14e-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable
in connection with the repurchase of the Notes of this series as a result of a Change of Control Triggering Event. To the extent that the provisions of any such securities laws or regulations conflict with the Change of Control Offer provisions of
the Notes of this series, the Company shall comply with those securities laws and regulations and shall not be deemed to have breached its obligations under the Change of Control Offer provisions of the Notes of this series by virtue of any such
conflict. 
 For purposes of the Change of Control Offer provisions of the Notes of this series, the following terms have the following
meanings: 
  

	 	•	 	 “Change of Control” means the occurrence of any of the following: (1) the direct or indirect sale,
lease, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more series of related transactions, of all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole, to any
person, other than the Company or a Subsidiary; (2) the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any person becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of more than 50% of the Company’s outstanding Voting Stock or other Voting Stock into which the
Company’s Voting Stock is reclassified, consolidated, exchanged or changed, measured by voting power rather than number of shares; (3) the Company consolidates with, or merges with or into, any person, or any person consolidates with, or
merges with or into, the Company, in any such event pursuant to a transaction in which any of the Company’s outstanding Voting Stock or the Voting Stock of such other person is converted into or exchanged for cash, securities or other property,
other than any such transaction where the shares of the Company’s Voting Stock outstanding immediately prior to such transaction constitute, or are converted into or exchanged for, a majority of the Voting Stock of the surviving person or any
direct or indirect parent company of the surviving person immediately after giving effect to such transaction; (4) the first day on which a majority of the members of the Company’s Board of Directors are not Continuing Directors; or
(5) the adoption of a plan relating to the Company’s liquidation or dissolution. Notwithstanding the foregoing, a transaction shall not be deemed to involve a Change of Control under clause (2) above if (i) the Company becomes a
direct or indirect wholly-owned subsidiary of a holding company and (ii)(A) the direct or 

  
 5 

	 	 
indirect holders of the Voting Stock of such holding company immediately following that transaction are substantially the same as the holders of the Company’s Voting Stock immediately prior
to that transaction or (B) immediately following that transaction no person (other than a holding company satisfying the requirements of this sentence) is the beneficial owner, directly or indirectly, of more than 50% of the Voting Stock of
such holding company. The term “person,” as used in this definition, has the meaning given thereto in Section 13(d)(3) of the Exchange Act. 

  

	 	•	 	“Change of Control Triggering Event” means the occurrence of both a Change of Control and a Rating Event. 

  

	 	•	 	“Continuing Directors” means, as of any date of determination, any member of the Company’s Board of Directors who (1) was a member of such Board of Directors on the date the Notes of this series were
issued or (2) was nominated for election, elected or appointed to such Board of Directors with the approval of a majority of the Continuing Directors who were members of such Board of Directors at the time of such nomination, election or
appointment (either by a specific vote or by approval of the Company’s proxy statement in which such member was named as a nominee for election as a director). 

 

	 	•	 	“Fitch” means Fitch, Inc., and its successors. 

  

	 	•	 	“Investment Grade Rating” means a rating equal to or higher than BBB- (or the equivalent) by Fitch, Baa3 (or the equivalent) by Moody’s and BBB- (or the equivalent) by S&P, and the equivalent investment grade credit rating from any replacement Rating Agency or Rating Agencies selected by the Company. 

 

	 	•	 	“Moody’s” means Moody’s Investors Service, Inc., and its successors. 

  

	 	•	 	“Rating Agencies” means (1) each of Fitch, Moody’s and S&P; and (2) if any of Fitch, Moody’s or S&P ceases to rate the Notes of this series or fails to make a rating of such Notes
publicly available for reasons outside of the Company’s control, a “nationally recognized statistical rating organization” within the meaning of Section 3(a)(62) under the Exchange Act selected by the Company (as certified by a
resolution of the Company’s Board of Directors) as a replacement agency for Fitch, Moody’s or S&P, or all of them, as the case may be. 

  

	 	•	 	“Rating Event” means the rating on the Notes of this series is lowered by each of the three Rating Agencies and the Notes of this series are rated below an Investment Grade Rating by each of the three Rating
Agencies on any day during the period (which period shall be extended so long as the rating of the Notes of this series is under publicly announced consideration for a possible downgrade by any of the Rating Agencies) commencing on the date of the
first public notice of the occurrence of a Change of Control or the Company’s intention to effect a Change of Control and ending 60 days following consummation of such Change of Control. 

 

	 	•	 	“S&P” means Standard & Poor’s Rating Services, a division of The McGraw-Hill Companies, Inc., and its successors. 

 

	 	•	 	“Voting Stock” means, with respect to any specified “person” (as that term is used in Section 13(d)(3) of the Exchange Act) as of any date, the capital stock of such person that is at the time
entitled to vote generally in the election of the board of directors of such person. 

  
 6 

	 	(10)	The Notes shall not be convertible into shares of Common Stock of the Company or exchangeable for any other securities. 

  

	 	(11)	The Trustee shall be the Security Registrar and the Paying Agent. 

  

	 	(12)	The amount of payments of principal of and any premium or interest on the Notes will not be determined with reference to an index. 

  

	 	(13)	The Notes shall be subject to the covenants and definitions set forth in the Indenture. 

  

	 	(14)	The Notes will be issued only in fully registered form and the minimum initial purchase amounts of the Notes shall be $2,000 and any whole multiples of $1,000 in excess thereof. 

 

	 	(15)	The Notes shall be subject to the Events of Default specified in Section 701, paragraphs (i) through (vii), of the Indenture. 

 

	 	(16)	The portion of the principal amount of the Notes which shall be payable upon declaration of acceleration of maturity thereof shall not be less than the principal amount thereof. 

 

	 	(17)	The Notes shall be “Global Securities” as defined in the Indenture, and shall be deposited with, or on behalf of, The Depository Trust Company, New York, New York, as Depositary, registered in the name of a
nominee of the Depositary. So long as the Depositary or its nominee is the registered holder of any Global Security, the Depositary or its nominee, as the case may be, shall be considered the sole Holder of the Notes represented by such Global
Security for all purposes under the Indenture. The forms and terms of the Notes and the Trustee’s certificate of authentication shall be substantially as set forth on Exhibit B hereto. The terms and provisions contained in the form of
Notes set forth on Exhibit B hereto shall constitute, and are hereby expressly made, a part of the Indenture as supplemented by this Officers’ Certificate and Company Order. 

 

	 	(18)	The defeasance provisions set forth in Article IX of the Indenture shall apply to the Notes. 

  

	 	(19)	The following additional terms shall apply to the Notes: 

  

	 	(a)	Further Issuances. The Company may, so long as no Event of Default has occurred, without the consent of the Holders of the Notes, issue additional notes with the same terms as the Notes in accordance with the
corporate authority existing at the time of such additional issuance, and such additional notes shall be considered part of the same series under the Indenture as the Notes and will vote together with the Notes as one class on all matters with
respect to the Notes. 

  

	 	(b)	Transfer and Exchange. 

  

	 	(i)	 The transfer and exchange of Global Securities or beneficial interests therein shall be effected through the
Depositary, in accordance with this Officers’ Certificate and Company Order (including applicable restrictions on transfer set forth herein, if any) and the procedures of the Depositary therefor. A transferor of a beneficial interest in a
Global Security shall deliver to the Security Registrar a written order given in accordance with the Depositary’s procedures containing information regarding the participant account of the Depositary to be credited with a beneficial interest in
the Global Security. The Security Registrar shall, in accordance with such instructions, instruct the Depositary to credit to the account of the Person specified in such instructions a beneficial interest in the Global

  
 7 

	 	
Security and to debit the account of the Person making the transfer the beneficial interest in the Global Security being transferred. Each Holder of a Security agrees to indemnify the Company and
the Trustee against any liability that may result from the transfer, exchange or assignment of such Holder’s Security in violation of any provision of the Indenture and/or applicable United States federal or state securities law.

  

	 	(ii)	Each Global Security shall bear the global security legend set forth on Exhibit A hereto. 

  

	 	(20)	The CUSIP number for the global Note is 91324P CZ3 and the ISIN number for the global Note is US91324PCZ36. 

  

	B.	Establishment of Forms of Securities Pursuant to Section 201 of Indenture. 

It is hereby established, pursuant to Section 201 of the Indenture, that the Global Security representing the Notes shall be substantially
in the form attached as Exhibit B hereto. 
  

	C.	Order for the Authentication and Delivery of Securities Pursuant to Section 303 of the Indenture. 

It is hereby ordered pursuant to Section 303 of the Indenture that the Trustee authenticate, in the manner provided by the Indenture, the
Notes in the aggregate principal amount of $725,000,000 registered in the name of Cede & Co., which Notes have been heretofore duly executed by the proper officers of the Company and delivered to you as provided in the Indenture, and to
deliver said authenticated Notes to or on behalf of The Depository Trust Company on or before 10:30 a.m., Central Time, on March 13, 2017. 
  

	D.	Other Matters. 

 The Company has provided to the Trustee true and correct copies of
resolutions adopted by the Board of Directors of the Company on October 30, 2007, January 18, 2008, November 8, 2016 and February 8, 2017; such resolutions have not been further amended, modified or rescinded and remain in full
force and effect except as otherwise provided therein; and such resolutions (together with this Officers’ Certificate and Company Order) are the only resolutions or other action adopted by the Company’s Board of Directors or any committee
thereof or by any officers of the Company relating to the offering and sale of the Notes. 
 The undersigned Senior Vice President and
Treasurer being an Authorized Representative as defined in the resolutions of the Board of Directors of the Company adopted on November 8, 2016 certifies that (i) he has approved the terms of the Notes as set forth in this Officers’
Certificate and Company Order, (ii) he has approved and ratified the terms and form of the Underwriting Agreement (the “Underwriting Agreement”) and the Pricing Agreement (the “Pricing Agreement”), each dated March 8,
2017, by and among the Company and J.P. Morgan Securities LLC, Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley & Co. LLC, as representatives of the underwriters named in Schedule
I to the Pricing Agreement, and (iii) he has approved and ratified the Indenture, all in accordance with the authority of such officer pursuant to such resolutions. 

The undersigned have read the pertinent sections of the Indenture including the related definitions contained therein. The undersigned have
examined the resolutions adopted by the Board of Directors of the Company. In the opinion of the undersigned, the undersigned have made such examination or investigation as is necessary to enable the undersigned to express an informed opinion as to
whether or not the conditions precedent to (i) the establishment of the Notes, (ii) the establishment of the form of the Notes and (iii) the authentication of the Notes contained in the Indenture have been complied with. In the
opinion of the undersigned, such conditions have been complied with. 

  
 8 

 Simpson Thacher & Bartlett LLP, Richard J. Mattera, Senior Deputy General Counsel for
the Company, and Hogan Lovells US LLP are entitled to rely on this Officers’ Certificate and Company Order in connection with the opinions they are rendering pursuant to Sections 10(b), 10(c), and 10(d), respectively, of the Underwriting
Agreement. 
 [SIGNATURE PAGE TO FOLLOW] 

  
 9 

 IN WITNESS WHEREOF, the undersigned have executed this Officers’ Certificate and Company
Order this 13th day of March, 2017. 
  

			
	UNITEDHEALTH GROUP INCORPORATED
	
	 /s/ Robert W. Oberrender

	Name: Robert W. Oberrender
	Title: Senior Vice President and Treasurer
	
	 /s/ Richard J. Mattera

	Name: Richard J. Mattera
	Title: Assistant Secretary

 EXHIBIT A 

FORM OF LEGENDS 
 Global Security
Legend 
 THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO BELOW AND IS REGISTERED IN THE NAME
OF A DEPOSITARY OR A NOMINEE OF A DEPOSITARY. THIS NOTE IS EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS NOTE
(OTHER THAN A TRANSFER OF THIS NOTE AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY) MAY BE REGISTERED EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED
IN THE INDENTURE. 
 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (55 WATER STREET,
NEW YORK, NEW YORK) TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE
DEPOSITORY TRUST COMPANY AND ANY PAYMENT IS MADE TO CEDE & CO., ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

 EXHIBIT B 

FORM OF GLOBAL SECURITY 

[See attached.] 

 
THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO BELOW AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE OF A DEPOSITARY. THIS NOTE IS
EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS NOTE (OTHER THAN A TRANSFER OF THIS NOTE AS A WHOLE BY THE
DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY) MAY BE REGISTERED EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (55 WATER STREET, NEW YORK, NEW YORK) TO THE ISSUER OR
ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY AND ANY PAYMENT
IS MADE TO CEDE & CO., ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 

 

					
	REGISTERED	  	 UNITEDHEALTH GROUP

INCORPORATED
	  	$[        ]
	No. [    ]	  	 4.250% Notes due

April 15, 2047
	  	 CUSIP No. 91324P CZ3
 ISIN No.
US91324PCZ36

 UNITEDHEALTH GROUP INCORPORATED, a Delaware corporation (hereinafter called the “Company,”
which term includes any successor corporation under the Indenture referred to on the reverse side hereof), for value received, hereby promises to pay to CEDE & CO., or registered assigns, the principal sum of
[        ] Dollars ($[        ]) on April 15, 2047 (the “Stated
Maturity”), and to pay interest thereon from March 13, 2017 or from the most recent date to which interest has been paid or duly provided for, semi-annually in arrears on April 15 and October 15 in each year (each, an
“Interest Payment Date”), commencing October 15, 2017, and at maturity, at the rate of 4.250% per annum, until the principal hereof is paid or duly made available for payment. Interest on this Note shall be calculated on the basis of
a 360-day year consisting of twelve 30-day months. The interest so payable and punctually paid or duly provided for on any Interest Payment Date shall, as provided in
the Indenture, be paid to the Person in whose name this Note (or one or more Predecessor Securities) is registered at the close of business on the “Regular Record Date” for such interest, which shall be the April 1 or October 1
(whether or not a Business Day, as hereinafter defined) immediately preceding each such Interest Payment Date. Any such interest which is payable, but is not punctually paid or duly provided for, on any Interest Payment Date shall forthwith cease to
be payable to the registered Holder hereof on the relevant Regular Record Date by virtue of having been such Holder, and may be paid (i) to the Person in whose name this Note (or one or more Predecessor Securities) is registered at the close of
business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to the Holder of this Note not less than 10 days prior to such Special Record Date, or (ii) in any other
lawful manner not inconsistent with the requirements of any securities exchange on which this Note may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the proposed payment
pursuant to this clause (ii), such manner of payment shall be deemed practicable by the Trustee. In the event that a payment of principal or interest is due on a date that is not a Business Day, the related payment of principal or interest shall be
made on the next succeeding Business Day with the same force and effect as if made on the date such payment was due, and 

 
no interest shall accrue on the amount so payable for the period from and after such Interest Payment Date or date of maturity, as the case may be. “Business Day” shall mean any day
other than a Saturday, a Sunday or a day on which banking institutions in New York, New York or Minneapolis, Minnesota are authorized or required by law, regulation or executive order to close. 

Payment of the principal of and the interest on this Note will be made at the corporate trust office of U.S. Bank National Association, in St.
Paul, Minnesota, in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts. The method of such payment shall be by wire transfer for a Note held in book-entry form or
at the option of the Company by check mailed to the Person entitled thereto as shown on the Security Register. Payment of the principal of and interest on this Note due at maturity will be made in immediately available funds upon presentation of
this Note. 
 Reference is hereby made to the further provisions of this Note set forth on the reverse side hereof, which further provisions
shall for all purposes have the same effect as if set forth at this place. 
 Unless the certificate of authentication hereon has been
executed by or on behalf of the Trustee under the Indenture by the manual signature of one of its authorized signatories, this Note shall not be entitled to any benefits under the Indenture or be valid or obligatory for any purpose. 

[SIGNATURE PAGE TO FOLLOW] 

  
 2 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

Dated: March 13, 2017 
  

					
	UNITEDHEALTH GROUP INCORPORATED
		
	By:	 	  

		 	Name:	 	Robert W. Oberrender
		 	Title:	 	Senior Vice President and Treasurer
		
	Attest:	 	  

		 	Name:	 	Richard J. Mattera
		 	Title:	 	Assistant Secretary

 TRUSTEE’S CERTIFICATE OF 

AUTHENTICATION 
  

			
	This is one of the Securities of the series designated herein and issued pursuant to the within-mentioned Indenture.
	
	Dated: March 13, 2017
	
	U.S. BANK NATIONAL ASSOCIATION,
	as Trustee
		
	By:	 	  

		 	Authorized Signatory

 UnitedHealth Group Incorporated 

4.250% Notes due April 15, 2047 

 [REVERSE SIDE OF NOTE] 

This Note is one of a duly authorized issue of securities of the Company (herein called the “Notes”) issued and to be issued in one
or more series under an indenture, dated as of February 4, 2008, between the Company and U.S. Bank National Association, as trustee (the “Trustee,” which term includes any successor trustee), as further supplemented by an
Officers’ Certificate and Company Order, dated March 13, 2017, pursuant to Section 301 of the indenture (together, the “Indenture”) between the Company and the Trustee, to which Indenture and all indentures supplemental
thereto reference is hereby made for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Notes, and the terms upon which the Notes are, and are to be,
authenticated and delivered. This Note is one of the series designated on the face hereof, limited in initial aggregate principal amount to $725,000,000; provided, however, that the Company may, so long as no Event of Default has occurred and
is continuing, without the consent of the Holders of the Notes of this series, issue additional notes with the same terms as the Notes of this series, and such additional notes shall be considered part of the same series under the Indenture as the
Notes of this series. 
 Optional Redemption 

This Note is redeemable, in whole or in part, at any time before October 15, 2046 (six months prior to its Stated Maturity), at the option
of the Company at a Redemption Price equal to the greater of (i) 100% of the principal amount of this Note to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on this Note to be
redeemed (excluding the portion of any such interest accrued to the Redemption Date) that would be due if this Note matured on October 15, 2046, discounted to the Redemption Date on a semi-annual basis (assuming a
360-day year consisting of twelve 30-day months) at the Treasury Yield (as defined below), plus 20 basis points, plus, in each case, accrued and unpaid interest
thereon to, but not including, the Redemption Date. 
 At any time on or after October 15, 2046 (six months prior to its Stated
Maturity), this Note will be redeemable, in whole or in part at any time and from time to time, at the option of the Company, on not less than 30 nor more than 60 days’ notice by mail, at a Redemption Price equal to 100% of the principal amount
of this Note to be redeemed plus accrued and unpaid interest thereon to, but not including, the Redemption Date. 
 For this purpose, the
following terms have the following meanings: 
  

	 	•	 	“Treasury Yield” means, with respect to any Redemption Date, the rate per year equal to the semi-annual equivalent yield to maturity or interpolated (on a day count basis) yield to maturity of the applicable
Comparable Treasury Issue, assuming a price for such Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the applicable Comparable Treasury Price for such Redemption Date. 

 

	 	•	 	“Comparable Treasury Issue” means the United States Treasury security selected by an Independent Investment Banker appointed by the Trustee after consultation with the Company as having an actual or
interpolated maturity comparable to the remaining term of this Note being redeemed (assuming that the Notes matured on October 15, 2046), or such other maturity that would be utilized at the time of selection and in accordance with customary
financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of this Note being redeemed. 

  
 4 

	 	•	 	“Comparable Treasury Price” means, with respect to any Redemption Date, (i) the average of the Reference Treasury Dealer Quotations for such Redemption Date, after excluding the highest and lowest such
Reference Treasury Dealer Quotations for such Redemption Date, or (ii) if the Trustee obtains fewer than four such Reference Treasury Dealer Quotations, the average of all such Reference Treasury Dealer Quotations. 

 

	 	•	 	“Independent Investment Banker” means any of J.P. Morgan Securities LLC, Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated or Morgan Stanley & Co. LLC or their
respective successors or, if such firms are unwilling or unable to select the Comparable Treasury Issue, one of the remaining Reference Treasury Dealers appointed by the Trustee after consultation with the Company. 

 

	 	•	 	“Reference Treasury Dealer” means each of (i) J.P. Morgan Securities LLC, Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Morgan Stanley & Co. LLC or
their affiliates and any other primary U.S. Government securities dealer in the United States (a “Primary Treasury Dealer”) designated by, and not affiliated with, any of J.P. Morgan Securities LLC, Goldman, Sachs & Co., Merrill
Lynch, Pierce, Fenner & Smith Incorporated or Morgan Stanley & Co. LLC; provided, however, that if J.P. Morgan Securities LLC, Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated or Morgan
Stanley & Co. LLC or any of their respective affiliates shall cease to be a Primary Treasury Dealer, the Company will appoint another Primary Treasury Dealer as a substitute for such entity; and (ii) any other Primary Treasury Dealer
selected by the Trustee. 

  

	 	•	 	“Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any Redemption Date, the average, as determined by the Trustee, of the bid and asked prices for the applicable
Comparable Treasury Issue (expressed, in each case, as a percentage of its principal amount) quoted in writing to the Trustee by such Reference Treasury Dealer at 5:00 p.m. on the third Business Day preceding such Redemption Date. 

A notice of redemption may provide that it is subject to certain conditions that will be specified in the notice. If those conditions are not
met, the redemption notice will be of no effect and the Company will not be obligated to redeem this Note. 
 A partial redemption of the
Notes may be effected on a pro rata basis (and in such manner as complies with applicable legal and stock exchange requirements, if any) or in such method as the Trustee, in the exercise of its reasonable discretion, deems fair and appropriate. The
Trustee may provide for the selection for redemption of portions in amounts of $1,000 or whole multiples of $1,000; except that if all of the Notes of a Holder are to be redeemed, the entire outstanding amount of Notes held by such Holder, even if
not a multiple of $1,000, shall be redeemed. 
 Notice of any redemption will be mailed at least 30 days but not more than 60 days before
the Redemption Date to each Holder of the Notes to be redeemed. 
 Unless any Note called for redemption shall not be paid upon surrender
thereof for redemption, on and after the Redemption Date interest will cease to accrue on the Notes or portions thereof called for redemption. 

This Note will not be entitled to any sinking fund. 

Change of Control Offer 
 If a
Change of Control Triggering Event (as defined herein) occurs, unless the Company has exercised its option to redeem all the Notes of this series, the Company shall be required to make an offer (a “Change of

  
 5 

 
Control Offer”) to each Holder of the Notes of this series to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of that Holder’s Notes on
the terms set forth herein. In a Change of Control Offer, the Company shall be required to offer payment in cash equal to 101% of the aggregate principal amount of Notes of this series repurchased, plus accrued and unpaid interest, if any, on the
Notes of this series repurchased to, but not including, the date of repurchase (a “Change of Control Payment”). Within 30 days following any Change of Control Triggering Event or, at the Company’s option, prior to any Change of
Control, but after public announcement of the transaction that constitutes or may constitute the Change of Control, a notice shall be transmitted to Holders of the Notes of this series describing the transaction that constitutes or may constitute
the Change of Control Triggering Event and offering to repurchase such Notes on the date specified in the notice, which date shall be no earlier than 30 days and no later than 60 days from the date such notice is transmitted (a “Change of
Control Payment Date”). The notice shall, if transmitted prior to the date of consummation of the Change of Control, state that the Change of Control Offer is conditioned on the Change of Control Triggering Event occurring on or prior to the
Change of Control Payment Date. 
 In order to accept the Change of Control Offer, the Holder must deliver to the Paying Agent, at least
five Business Days prior to the Change of Control Payment Date, this Note together with the form entitled “Election Form” (which form is annexed hereto) duly completed, or a telegram, telex, facsimile transmission or a letter from a member
of a national securities exchange, or the Financial Industry Regulatory Authority or a commercial bank or trust company in the United States setting forth: 

(i)    the name of the Holder of this Note; 

(ii)    the principal amount of this Note; 

(iii)    the principal amount of this Note to be repurchased; 

(iv)    the certificate number or a description of the tenor and terms of this Note; 

(v)    a statement that the Holder is accepting the Change of Control Offer; and 

(vi)    a guarantee that this Note, together with the form entitled “Election Form” duly completed, will be
received by the Paying Agent at least five Business Days prior to the Change of Control Payment Date. 
 Any exercise by a Holder of its
election to accept the Change of Control Offer shall be irrevocable. The Change of Control Offer may be accepted for less than the entire principal amount of this Note, but in that event the principal amount of this Note remaining outstanding after
repurchase must be equal to $2,000 or an integral multiple of $1,000 in excess thereof. 
 On the Change of Control Payment Date, the
Company shall, to the extent lawful: 
 (i)    accept for payment all Notes of this series or portions of such Notes
properly tendered pursuant to the Change of Control Offer; 
 (ii)    deposit with the Paying Agent an amount equal to
the Change of Control Payment in respect of all Notes of this series or portions of such Notes properly tendered; and 

(iii)    deliver or cause to be delivered to the Trustee the Notes of this series properly accepted together with an
Officers’ Certificate stating the aggregate principal amount of Notes of this series or portions of such Notes being repurchased. 

The Company shall not be required to make a Change of Control Offer upon the occurrence of a Change of Control Triggering Event if a third
party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for an offer made by the Company and the third party purchases 

  
 6 

 
all Notes of this series properly tendered and not withdrawn under its offer. In addition, the Company shall not repurchase any Notes of this series if there has occurred and is continuing on the
Change of Control Payment Date an Event of Default under the Indenture, other than a default in the payment of the Change of Control Payment upon a Change of Control Triggering Event. 

The Company shall comply with the requirements of Rule 14e-1 under the Securities Exchange Act of
1934, as amended (the “Exchange Act”), and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the Notes of this series as a result of a Change
of Control Triggering Event. To the extent that the provisions of any such securities laws or regulations conflict with the Change of Control Offer provisions of the Notes of this series, the Company shall comply with those securities laws and
regulations and shall not be deemed to have breached its obligations under the Change of Control Offer provisions of the Notes of this series by virtue of any such conflict. 

For purposes of the Change of Control Offer provisions of the Notes of this series, the following terms are applicable: 

 

	 	•	 	“Change of Control” means the occurrence of any of the following: (1) the direct or indirect sale, lease, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one
or more series of related transactions, of all or substantially all of the assets of the Company and its Subsidiaries, taken as a whole, to any person, other than the Company or a Subsidiary; (2) the consummation of any transaction (including,
without limitation, any merger or consolidation) the result of which is that any person becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 under the
Exchange Act), directly or indirectly, of more than 50% of the Company’s outstanding Voting Stock or other Voting Stock into which the Company’s Voting Stock is reclassified, consolidated, exchanged or changed, measured by voting power
rather than number of shares; (3) the Company consolidates with, or merges with or into, any person, or any person consolidates with, or merges with or into, the Company, in any such event pursuant to a transaction in which any of the
Company’s outstanding Voting Stock or the Voting Stock of such other person is converted into or exchanged for cash, securities or other property, other than any such transaction where the shares of the Company’s Voting Stock outstanding
immediately prior to such transaction constitute, or are converted into or exchanged for, a majority of the Voting Stock of the surviving person or any direct or indirect parent company of the surviving person immediately after giving effect to such
transaction; (4) the first day on which a majority of the members of the Company’s Board of Directors are not Continuing Directors; or (5) the adoption of a plan relating to the Company’s liquidation or dissolution.
Notwithstanding the foregoing, a transaction shall not be deemed to involve a Change of Control under clause (2) above if (i) the Company becomes a direct or indirect wholly-owned subsidiary of a holding company and (ii)(A) the direct or
indirect holders of the Voting Stock of such holding company immediately following that transaction are substantially the same as the holders of the Company’s Voting Stock immediately prior to that transaction or (B) immediately following
that transaction no person (other than a holding company satisfying the requirements of this sentence) is the beneficial owner, directly or indirectly, of more than 50% of the Voting Stock of such holding company. The term “person,” as
used in this definition, has the meaning given thereto in Section 13(d)(3) of the Exchange Act. 

  

	 	•	 	“Change of Control Triggering Event” means the occurrence of both a Change of Control and a Rating Event. 

  

	 	•	 	 “Continuing Directors” means, as of any date of determination, any member of the Company’s Board
of Directors who (1) was a member of such Board of Directors on the date the Notes of this series were issued or (2) was nominated for election, elected or appointed to such Board of Directors with the approval of a majority of the
Continuing Directors who were members of 

  
 7 

	 	 
such Board of Directors at the time of such nomination, election or appointment (either by a specific vote or by approval of the Company’s proxy statement in which such member was named as a
nominee for election as a director). 

  

	 	•	 	“Fitch” means Fitch, Inc., and its successors. 

  

	 	•	 	“Investment Grade Rating” means a rating equal to or higher than BBB- (or the equivalent) by Fitch, Baa3 (or the equivalent) by Moody’s and BBB- (or the equivalent) by S&P, and the equivalent investment grade credit rating from any replacement Rating Agency or Rating Agencies selected by the Company. 

 

	 	•	 	“Moody’s” means Moody’s Investors Service, Inc., and its successors. 

  

	 	•	 	“Rating Agencies” means (1) each of Fitch, Moody’s and S&P; and (2) if any of Fitch, Moody’s or S&P ceases to rate the Notes of this series or fails to make a rating of such Notes
publicly available for reasons outside of the Company’s control, a “nationally recognized statistical rating organization” within the meaning of Section 3(a)(62) under the Exchange Act selected by the Company (as certified by a
resolution of the Company’s Board of Directors) as a replacement agency for Fitch, Moody’s or S&P, or all of them, as the case may be. 

  

	 	•	 	“Rating Event” means the rating on the Notes of this series is lowered by each of the three Rating Agencies and the Notes of this series are rated below an Investment Grade Rating by each of the three Rating
Agencies on any day during the period (which period shall be extended so long as the rating of the Notes of this series is under publicly announced consideration for a possible downgrade by any of the Rating Agencies) commencing on the date of the
first public notice of the occurrence of a Change of Control or the Company’s intention to effect a Change of Control and ending 60 days following consummation of such Change of Control. 

 

	 	•	 	“S&P” means Standard & Poor’s Rating Services, a division of The McGraw-Hill Companies, Inc., and its successors. 

 

	 	•	 	“Voting Stock” means, with respect to any specified “person” (as that term is used in Section 13(d)(3) of the Exchange Act) as of any date, the capital stock of such person that is at the time
entitled to vote generally in the election of the board of directors of such person. 

 Miscellaneous Provisions 

If an Event of Default with respect to the Notes shall occur and be continuing, the principal of the Notes may be declared due and payable in
the manner and with the effect provided in the Indenture. 
 The Indenture contains provisions for defeasance at any time of the
Company’s obligations in respect of (i) the entire indebtedness of this Note or (ii) certain restrictive covenants with respect to this Note, in each case upon compliance with certain conditions set forth therein. 

The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations
of the Company and the rights of the Holders of the Securities of each series issued under the Indenture at any time by the Company and the Trustee with the consent of the Holders of not less than a majority in aggregate principal amount of the
Securities of all series at the time Outstanding affected thereby. The Indenture also contains provisions permitting the Holders of specified percentages in aggregate principal amount of the Securities of any series at the time Outstanding to waive
certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Note shall be conclusive and binding upon such Holder and upon all future Holders of this Note and of any Notes issued upon the
registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Note. 

  
 8 

 No reference herein to the Indenture and no provision of this Note or of the Indenture shall
alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of (and premium, if any) and interest on this Note, at the time, place and rate, and in the coin or currency, herein and in the Indenture
prescribed. 
 As provided in the Indenture and subject to certain limitations set forth therein and in this Note, the transfer of this Note
is registrable in the registry books of the Company, upon surrender of this Note for registration of transfer at the office or agency of the Company where the principal of (and premium, if any) and interest on this Note are payable, duly endorsed,
or accompanied by a written instrument of transfer in form satisfactory to the Company and the Trustee, duly executed by the Holder hereof or by his attorney duly authorized in writing, and thereupon one or more new Notes, of authorized
denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. 
 The Notes of this
series are issuable only in fully registered form without coupons in minimal initial purchase amounts of $2,000 and whole multiples of $1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Notes
of this series are exchangeable for a like aggregate principal amount of Notes of this series which are of like tenor for any authorized denomination, as requested by the Holder surrendering the same. 

No service charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to
cover any tax or other governmental charge payable in connection therewith, other than in certain cases provided in the Indenture. 
 Prior
to due presentment of this Note for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Note is registered as the owner hereof for all purposes, whether or not this
Note be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary. 
 This Note shall be
governed by and construed in accordance with the laws of the State of New York, without regard to its conflicts of laws provisions. 
 All
capitalized terms used in this Note which are not defined herein shall have the meanings assigned to them in the Indenture. 

  
 9 

 ASSIGNMENT FORM 

I or we assign and transfer this Note to 
  

 
  

 
 (Print or type name, address and zip code of assignee
or transferee) 
  
  

(Insert Social Security or other identifying number of assignee or transferee) 

and irrevocably appoint
                                         
                    agent to transfer this Note on the books of the Issuer. The agent may substitute another to act for him. 

 

									
	Dated:	 	  
	 		 	Signed:	 	  

		 		 		 		 	(Sign exactly as name appears on the other side of this Note)

									
				
	Signature Guarantee:	 	  
	 		 	
		 	Participant in a recognized Signature Guarantee	 		 	
		 	Medallion Program (or other signature guarantor	 		 	
		 	program reasonably acceptable to the Trustee)	 		 	

  
 10 

 SCHEDULE OF EXCHANGES OF INTERESTS IN THE GLOBAL SECURITY 

Initial Principal Amount at maturity of Global Security:
[            ] Dollars ($[        ]). 

The following exchanges of a part of this Global Security for an interest in another Global Security or for a certificated note, or exchanges of a part of
another Global Security or certificated note for an interest in this Global Security, have been made: 
  

									
	 Date of Exchange
	 	 Amount of decrease

in

Principal Amount of

this Global Security
	 	 Amount of increase

in

Principal Amount of

this Global Security
	 	 Principal Amount of

this Global Security

following such

decrease
 (or
increase)
	 	 Signature of

authorized officer

of

Trustee or Note

Custodian

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

  
 11 

 
ELECTION FORM 
 TO BE COMPLETED ONLY IF THE HOLDER 

ELECTS TO ACCEPT THE CHANGE OF CONTROL OFFER 
  

 
 The undersigned
hereby irrevocably requests and instructs the Company to repurchase the within Note (or the portion thereof specified below), pursuant to its terms, on the Change of Control Payment Date specified in the Change of Control Offer, for the Change of
Control Payment specified in the within Note, to the undersigned,
                                         
                   , at
                                         
                    (please print or typewrite name and address of the undersigned). 

For this election to accept the Change of Control Offer to be effective, the Company must receive, at the address of the Paying Agent set
forth below or at such other place or places of which the Company shall from time to time notify the Holder of the within Note, either (i) this Note with this “Election Form” form duly completed, or (ii) a telegram, telex,
facsimile transmission or a letter from a member of a national securities exchange or the Financial Industry Regulatory Authority or a commercial bank or a trust company in the United States setting forth (a) the name of the Holder of the Note,
(b) the principal amount of the Note, (c) the principal amount of the Note to be repurchased, (d) the certificate number or description of the tenor and terms of the Note, (e) a statement that the option to elect repurchase is
being exercised, and (f) a guarantee stating that the Note to be repurchased, together with this “Election Form” duly completed will be received by the Paying Agent five Business Days prior to the Change of Control Payment Date. The
address of the Paying Agent is U.S. BANK NATIONAL ASSOCIATION, 60 Livingston Avenue, EP-MN-WS3C, St. Paul, MN 55107-2292. 

If less than the entire principal amount of the within Note is to be repurchased, specify the portion thereof (which principal amount must be
$2,000 or an integral multiple of $1,000 in excess thereof) which the Holder elects to have repurchased: $        . 

  
 12Exhibit 10.16

 

***Certain portions of this exhibit have been omitted based on a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The omitted portions have been filed separately with the Securities and Exchange Commission.

 

 

 

 

 

CO-DEVELOPMENT AND CO-COMMERCIALISATION AGREEMENT

BETWEEN

ADAPTIMMUNE LIMITED

AND

BELLICUM PHARMACEUTICALS, INC.

 

 

Execution Copy

 

 

TABLE OF CONTENTS

	
Article

 
    	
 
    	
Page

 
    
	
ARTICLE 1
    	
DEFINITIONS
    	
3
    
	
ARTICLE 2
    	
GOVERNANCE
    	
13
    
	
ARTICLE 3
    	
POC PHASE
    	
20
    
	
ARTICLE 4
    	
SELECTION OF TARGETS
    	
21
    
	
ARTICLE 5
    	
CO-DEVELOPMENT PLAN
    	
22
    
	
ARTICLE 6
    	
REGULATORY
    	
26
    
	
ARTICLE 7
    	
COMMERCIALISATION
    	
27
    
	
ARTICLE 8
    	
LICENSES
    	
28
    
	
ARTICLE 9
    	
TECHNOLOGY TRANSFER
    	
29
    
	
ARTICLE 10
    	
FINANCIAL TERMS
    	
30
    
	
ARTICLE 11
    	
PAYMENTS
    	
32
    
	
ARTICLE 12
    	
INTELLECTUAL PROPERTY; OWNERSHIP
    	
33
    
	
ARTICLE 13
    	
CONFIDENTIALITY
    	
38
    
	
ARTICLE 14
    	
PUBLICITY; PUBLICATIONS; USE OF NAME
    	
40
    
	
ARTICLE 15
    	
REPRESENTATIONS
    	
40
    
	
ARTICLE 16
    	
INDEMNIFICATION
    	
41
    
	
ARTICLE 17
    	
TERM AND TERMINATION
    	
43
    
	
ARTICLE 18
    	
DISPUTE RESOLUTION
    	
50
    
	
ARTICLE 19
    	
ANTI-BRIBERY
    	
52
    
	
ARTICLE 20
    	
DATA PROTECTION
    	
53
    
	
ARTICLE 21
    	
MISCELLANEOUS
    	
53
    

 

Exhibits

 

Exhibit 1 – POC Plan

Exhibit 2 – FTE Rates

Exhibit 3 – Co-Commercialisation Agreement Principles

Exhibit 4 – Technology Descriptions

Exhibit 5 – Press Release

Exhibit 6 – Co-Development Rresponsibilities

Exhibit 7 – Designation Criteria

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Page 2

 

Execution Copy

 

CO-DEVELOPMENT AND CO-COMMERCIALISATION AGREEMENT

THIS CO-DEVELOPMENT AND CO-COMMERCIALISATION AGREEMENT (“Agreement”) is made and entered into on December 16, 2016 (“Effective Date”) BETWEEN

(A)          ADAPTIMMUNE LIMITED having its principal place of business at 101 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RX, United Kingdom (“Adaptimmune”); and

(B)          BELLICUM PHARMACEUTICALS, INC., having its principal place of business at 2130 W. Holcombe Blvd., #800, Houston, TX 77030, United States of America (“Bellicum”).

Bellicum and Adaptimmune are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

BACKGROUND:

(A)          Adaptimmune is a biotechnology company that is engaged in research and development of TCR therapies for pharmaceutical therapy use.

(B)          Bellicum is a biopharmaceutical company that is engaged in the research, development, manufacture and anticipated commercialisation of pharmaceutical immunotherapies, and has specific technologies which it is interested in combining with Adaptimmune’s TCR therapies.

(C)          Bellicum and Adaptimmune desire to collaborate in relation to the development of certain T cell therapies wherein such T cell bears a membrane bound exogenous TCR and which T cell therapies include technologies developed by both Parties.

(D)          Based on the foregoing premises and the mutual covenants and obligations set forth below, the Parties agree as follows.

THE PARTIES AGREE:

ARTICLE 1     DEFINITIONS

Capitalized terms used in this Agreement, whether used in the singular or plural, shall have the meanings set forth below or elsewhere herein, unless otherwise specifically indicated herein.

	
 

Accounting Standard
    	
 
    	
 

means, either (a) International Financial   Reporting Standards (“IFRS”) or (b) US generally accepted accounting   principles (“GAAP”), in either case, which standards or principles (as   applicable) are currently used at the applicable time, and as consistently applied,   by the applicable Party;

 
    
	
 

Adaptimmune Background IP
    	
 
    	
 

means   Background IP Controlled by Adaptimmune or its Affiliates;

 
    
	
 

Adaptimmune Candidate
    	
 
    	
 

means   any Candidate (including the Joint Selected Candidate) directed to the   Adaptimmune Target;

 
    
	
 

Adaptimmune Foreground IP
    	
 
    	
 

means   any Foreground IP Controlled by Adaptimmune or its Affiliates, and as defined   further in Article 12;
    

 

 

Page 3

 

Execution Copy

 

	
 

Adaptimmune Licensed Know-How
    	
 
    	
 

means,   as Controlled by Adaptimmune or its Affiliates as of the Effective Date or   during the Term, any Intellectual Property Rights specific to any Selected   Target, Therapy or Candidate or otherwise necessary for the performance of   any Co-Development Plan or for performing any manufacturing or   commercialisation activities for such Therapy or Candidate, but in all cases   excluding any Patents;  

 
    
	
 

Acquiring Third Party
    	
 
    	
 

means   a Third Party (including in each case any entity which directly or indirectly   controls, is controlled by, or is under common control with such Third Party)   which, as at the date of the Change of Control, controls or owns ***

 

 

                               .  
    
	
 

Adaptimmune Licensed Patents
    	
 
    	
 

means   any Patents Controlled by Adaptimmune or its Affiliates as of the Effective   Date or during the Term and which either (a) Cover a Therapy or Joint   Selected Candidate or Selected Target, or a method related to use thereof; or   (b) which would, in the absence of the licences under this Agreement, be   infringed by the performance of the Co-Development Plan or manufacture or   commercialisation of any Therapy or Candidate;  

 
    
	
 

Adaptimmune   Reserved Activities
    	
 
    	
 

is defined in Clause 5.6;
    
	
 

Adaptimmune Target
    	
 
    	
 

means   the Initial Target or the Target jointly agreed between the Parties to be the   Adaptimmune Target for the purposes of development of Adaptimmune Candidates   under the Co-Development Phase and as designated in accordance with Clause   4.1.1;

 
    
	
 

Adaptimmune Technology
    	
 
    	
 

shall   have the meaning given in Exhibit 4A;

 
    
	
 

Adaptimmune Therapy
    	
 
    	
 

has   the meaning provided for in Exhibit 3;

 
    
	
 

Additional HLA Candidates
    	
 
    	
 

means,   on a Selected Target-by-Selected Target basis, a Candidate directed to an   epitope derived from such Selected Target presented by a different HLA Type   than the HLA Type used to develop the Joint Selected Candidate directed to   such Selected Target;

 
    
	
 

Affiliate
    	
 
    	
 

means   any Person that, directly or indirectly (through one or more intermediaries)   controls, is controlled by, or is under common control with a Party.  For purposes of this Clause, “control”   means the direct or indirect ownership of more than fifty percent (50%) of   the voting stock or other voting interests or interest in the profits of the   Party;
    

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 4

 

Execution Copy

 

	
 

Agreed FTE Rates
    	
 
    	
 

means   the rates set out in Exhibit 2 as amended by the Parties from time to   time. 

 
    
	
 

Agreement
    	
 
    	
 

means   this Co-Development and Pre-Commercialisation Agreement;

 
    
	
 

Alliance Manager
    	
 
    	
 

means   the individual appointed by each Party as the principal point of contact for   communication between the Parties under this Agreement;

 
    
	
 

Applicable Laws
    	
 
    	
 

means   all applicable international, multi-national, national, regional, state,   provincial and local laws, rules, regulations, ordinances, declarations,   requirements, directives, guidance, policies and guidelines which are in   force during the Term and in any jurisdiction in which any Clinical Trial or   other activity under this Agreement is performed or in which any Therapy is   manufactured, sold or supplied to the extent in each case applicable to any   Party to this Agreement, including, as applicable to activities hereunder,   the regulations and regulatory guidance promulgated by the FDA, the Consolidated Guidance E6 on Good   Clinical Practice adopted by the International Conference on Harmonisation of   Technical Requirements for Registration of Pharmaceuticals for Human Use, as   ratified by the FDA, the Clinical Trials Directive (Directive 2001/20/EC of   4th April 2001) and the Data Protection Directive (Directive 95/46/EC of   24th October 1995) and the respective implementing legislation, the conditions and requirements imposed by the related   ethics committee and   any of the foregoing which relate to ethical business conduct,   the import or export of goods, technical data or other items, and data   protection and privacy rules, as any of the foregoing may be amended from   time to time;

 
    
	
 

Background IP
    	
 
    	
 

means   all Intellectual Property Rights Controlled by either Party as of the   Effective Date or during the Term, but excluding the Foreground IP; 

 
    
	
 

Bellicum Background IP
    	
 
    	
 

means   Background IP Controlled by Bellicum or its Affiliates;

 
    
	
 

Bellicum Candidate
    	
 
    	
 

means any Candidate (including the Joint Selected   Candidate) directed to the Bellicum Target;

 
    
	
 

Bellicum Foreground IP
    	
 
    	
 

means   any Foreground IP Controlled by Bellicum or its Affiliates, and as defined   further in Article 12;

 
    
	
 

Bellicum Licensed Know-How
    	
 
    	
 

means,   as Controlled by Bellicum or its Affiliates as of the Effective Date or   during the Term, any Intellectual Property Rights specific to any Selected   Target, Therapy or Candidate or otherwise necessary for the performance of   any Co-Development Plan or for performing any manufacturing or   commercialisation activities for such Therapy or Candidate, but in all cases   excluding any Patents;  

 
    
	
 

Bellicum Licensed Patents
    	
 
    	
 

means   any Patents Controlled by Bellicum or its Affiliates as of the Effective Date   or during the Term and which either (a) Cover a Therapy or Joint   Selected Candidate or Selected Target, or a 
    

 

Page 5

 

Execution Copy

 

	
 
    	
 
    	
 

method   related to use thereof; or (b) which would, in the absence of the   licences under this Agreement, be infringed by the performance of the   Co-Development Plan or manufacture or commercialisation of any Therapy or   Candidate;  

 
    
	
 

Bellicum Reserved Activities
    	
 
    	
 

is defined in Clause 5.6;

 
    
	
 

Bellicum Target
    	
 
    	
 

means   the Target jointly agreed between the Parties to be the Bellicum Target for   the purposes of development of Bellicum Candidates under the Co-Development   Phase and as designated in accordance with Clause 4.1.1;

 
    
	
 

Bellicum Technology
    	
 
    	
 

shall   have the meaning given in Exhibit 4B;

 
    
	
 

Candidate
    	
 
    	
 

means any starting TCR, as well as any product or   Therapy that comprises T cells bearing a corresponding membrane bound   exogenous TCR, and in each case which is developed under any Co-Development   Plan;

 
    
	
 

Change of Control
    	
 
    	
 

means   with respect to a Party, (a) the sale or disposition to an Acquiring   Third Party of all or substantially all of the business or assets of such   Party to which the subject matter of this Agreement relates, including all of   or substantially all of the Licensed Intellectual Property under which such   Party has granted rights to the other Party under this Agreement; or   (b) (i) the acquisition by an Acquiring Third Party of more than   fifty percent (50%) of the issued voting shares or stock in such Party, or   (ii) the acquisition, merger or consolidation of such Party with or into   an Acquiring Third Party.  A Change of   Control will not include an acquisition, merger or consolidation or similar   transaction of a Party in which the holders of the voting shares in such   Party immediately prior to such acquisition, merger, consolidation or   transaction, will beneficially own, directly or indirectly, at least fifty   percent (50%) of the voting shares in the Acquiring Third Party or the   surviving entity in such acquisition, merger, consolidation or transaction,   as the case may be, immediately after such acquisition, merger, consolidation   or transaction;

 
    
	
 

Clinical Trial
    	
 
    	
 

means   a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial,   or Phase IV Clinical Trial, as the case may be, and any clinical studies   specifically including pediatric subjects, or any other equivalent, combined   or other trial in which any Therapy is administered to a human subject;

 
    
	
 

CMC
    	
 
    	
 

means   chemistry, manufacturing and control;

 
    
	
 

Co-Commercialisation Agreement
    	
 
    	
 

is   defined in Clause 7.2;

 
    
	
 

CoC Party
    	
 
    	
 

is   defined in Clause 17.5.4;

 
    
	
 

Co-Development Phase
    	
 
    	
 

means   the phases of the Co-Development Plan in which a Candidate or Joint Selected   Candidate is being developed including pre-clinical testing and Clinical   Trials using such Joint Selected Candidate;
    

 

Page 6

 

Execution Copy

 

	
 

Co-Development Plan
    	
 
    	
 

means   a program of activities and work for the development of Candidates directed   to a Selected Target and including a Joint Selected Candidate;

 
    
	
 

CMO
    	
 
    	
 

means   a Third Party with which a Party has contracted to conduct manufacturing (including   process development and scale-up) of a Joint Selected Candidate or Therapy on   behalf of such Party;

 
    
	
 

Commercially   Reasonable Efforts
    	
 
    	
 

means, on a Party-by-Party basis, that level of efforts and resources required to   carry out a particular task or obligation in an active and sustained manner,   consistent with the general practice followed by the Party in the exercise of   its reasonable business discretion relating to other pharmaceutical   therapies or products owned by it, or to which it has exclusive rights, which   are of similar market potential at a similar stage in their development or   life, taking into account issues of patent coverage, safety and efficacy,   therapy profile, the competitiveness of any therapy in development and in the   marketplace, supply chain management considerations, the proprietary position   of the product or therapy, the regulatory structure involved, the   profitability of the applicable therapies (including pricing and   reimbursement status achieved), and other relevant factors, including   technical, legal, scientific and/or medical factors;

 
    
	
 

Completion
    	
 
    	
 

means   (a) in relation to any POC Plan or Co-Development Plan, or any phase of   any such plan, substantial completion of all activities under such plan or   phase of such plan, including as relevant delivery of any final report and   the attainment of any mutually agreed success criteria for such phase; and   (b) in relation to any Clinical Trial, provision of a final report in   relation to such Clinical Trial in accordance with the applicable Clinical   Trial protocol; 

 
    
	
 

Confidential Information
    	
 
    	
 

means   non-public, proprietary information (of whatever kind and in whatever form or   medium, including copies thereof), tangible materials or other deliverables   (a) disclosed by or on behalf of a Party in connection with this   Agreement, whether prior to or during the Term and whether disclosed orally,   electronically, by observation or in writing, or (b) created by, or on behalf   of, either Party and provided to the other Party, or created jointly by the   Parties, in the course of this Agreement; provided, that, notwithstanding the   foregoing, to the extent a Party is allocated ownership of Intellectual   Property Rights embodied by or containing a given piece of information under   this Agreement in accordance with Article 12, such information shall be   deemed to be solely the Confidential Information of such Party regardless of   which Party initially disclosed or created such information;

 
    
	
 

Control   or Controlled by
    	
 
    	
 

means   the rightful possession by a Party, whether directly or indirectly and   whether by ownership, license (other than pursuant to this Agreement) or   otherwise, as of the Effective Date or during the Term, of the right   (excluding where any required Third Party consent cannot be obtained) to   grant a license, sublicense or other right to exploit as provided herein,   without violating the terms of any agreement with any Third Party;
    

 

Page 7

 

Execution Copy

 

	
 

Covers   or Covered or Covering
    	
 
    	
 

means,   with respect to a particular Patent and in reference to a particular   compound, process, Candidate or Therapy (whether alone or in combination with   one or more other ingredients) that the use, manufacture, sale, supply,   import, offer for sale of such compound, Candidate or Therapy or use of such   process would infringe a Valid Claim of such Patent in the absence of any   license granted under this Agreement or in the case of a patent application   would infringe the claim of such patent application if such patent   application was a granted patent;  

 
    
	
 

Development Costs
    	
 
    	
 

is   defined in Clause 10.2.3;

 
    
	
 

Dispute
    	
 
    	
 

is   defined in Clause 18.1;

 
    
	
 

Effective Date
    	
 
    	
 

is   defined in the Preamble;

 
    
	
 

EMA
    	
 
    	
 

means   the European Medicines Agency and any successor thereto;

 
    
	
 

Enforcement
    	
 
    	
 

is   defined in Clause 12.6.3;

 
    
	
 

EU
    	
 
    	
 

means   the member states of the European Union and Switzerland, or any successor   entity thereto performing similar functions;

 
    
	
 

Exclusive License
    	
 
    	
 

is   defined in Clause 8.2.1;

 
    
	
 

FDA
    	
 
    	
 

means   the US Food and Drug Administration, or any successor entity thereto   performing similar functions;

 
    
	
 

Field
    	
 
    	
 

means   any and all uses, including human and animal therapeutic, palliative,   prophylactic and diagnostic uses, of a product or therapy that comprises T   cells bearing a membrane bound exogenous TCR, therefore expressly excluding   any product or therapy that comprises soluble TCRs;  

 
    
	
 

Foreground IP
    	
 
    	
 

means   any Intellectual Property Rights created in the performance of this Agreement   including under any POC Plan or Co-Development Plan;

 
    
	
 

FTE
    	
 
    	
 

means   the equivalent of the work of one employee full time (equivalent to a twelve   month period of work), including experimental laboratory work, recording and   writing up results, reviewing literature and references, holding scientific   discussions, managing and leading scientific staff, conducting development   activities, carrying out related management duties, and training (including   health and safety training);  

 
    
	
 

GMP
    	
 
    	
 

means   all current Good Manufacturing Practices applicable to biopharmaceuticals in   the US and/or in the European Union, as are in effect from time to time   during the Term and in each case as applicable to the activities being   carried out under this Agreement;  
    

 

Page 8

 

Execution Copy

 

	
 

GLP
    	
 
    	
 

means   all applicable current Good Laboratory Practice standards for laboratory   activities for pharmaceuticals, as set forth in the FDA’s Good Laboratory   Practice regulations as defined in 21 C.F.R. Part 58 and/or the Good   Laboratory Practice principles of the Organization for Economic Co-Operation   and Development (“OECD”), and such standards of good laboratory practice as   are required by the European Union and other organizations and governmental   agencies in countries in which the relevant activity under this Agreement is   being performed;
    
	
 

GxP
    	
 
    	
 

means   any of the following as applicable to this Agreement: GLP and GMP;
    
	
 

HLA
    	
 
    	
 

means   a human leukocyte antigen; 
    
	
 

HLA Type
    	
 
    	
 

means   a human leukocyte antigen type;
    
	
 

iCasp9 Switch
    	
 
    	
 

means   Bellicum’s proprietary, inducible iCasp9 safety switch ***

 

                                                                                  that has a binding site which is activated with rimiducid to fully or   partially eliminate the cells; 
    
	
 

iCasp9 Technology
    	
 
    	
 

means   any technology utilizing a small molecule to dimerize caspase-9 molecule(s);
    
	
 

iMC Switch
    	
 
    	
 

means   Bellicum’s proprietary, inducible iMC safety switch ***

 

                                                                                  that has a binding site which is activated with rimiducid to fully or   partially eliminate the cells;
    
	
 

iMC Technology
    	
 
    	
 

means   any technology utilizing a small molecule to dimerize co-stimulatory   molecule(s);
    
	
 

IND
    	
 
    	
 

means   an investigational new drug application filed with the FDA pursuant to 21 CFR   Part 312 before the commencement of Clinical Trials of a Therapy, or any   comparable or equivalent filing (including any Clinical Trial Authorization   filed in the EU) with any relevant regulatory authority in any other   jurisdiction required before the commencement of any Clinical Trial in such   jurisdiction;
    
	
 

Indemnitee
    	
 
    	
 

is   defined in Clause 16.3;
    
	
 

Indemnitor
    	
 
    	
 

is   defined in Clause 16.3;
    
	
 

Infringement 
    	
 
    	
 

is   defined in Clause 12.6.1;
    
	
 

Initial Success Criteria
    	
 
    	
 

means   the criteria mutually agreed between the Parties in writing, the fulfillment   of which indicate initial success in POC Phase;
    

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 9

 

Execution Copy

 

	
 

Intellectual Property Rights
    	
 
    	
 

means   Patents, rights to discoveries, inventions, copyrights and related rights,   trademarks, trade names and domain names, rights in designs, rights in   computer software, database rights, rights in confidential information   (including know-how) and any other intellectual property rights, in each case   whether registered or unregistered and including all applications (or rights   to apply) for, and renewals or extensions of, such rights and all similar or   equivalent rights or forms of protection which subsist or will subsist now or   in the future in any part of the world; 

 
    
	
 

JCC
    	
 
    	
 

is   defined in Clause 2.4.1;

 
    
	
 

JDC
    	
 
    	
 

is   defined in Clause 2.3.1;

 
    
	
 

Joint IP
    	
 
    	
 

is   defined in Clause 12.1.2;

 
    
	
 

Joint Selected Candidate
    	
 
    	
 

means   a Candidate selected by the JDC for pre-clinical development in accordance   with Clause 5.1.5, and includes any Candidate that is mutually agreed to   replace any previously designated Joint Selected Candidate in accordance with   Clause 5.1.5;

 
    
	
 

JPT
    	
 
    	
 

is   defined in Clause 2.5;

 
    
	
 

JSC 
    	
 
    	
 

is   defined in Clause 2.2.1;

 
    
	
 

Licensed Intellectual Property
    	
 
    	
 

means,   as applicable, the Bellicum Licensed Know-How, Bellicum Licensed Patents,   Adaptimmune Licensed Know-How and Adaptimmune Licensed Patents;

 
    
	
 

Loss   or Losses
    	
 
    	
 

is   defined in Clause 16.1;

 
    
	
 

MAA   or Marketing Approval Application
    	
 
    	
 

means   a BLA, sBLA, NDA, sNDA and any equivalent thereof in the US or any other   country or jurisdiction.  As used   herein: “BLA” means a Biologics License   Application and amendments thereto filed pursuant to the requirements of the   FDA, as defined in 21 C.F.R. § 600 et seq., for FDA approval of a Therapy and   “sBLA” means a supplemental BLA; and “NDA” means a New Drug Application and amendments thereto   filed pursuant to the requirements of the FDA, as defined in 21 C.F.R. § 314   et seq., for FDA approval of a Therapy and “sNDA”   means a supplemental NDA;  

 
    
	
 

Non-Publishing Party
    	
 
    	
 

is   defined in Clause 14.4.1;

 
    
	
 

Opt-Out Candidate/ Therapy
    	
 
    	
 

Is   defined in Clause 17.2.1;

 
    
	
 

Party or   Parties
    	
 
    	
 

is   defined in the Preamble;
    

 

Page 10

 

Execution Copy

 

	
 

Patent(s)
    	
 
    	
 

means   any and all patents and patent applications and any patents issuing therefrom   or claiming priority therefrom, worldwide, together with any extensions   (including patent term extensions and supplementary protection certificates)   and renewals thereof, reissues, reexaminations, substitutions, confirmation   patents, registration patents, invention certificates, patents of addition,   renewals, divisionals, continuations, and continuations-in-part of any of the   foregoing;

 
    
	
 

Person
    	
 
    	
 

means   an individual, sole proprietorship, partnership, limited partnership, limited   liability partnership, corporation, limited liability company, business   trust, joint stock company, trust, unincorporated association, joint venture   or other similar entity or organization;

 
    
	
 

Phase I Clinical Trial
    	
 
    	
 

means   a human clinical trial, the principal purpose of which is preliminary   determination of safety of a Therapy in healthy individuals or patients as   described in 21 C.F.R. §312.21(a), or similar clinical study in a country   other than the US;

 
    
	
 

Phase II Clinical Trial
    	
 
    	
 

means   a human clinical trial, the principal purpose of which is a preliminary   determination of efficacy of a Therapy in patients being studied as described   in 21 C.F.R. §312.21(b), or similar clinical study in a country other than   the US; provided, that, to the extent there is any ambiguity as to whether a   given human clinical trial constitutes a Phase II Clinical Trial or a “Phase   I(b)” clinical trial, such trial shall be a Phase II Clinical Trial for the   purposes of this Agreement; 

 
    
	
 

Phase III Clinical Trial
    	
 
    	
 

means   a human clinical trial, the principal purpose of which is to demonstrate   clinically and statistically the efficacy and safety of a Therapy for one or   more indications in order to obtain Marketing Approval of such Therapy for   such indication(s), as further defined in 21 C.F.R. §312.21(c) or a   similar clinical study in a country other than the US; provided, that, to the   extent there is any ambiguity as to whether a given human clinical trial   constitutes a Phase III Clinical Trial or a “Phase II(b)” clinical trial,   such trial shall be a Phase III Clinical Trial for the purposes of this   Agreement;  
    

 

 

 

 

 

 

 

 

 

 

 

Page 11

 

Execution Copy

 

	
Phase IV   Clinical Trial
    	
 
    	
means a human   clinical trial, or other test or study, of a Therapy that is   (a) commenced after receipt of the initial Regulatory Approval for such   Therapy in the country for which such clinical trial is being conducted, and   that is conducted within the parameters of the Regulatory Approval for such   Therapy (and which may include investigator sponsored clinical trials),   including a clinical trial conducted due to the request or requirement of a   Regulatory Authority or as a condition of a previously granted Regulatory   Approval, but shall not include any Phase III Clinical Trial (including any   “Phase III(b)” trial), (b) an investigator sponsored clinical trial   approved by the JCC that does not fall within the parameters of a Therapy’s   Regulatory Approval, or (c) any REMS (Risk Evaluation and Mitigation   Strategy)/RMP (Risk Management Plan) related study of a Therapy in a country   in the Territory after Regulatory Approval of such Therapy has been obtained   from an appropriate Regulatory Authority in such country. Phase IV Clinical   Trials may include trials or studies conducted in support of post-Regulatory   Approval exploitation of such Therapy (for example only,   pricing/reimbursement, epidemiological studies, modeling and pharmacoeconomic   studies, post-marketing surveillance studies and health economics studies);
    
	
 
    	
 
    	
 
    
	
POC Criteria
    	
 
    	
means the criteria   mutually agreed between the Parties in writing the fulfillment of which will   constitute successful Completion of the POC Phase;
    
	
 
    	
 
    	
 
    
	
POC Phase
    	
 
    	
means the initial   proof of concept phase performed in accordance with the POC Plan;
    
	
 
    	
 
    	
 
    
	
POC Plan
    	
 
    	
means the plan for   the POC Phase as set out in Exhibit 1 as amended from time to time in   accordance with this Agreement;
    
	
 
    	
 
    	
 
    
	
POC Target
    	
 
    	
means the Target that   is the subject of the POC Plan;
    
	
 
    	
 
    	
 
    
	
Prosecute or Prosecute and Maintain or   Prosecution and Maintenance
    	
 
    	
means, with respect   to a Patent, all activities associated with the preparation, filing,   prosecution and maintenance of such Patent , as well as activities associated   with re-examinations, reissues, applications for patent term adjustments and   extensions, supplementary protection certificates and the like with respect   to that Patent, together with the conduct of interferences, derivation   proceedings, pre- and post-grant proceedings, the defense of oppositions and   other similar proceedings with respect to that Patent;
    
	
 
    	
 
    	
 
    
	
Prosecuting Party
    	
 
    	
means the Party   responsible for Prosecution under Clauses 12.2 and 12.3 of this Agreement;
    
	
 
    	
 
    	
 
    
	
Publishing Party
    	
 
    	
is defined in Clause   14.4.1;
    
	
 
    	
 
    	
 
    
	
Quality Agreement
    	
 
    	
means, as relevant in   the context of this Agreement, a written agreement that documents the responsibilities   and quality expectations between (a) Bellicum and any internal or   external supplier, contract manufacturer or service provider (including, to   the extent applicable, Adaptimmune) or (b)  Adaptimmune and any internal   or external supplier, contract manufacturer or service provider (including,   to the extent applicable, Bellicum);
    

 

Page 12

 

Execution Copy

 

	
Regulatory Approval
    	
 
    	
means the technical,   medical and scientific licenses, registrations, authorizations and approvals   required for marketing or use of a Therapy (including approvals of,   BLAs, IND applications, pre- and post- approvals, and labeling approvals   and any supplements and amendments to any of such approvals) of any national,   supra-national, regional, state or local regulatory agency, department,   bureau, commission, council or other governmental entity, necessary for the   development, manufacture, distribution, marketing, promotion, offer for sale,   use, import, export or sale of a Therapy in a regulatory jurisdiction. In the   US, Regulatory Approval means approval of any Marketing Approval Application   or equivalent by the FDA. Regulatory Approval shall include obtaining any   pricing reimbursement or other pricing approval requirement;
    
	
 
    	
 
    	
 
    
	
Regulatory Authority
    	
 
    	
means the FDA, EMA,   any other regulatory authority or body with regulation or governance over the   performance of any part of the activities under this Agreement;
    
	
 
    	
 
    	
 
    
	
Release
    	
 
    	
is defined in Clause   14.1;
    
	
 
    	
 
    	
 
    
	
Reserved Activities
    	
 
    	
is defined in Clause   5.6;
    
	
 
    	
 
    	
 
    
	
Rules 
    	
 
    	
is defined in Clause   18.2.1;
    
	
 
    	
 
    	
 
    
	
SAE
    	
 
    	
means a serious   adverse effect resulting from any Clinical Trial or administration of a   Therapy;
    
	
 
    	
 
    	
 
    
	
Selected Target
    	
 
    	
is defined in Clause   4.1.2;
    
	
 
    	
 
    	
 
    
	
Sublicensee
    	
 
    	
means a Third Party   or Affiliate who has been granted a sublicense under any license under this   Agreement;
    
	
 
    	
 
    	
 
    
	
SUSAR
    	
 
    	
means a suspected   unexpected serious adverse reaction resulting from any Clinical Trial or   administration of any Therapy to a human being;
    
	
 
    	
 
    	
 
    
	
Target
    	
 
    	
means the protein   from which a peptide antigen is derived to form an HLA-peptide antigen   epitope (including all HLA Types);
    
	
 
    	
 
    	
 
    
	
Target List
    	
 
    	
is defined in Clause   3.1.3;
    
	
 
    	
 
    	
 
    
	
TCR
    	
 
    	
means T-cell   receptor;
    
	
 
    	
 
    	
 
    
	
Term
    	
 
    	
is defined in Clause   17.1;
    
	
 
    	
 
    	
 
    
	
Therapy
    	
 
    	
means a therapy   (including T cell products and the production and/or delivery of T cells to   human or animal subjects) utilising the genetic engineering of T-cells to   express an affinity-optimized membrane bound exogenous TCR, and comprising a   Joint Selected Candidate;
    

 

 

Page 13

 

Execution Copy

 

	
Third Party
    	
 
    	
means any entity   other than Adaptimmune or Bellicum or an Affiliate of either of them;
    
	
 
    	
 
    	
 
    
	
Third Party Claims
    	
 
    	
is defined in Clause   16.1;
    
	
 
    	
 
    	
 
    
	
Third Party Infringement Claim
    	
 
    	
is defined in Clause   12.7.1;
    
	
 
    	
 
    	
 
    
	
Title 11
    	
 
    	
is defined in Clause   17.4;
    
	
 
    	
 
    	
 
    
	
US
    	
 
    	
means the United   States of America and its territories and possessions;
    
	
 
    	
 
    	
 
    
	
Valid Claim
    	
 
    	
means, with respect   to a particular country, a claim in an unexpired Patent within the Licensed   Intellectual Property in such country that has not lapsed or been disclaimed,   revoked, held unenforceable, unpatentable or invalid by a decision of a court   or other governmental agency of competent jurisdiction, unappealable or   unappealed within the time allowed for appeal, and that has not been admitted   to be invalid or unenforceable through re-examination, re-issue, disclaimer   or otherwise, or lost in an interference proceeding; and
    
	
 
    	
 
    	
 
    
	
VAT
    	
 
    	
means, in the EU,   value added tax calculated in accordance with Council Directive 2006/112/EC   and, in a jurisdiction outside the EU, any equivalent tax.
    

 

 

 

ARTICLE 2            GOVERNANCE

 

 

2.1        Governance Generally.  Up to three (3) voting committees (the JSC, JDC and JCC) may be formed, and two non-voting teams (one for the Adaptimmune Candidate and one for the Bellicum Candidate; each, a JPT) will be set up, to govern and act as reporting bodies during the Term.

 

2.2        Joint Steering Committee.

 

2.2.1          Formation and Composition.  As soon as reasonably possible and in any event within ***                after the Effective Date, Adaptimmune and Bellicum shall establish a joint steering committee (the “JSC”) to monitor and coordinate the communication and activities of both Parties under this Agreement.  The JSC shall be composed of at least ***    but no more than ***           representatives designated by each Party and in each case an equal number of representatives from each Party.  Representatives must be appropriate for the tasks then being undertaken and the stage of development or commercialisation applicable, in terms of their seniority, decision-making authority, availability, function in their respective organizations, training and experience.  Each Party may replace its JSC representatives from time to time upon written notice to the other Party; provided, however, if a Party’s JSC representative is unable to attend a JSC meeting, such Party may designate an alternate to attend such JSC meeting by providing notification in writing to the other Party’s Alliance Manager and following provision of such written notification the alternate will be entitled to perform the functions of such JSC representative at such JSC meeting.  The Alliance Managers may attend meetings of the JSC but shall have no right to vote on any decisions of the JSC.

 

2.2.2          JSC Responsibilities.  In addition to its overall responsibility for monitoring the

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

 

Page 14

 

Execution Copy

 

activities of the Parties under this Agreement, the JSC shall, in particular:

 

(a)    work to resolve, through good faith discussions, any dispute, controversy or claim between the Parties arising during the performance of any POC Plan or Co-Development Plan and related to the matters under the authority of the JSC;

 

(b)    review and, pending or after consultation of a Party’s JSC representatives with its own management team regarding any material changes in an existing allocation, approve the allocation of each Party’s resources and efforts necessary to perform the POC Plan or Co-Development Plan to the extent not agreed by the applicable JPT;

 

(c)    review and approve any material amendments to any POC Plan or Co-Development Plan proposed by the JDC or the applicable JPT;

 

(d)    review and approve any criteria (and amendments to such criteria) for development of any Candidate including criteria required for any Candidate to proceed to the next phase of development;

 

(e)    oversee the implementation of the POC Phase;

 

(f)    oversee the implementation of the Co-Development Plan(s);

 

(g)    ensure that each Party is regularly informed regarding all material activities performed by the other Party under any Co-Development Plan(s), and all material re-allocations under and/or amendments to any POC Plan or Co-Development Plan;

 

(h)    perform such other functions as may be agreed to by the Parties in writing (in each case subject to Clause 2.3) or as specified in this Agreement.

 

2.2.3          Decision making for JSC.  Each Party will discuss and attempt to resolve any potential or evolving disagreement related to a POC Plan or Co-Development Plan through its respective Alliance Managers and/or the applicable JPT before it is brought before the JSC for resolution.  With respect to the responsibilities of the JSC, each Party shall have one vote on all matters brought before the JSC.  The JSC shall operate as to matters within its responsibility by unanimous vote.  ***

 

.  If the JSC is unable to achieve a unanimous vote within ***              of any matter being brought before the JSC, then such matter may be referred in writing to the Alliance Managers under Clause 18.1 at either Party’s discretion; provided, that, for clarity, the arbitration provisions in Clause 18 shall not apply and, unless otherwise provided explicitly in this Agreement, neither Party shall have final decision-making authority with respect to such matter.  Unless otherwise provided explicitly in this Agreement and subject to Clause 2.2.4, where any decision regarding such disagreement is not made within a period of ***        of such referral to the Party’s Alliance Managers in accordance with Clause 18.1 then:

(i)     In the case of a decision ***

 

decision-making authority;

 

(ii)    in the case of a decision ***

decision-making authority;

 

(iii)   in the case of a decision ***

 

decision-making authority;

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

 

Page 15

 

Execution Copy

 

(iv)   in the case of a decision ***

 

decision-making authority.

 

2.2.4          Any JSC decisions, any decisions of the Party’s senior managers under Clause 2.2.3, and any decision-making authority exercised by a Party under Clause 2.2.3, are subject to the following: (i) neither the JSC, the senior managers nor either Party shall have the unilateral or overriding authority to amend or modify, or waive a Party’s own compliance with, this Agreement including in relation to the scope or terms of any license to Intellectual Property Rights; and (ii) ***

 

 

 

             ; and (iii) neither the JSC, the senior managers nor either Party will have the unilateral or overriding authority to amend any POC Plan or Co-Development Plan in any way which would introduce additional safety or ethical concerns in relation to any Clinical Trial; and (iv) neither the JSC, the senior managers nor either Party will have the unilateral or overriding authority to require the other Party to carry out any act which it is not already required to perform under any Co-Development Plan.

 

2.3        Joint Development Committee.

 

2.3.1          Formation and Composition.  As soon as reasonably possible after ***                    , Adaptimmune and Bellicum shall establish a joint development committee (the “JDC”) to monitor and coordinate the communication and activities of both Parties under each Co-Development Plan.  The JDC shall be composed of at least ***      but no more than ***       representatives designated by each Party and in each case an equal number of representatives from each Party.  Representatives must be appropriate for the tasks then being undertaken and the applicable stage of research, pre-clinical development or clinical development, in terms of their seniority, decision-making authority, availability, function in their respective organisations, training and experience.   Each Party may replace its JDC representatives from time to time upon written notice to the Alliance Manager of the other Party; provided, however, if a Party’s JDC representative is unable to attend a JDC meeting, such Party may designate an alternate to attend such JDC meeting by providing notification in writing to the other Party’s Alliance Manager and following provision of such written notification the alternate will be entitled to perform the functions of such JDC representative at such JDC meeting.  The Alliance Managers may attend meetings of the JDC but shall have no right to vote on any decisions of the JDC.

 

2.3.2          JDC Responsibilities for a Co-Development Plan.  The JDC shall have overall responsibility for monitoring the activities of the Parties under this Agreement during co-development (including Clinical Trials) of any Joint Selected Candidates or Therapies containing any Joint Selected Candidates.  The JDC shall, in particular:

 

(a)              work to resolve, through good faith discussions, any dispute, controversy or claim related to the matters under the authority of the JDC;

 

(b)             approve each initial POC Plan and Co-Development Plan and recommend to the JSC any material changes to the POC Plan or a Co-Development Plan, including updating the POC Plan or a Co-Development Plan;

 

(c)              monitor performance of the POC Plan or any Co-Development Plan;

 

(d)             review any data arising from any Clinical Trials being conducted under a Co-Development Plan, including any SUSARs and SAEs;

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 16

 

Execution Copy

 

(e)              discuss any material regulatory submissions or material correspondence related to Therapies containing a Joint Selected Candidate;

 

(f)                discuss protocols for any Clinical Trial of a Therapy utilising a Joint Selected Candidate, including patient numbers, location numbers, Clinical Trial site and any modifications or amendments to such protocols;

 

(g)             receive reports on any investigation or audit carried out by either Party or by any Regulatory Authority, to the extent such investigation or audit is initiated in connection with any Joint Selected Candidate or any Therapy utilising a Joint Selected Candidate or any facility used for the manufacture of such Joint Selected Candidate or such Therapy, or any Clinical Trial involving such Joint Selected Candidate or such Therapy; and

 

(h)              report to the Parties on the progress of any corrections to any identified non-compliances with Applicable Laws to the extent relevant to any Co-Development Plan.

 

2.3.3          JDC Decision Making.

 

(a)              With respect to the responsibilities of the JDC, each Party shall have one vote on all matters brought before the JDC and the JDC shall operate by unanimous vote.  If the JDC is unable to achieve a unanimous vote within   ***          of any matter being brought before the JDC, then such matter may be referred in writing to the JSC at either Party’s discretion.  Each Party shall make decisions within the JDC in good faith and on a timely basis; provided that any JDC decisions shall be subject to the conditions applied to JSC decisions, as set forth in Clause 2.2.4, and to Clause 5.7.

 

2.4        Joint Commercialisation Committee.

 

2.4.1          Formation and Composition.  In the event that a Phase III Clinical Trial for a Therapy utilising a Joint Selected Candidate is initiated, as soon as reasonably practicable after ***

 

                                                                                                , Adaptimmune and Bellicum shall establish a joint commercialisation committee (the “JCC”).  As of the Effective Date, the Parties anticipate that the JCC will monitor and coordinate the communication and activities of both Parties relating to the further supply, manufacture and commercialisation of such Therapy utilising a Joint Selected Candidate, and any subsequent Therapies containing a Joint Selected Candidate that enter Phase III Clinical Trials.  Unless otherwise set forth in a Co-Commercialisation Agreement executed by the Parties, the JCC shall function in accordance with the remainder of this Clause 2.4 (for clarity, to the extent this Clause 2.4 is inconsistent with the Co-Commercialisation Agreement, the Co-Commercialisation Agreement shall control).  The JCC shall be composed of at least ***      but no more than ***           representatives designated by each Party and in each case an equal number of representatives from each Party.  Representatives must be appropriate for the tasks then being undertaken and the stage of development and commercialisation, in terms of their seniority, decision-making authority, availability, function in their respective organisations, training and experience.  Each Party may replace its JCC representatives from time to time upon written notice to the Alliance Manager of the other Party; provided, however, if a Party’s JCC representative is unable to attend a JCC meeting, such Party may designate an alternate to attend such JCC meeting by providing notification in writing to the other Party’s Alliance Manager and following provision of such written notification the alternate will be entitled to perform the functions of such JCC representative at such JCC meeting.  The Alliance Managers may attend meetings of the JCC but shall have no right to vote on any decisions of the JCC.

 

2.4.2          JCC Responsibilities.  In addition to its overall responsibility for monitoring the

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 17

 

Execution Copy

 

activities of the Parties under this Agreement with respect to Therapies containing a Joint Selected Candidate, following initiation of Phase III Clinical Trials thereof and during the supply, manufacture and commercialisation of any Therapy utilising a Joint Selected Candidate resulting from such Phase III Clinical Trials, the JCC shall, in particular, with respect to each such Therapy utilising such Joint Selected Candidates):

 

(a)              review and approve an initial worldwide commercialisation plan;

 

(b)             review and approve changes to the then-current worldwide commercialisation plan;

 

(c)              receive reports regarding material submissions to Regulatory Authorities pertaining to any Therapy utilising a Joint Selected Candidate, as needed;

 

(d)             review manufacturing and commercial supply plans pertaining to any Therapy utilising a Joint Selected Candidate;

 

(e)              review and, to the extent permitted by Applicable Laws, approve any applicable policies with respect to pricing reimbursement required for sale and supply of any Therapy utilising a Joint Selected Candidate;

 

(f)                subject to the Co-Commercialisation Agreement, discuss and agree to mechanisms for co-promotion of any Therapy utilising a Joint Selected Candidate in those specific countries where co-promotion will occur in accordance with the Co-Commercialisation Agreement;

 

(g)             discuss pre-marketing and marketing activities pertaining to any Therapy utilising such Joint Selected Candidate;

 

(h)              discuss launch of any Therapy utilising such Joint Selected Candidate;

 

(i)                  receive from each Party reports on Net Sales of any Therapy utilising such Joint Selected Candidate; and

 

(j)                  perform such other responsibilities as are assigned to the JCC in this Agreement or in the Co-Commercialisation Agreement.

 

2.4.3          Decision making for JCC.  Each Party will discuss and attempt to resolve any potential or evolving disagreement related to commercialisation of any Therapy utilising a Joint Selected Candidate through its Alliance Managers before it is brought before the JCC for resolution.  With respect to the responsibilities of the JCC, each Party shall have one vote on all matters brought before the JCC.  Each JCC shall operate as to matters within its responsibility by unanimous vote.  Each Party shall make decisions in good faith and on a timely basis, provided that any JCC decisions shall be subject to the conditions applied to JSC decisions, as set forth in Clause 2.2.4.  If the JCC is unable to achieve a unanimous vote within     ***                        of any matter being brought before the JCC, then such matter may be referred to Alliance Managers under Clause 18.1 at either Party’s discretion.  Where any matter or dispute remains unresolved for a further ***                                            after such referral, the matter or dispute may be referred in writing to the JSC at either Party’s discretion.

 

2.5        JPT.  The Parties shall also set-up up joint project teams for each Party’s Candidates (each, a “JPT”) as and when required, the first to be set up as soon as practicable after ***

                                             .  Each JPT shall be specific to a Selected Target and to the corresponding Co-Development Plan, save that the Parties may nominate the same representatives to be present on more than one JPT.  The JPT for each Selected Target and corresponding Co-Development Plan shall be responsible for governing the day to day performance of the relevant Co-Development Plan including ensuring that activities thereunder are performed in accordance with the approved timelines and budgets and, as

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 18

 

Execution Copy

 

relevant, agreeing to any non-material changes to such Co-Development Plan and for producing the final report and recommendations on completion of the relevant Co-Development Plan.  The Parties shall each nominate up to ***             representatives (and in each case an equal number of representatives) to represent it on each JPT.  Each Party may replace its JPT representatives from time to time upon written notice to the other Party; provided, however, if a Party’s JPT representative is unable to attend a JPT meeting, such Party may designate an alternate to attend such JPT meeting by providing notification in writing to the other Party’s representatives on such JPT and following provision of such written notification the alternate will be entitled to perform the functions of such JPT representative at such JPT meeting.  The JPT shall report regularly to the JDC.  The final report and recommendations following completion of any phase of a Co-Development Plan shall be provided to the JDC within a maximum of ***                  following completion of the relevant phase and the Parties shall provide all support to the applicable JPT as may be reasonably necessary to meet such timelines.  The JPT in relation to any Selected Target shall automatically cease to exist on completion or termination of the Co-Development Plan for such Selected Target.

 

2.6        Ad-hoc Committees.  The JSC, JDC or JCC, as appropriate, may also authorise the setting up of sub-committees in relation to particular or specific aspects of any Co-Development Plan or other performance of this Agreement, for example CMC.  Such sub-committees shall act in the same way as the JPT and regularly report into the relevant JSC, JDC or JCC.

 

2.7        Meetings.

 

2.7.1          JSC Meetings.  During the POC Phase and Co-Development Phase, the JSC shall meet at least ***                         at Adaptimmune’s facilities in Abingdon, Oxfordshire, England or at Bellicum’s facilities in Houston, TX, USA, or via teleconference or otherwise, in each case as agreed by the JSC.  During the Co-Commercialisation Phase, the JSC shall meet at least ***                     at Adaptimmune’s facilities in Abingdon, Oxfordshire, England or at Bellicum’s facilities in Houston, TX, USA, or via teleconference or otherwise, in each case as agreed by the JSC.  Where possible, meetings will be held by telephone conference with only ***       meetings per ***        being face to face and at either Adaptimmune’s or Bellicum’s facility, unless the Parties decide otherwise.  Where necessary, for example to resolve any dispute or to agree upon changes to any POC Plan or Co-Development Plan, the JSC shall meet more frequently.

 

2.7.2          JCC and JDC Meetings.  The JCC or JDC shall meet at least ***                at Adaptimmune’s facilities in Abingdon, Oxfordshire, England or at Bellicum’s facilities in Houston, TX, USA, or via teleconference or otherwise, in each case as agreed by the JDC or JCC.  Where possible, meetings will be held by telephone conference with only ***     meetings per ***          being face to face and at either Adaptimmune’s or Bellicum’s facility, unless the Parties decide otherwise.  Where necessary, for example to resolve any dispute or to agree upon changes to any Co-Development Plan, as applicable, the JDC shall meet more frequently.  The JCC shall meet more regularly where reasonably necessary.

 

2.7.3          Meeting Agendas and Minutes.  Not later than ***                  after each of the JSC, JDC, JCC and/or JPT, as applicable, are formed, the respective committees shall each hold an organizational meeting by videoconference or teleconference to establish their respective operating procedures, including establishment of agendas, and preparation and approvals of minutes.  The Parties shall alternate responsibility for taking the meeting minutes; provided that Bellicum shall be responsible for taking the meeting minutes at the first meeting of each committee or team.  Meeting minutes shall be sent to both Parties promptly (and in any event within ***                      ) after a meeting for review, comment and approval by each Party.  Where minutes are not approved by both Parties, the dispute shall be resolved at the next committee or team meeting.  A decision that is made at any meeting shall be recorded in meeting minutes.

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 19

 

Execution Copy

 

2.7.4          General.  Employees of each Party, other than its nominated committee or team representatives, may attend meetings of the JSC, JDC, JCC or JPT as applicable, as non-voting participants.  A Party’s consultants and advisors involved in a POC Plan or Co-Development Plan may attend meetings of the JSC, JDC, JCC or JPT as non-voting observers; provided that such consultants and advisors are under obligations of confidentiality and non-use applicable to the Confidential Information of the other Party as required by Clause 13.3(e).  Each Party shall be responsible for all of its own expenses of participating in the JSC, JDC, JCC or JPT.  In addition each Party may nominate the same individuals as representatives on multiple committees.

 

2.8        Dissolution.

 

2.8.1          Dissolution of JSC.  The JSC shall dissolve on termination of this Agreement or by mutual agreement of the Parties.

 

2.8.2          Dissolution of JDC.  The JDC shall automatically dissolve on completion of all Co-Development Plans or, if earlier, termination of this Agreement.

 

2.8.3          Dissolution of JCC.  The JCC shall continue for so long as there is any Joint Selected Candidate (or Therapies containing such Joint Selected Candidates) undergoing Phase III Clinical Trials and/or being commercialized hereunder and, at such time as there are no Joint Selected Candidates (or Therapies containing such Joint Selected Candidates) undergoing Phase III Clinical Trials and/or being commercialized hereunder, the JCC will have no further responsibilities or authority under this Agreement and the JCC will be deemed dissolved by the Parties.  The JCC will also be deemed dissolved by the Parties if all Co-Development Plans are terminated or if all Therapies resulting from any Co-Development Agreement fail to obtain at least one Regulatory Approval in at least one country.

 

2.8.4          Dissolution of JPT.  Each JPT will be deemed dissolved by the Parties on completion or termination of the applicable Co-Development Plan.

 

2.8.5          Dissolution of Ad-hoc sub-committees.  Each Ad-hoc sub-committee will be deemed dissolved by the Parties on completion of the relevant activity in relation to which the sub-committee was set up.

 

2.9        Alliance Managers.  Within ***                      of the Effective Date, each Party shall appoint an Alliance Manager to be the principal point of contact for communications under this Agreement.  The Alliance Managers shall facilitate the flow of information and collaboration between the Parties and assist in the resolution of potential and pending issues and potential disputes in a timely manner to enable the JSC, JDC, JCC and JPT, in each case for so long as such committee(s) are in existence, and the Parties to reach consensus and avert escalation of such issues or potential disputes.  Either Party may replace its Alliance Manager at any time upon prior written notice (including by email) to the other Party’s Alliance Manager.  Each Party shall ensure that its Alliance Manager is capable of performing the obligations required of an Alliance Manager under this Agreement.

 

ARTICLE 3            POC PHASE

 

3.1        Commencement of POC Phase

 

3.1.1          Within ***                     of the Effective Date (or such longer time as mutually agreed by the Parties in writing), the Parties shall commence activities in furtherance of the POC Plan.  The POC Plan will describe with specificity ***                   .  As of ***

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 20

 

Execution Copy

 

                                                                                                                                                               . Each Party will perform a battery of tests during the POC Phase, as set forth in greater detail in the POC Plan, with the intention that the Parties will conduct mirrored testing where practicable.

 

3.1.2          Adaptimmune and Bellicum shall use Commercially Reasonable Efforts to perform the activities assigned to them under the POC Plan in accordance with the agreed timescales, including making resources available as and when required and supplying any product, equipment or materials as and when required for performance of the POC Plan.  Each Party shall reasonably assist the other Party to facilitate the performance of the POC Plan.  Each Party is responsible for the costs incurred by it in performing activities assigned to it under the POC Plan.

 

3.1.3          As part of the performance of the POC Plan, and with respect to Targets other than the POC Target, the Parties will jointly identify Target criteria that will support the Parties’ development and commercialization of viable Candidates.  On achievement of Initial Success Criteria for the POC Phase and following mutual agreement to the related Target criteria identified in accordance with this Clause 3.1.3, Adaptimmune will provide to Bellicum a list of at least *** Targets (“Target List”) and supporting validation information, with the mutually desired objective that such Targets on the Target List will meet the agreed Target criteria.  Bellicum understands that the Targets on the Target List provided by Adaptimmune will be provided from its internal Target projects and that not all provided Targets will be fully validated; however, as part of Adaptimmune’s identification and presentation of the Target List, the Parties will reach a consensus as to what constitutes “validation” of a Target, and then Bellicum will have a right to review all of Adaptimmune’s available documentation for each such Target, including but not limited to information relevant to Target validation status.  Adaptimmune will select the Targets on the Target List for provision to Bellicum in good faith.  The Parties will work together to agree upon which Targets from the Target List may be selected for further validation and development of Candidates during any subsequent Co-Development Phase.

 

3.1.4          Subject to the limitations set forth in Clause 2.2.4 (as applied to the JDC), and subject to Clauses 2.3.2(b) and 5.7, the JDC may amend in writing the POC Plan from time to time as the POC Phase progresses and results become available.

 

3.2        Subcontractors.  A Party may subcontract portions of its work under the POC Plan to (i) any Affiliate or (ii) Third Parties; provided, that such subcontract is in writing and is consistent with the terms and conditions of this Agreement including the confidentiality provisions of Article 13 and any rights granted to such subcontractor are restricted to only those rights necessary for performance by such subcontractor of the portions of work on behalf of such subcontracting Party.  Such subcontracting Party will remain fully responsible (at its cost) for all acts or omissions of any subcontractor it appoints (including any acts or omissions which result in a breach of the terms of this Agreement) and shall ensure that each subcontractor complies with the terms and conditions of this Agreement.

 

3.3        Progress Reports.  Each Party shall keep the other Party (through the JPT and JDC) informed of its activities, results and accomplishments under the POC Plan and shall provide to the other Party’s representatives on the JDC regular written summary updates (for example Word or Powerpoint documents) at each JDC meeting.  All such reports, information and data provided by a Party shall be considered the providing Party’s Confidential Information.

 

3.4        Completion of POC Phase.  Completion of the POC Phase shall occur on ***

                                                                                                                 under the POC Plan, or upon a JDC decision that no further activities are required (“POC Phase Completion”).  Where POC Phase Completion has not been met within a period of ***                  from the estimated date of POC Phase Completion in accordance with the POC Plan, or where either Party believes at any time on a reasonable and scientifically supported basis that the Initial Success Criteria or POC Criteria will not be met, the Parties (whether directly or through a

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 21

 

Execution Copy

 

meeting of the JSC or JDC) shall discuss and mutually agree whether any further proof of concept work should be conducted (for example, in relation to an alternative Candidate or an alternative Target ), or whether the POC Plan should terminate.  Any termination of the POC Plan shall result in termination of this Agreement (and in this event, Clause 17.7 shall apply), and there shall be no obligation on either Party to carry out any further proof of concept work on any alternative Candidate or Target.

 

3.5        Progression to Co-Development Phase.  Within ***              of the date of POC Phase Completion, Adaptimmune shall provide to Bellicum ***

 

                                      .        The Adaptimmune ***                                                     will be reviewed by the JDC and JSC, and the Parties will discuss in good faith and will mutually agree whether or not to proceed to the Co-Development Phase; provided that neither Party is required to proceed to the Co-Development Phase under discussion.  The date of such mutual agreement of the Parties to proceed to the Co-Development Phase, as evidenced by minutes of the applicable JSC meeting, shall constitute “Co-Development Start”.  Where the JSC does not and/or the Parties do not agree to proceed to the Co-Development Phase within ***                                    of provision of such Adaptimmune ***    and the POC Phase results by Adaptimmune, then this Agreement shall automatically terminate in accordance with Clause 17.5 (and in this event, Clause 17.7 shall apply).

 

ARTICLE 4            SELECTION OF TARGETS

 

 

4.1        Selected Targets.

 

4.1.1          Selected Target Identification.  During the POC Phase, the Parties shall consult on and discuss at the JSC any Target being considered by a Party, either by selection from the Target List or the POC Target.  The JSC shall agree upon which two Targets will be selected for co-development.  The date of such selection by the JSC, as evidenced in minutes of the applicable JSC meeting, shall be the “Acceptance Date” for such two Targets.  The JSC shall also designate which of the two Selected Targets is the Bellicum Target and which is the Adaptimmune Target.  Agreement of the JSC on both Selected Targets must, unless otherwise mutually agreed between the Parties in writing, be made at the latest by ***

from Co-Development Start.  Notwithstanding the foregoing, ***

 

 

 

 

 

 

 

 

 

.

 

4.1.2          Target Exclusivity.  On the Acceptance Date, each of the two selected Targets shall thereafter be designated as a “Selected Target”.  As of the Acceptance Date, a Selected Target will not be made available by Adaptimmune or Bellicum to any Third Party for development, and Adaptimmune will not develop any TCRs or Therapies to such Selected Targets for itself or for or on behalf of any Third Party.

 

4.1.3          Target List.  Only Targets set out on the Target List shall be eligible for selection as a Selected Target.

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 22

 

Execution Copy

 

ARTICLE 5                                                CO-DEVELOPMENT PLAN

 

5.1        Co-Development Plan.

 

5.1.1           Within ***                after the Acceptance Date (or such longer time as mutually agreed by the Parties in writing) with respect to a given Selected Target, the JPT shall draft and agree upon a Co-Development Plan for the generation of Candidates directed to each Party’s Selected Target, which plan is intended to generate the data necessary to support an IND filing for such Party’s Joint Selected Candidate.  No activities will be performed in connection with a proposed Co-Development Plan (and accordingly, no costs will be incurred under Clause 10.2) before the applicable JPT has agreed upon such Co-Development Plan.  Each of the two Co-Development Plans shall:

 

(a)    be prepared on a global basis;

 

(b)    include the responsibilities of each of the Parties under the Co-Development Plan including as relates to any manufacture of Therapy for Clinical Trials;

 

(c)    include a high level plan setting out an anticipated route (including Phase III Clinical Trials and other required trials) to obtain Regulatory Approval for such Therapy including estimated timelines and estimated budget; and

 

(d)    include the basis for calculation of any budgeted costs, including relevant FTE and FTE Rate information to be applied to such budget (which FTE Rate(s) shall be used to calculate any Development Costs reimbursable in accordance with Clause 10).

 

5.1.2                                      Under each Co-Development Plan, each Party shall use Commercially Reasonable Efforts to perform any part of the Co-Development Plan assigned to it, including making resources available as and when required and supplying any product, equipment or materials as and when required and specified under the Co-Development Plan.  The Parties may supplement the terms of this Agreement, as necessary, with terms relating to manufacture and supply, quality and/or any other terms deemed necessary or reasonably useful by a Party to govern the Parties’ co-development of such Party’s respective Candidate.  The Parties will negotiate any such supplemental terms in good faith and on a timely basis to prevent any unreasonable delay to activities performed under the Co-Development Plan.

 

5.1.3                                      Under each Co-Development Plan, Adaptimmune shall use Commercially Reasonable Efforts to develop and validate starting TCRs (“Initial Candidates”) directed to each Party’s Selected Target within the timescales agreed for the relevant Co-Development Plan. ***

 

.

 

5.1.4                                      Subject to Clause 2.3.2(b), Clause 2.3.3 (which references the limitations set forth in Clause 2.2.4) and Clause 5.7, the JDC may amend in writing the Co-Development Plan for each Party’s Initial Candidate and Joint Selected Candidate from time to time and will regularly update the Parties’ Co-Development Plans as each phase of the plan progresses.  It is envisioned that after ***

 

 

.  Exhibit 6 outlines the anticipated responsibilities of each Party for any Co-Development Plan but may be amended for any particular Co-Development Plan.

 

5.1.5                                      The JDC shall also agree upon the criteria for any Initial Candidate to proceed

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 23

 

Execution Copy

 

through each Co-Development Phase and in particular the criteria for designation of an Initial Candidate as a Joint Selected Candidate for progression into preclinical development and onwards into Clinical Trials.  Initial criteria are set out in Exhibit 7 and these will be amended and reviewed by the JDC as appropriate.  Only one Joint Selected Candidate shall proceed to pre-clinical development for any Co-Development Plan at any one time, and an alternative Candidate will only be selected for pre-clinical development where such initial Joint Selected Candidate fails to achieve the agreed criteria for completion of pre-clinical development (such alternative Candidate will be deemed the Joint Selected Candidate upon replacement of the original Joint Selected Candidate).  ***

 

 

 

 

 

.

 

5.2         Subcontractors.  Each Party may subcontract portions of its work under the Co-Development Plan to (i) any Affiliate or (ii) Third Parties; provided in the case of a Third Party, (a) there are no reasonably based objections from the other Party regarding the use of said subcontractor, and (b) such subcontract is in writing and is consistent with the terms and conditions of this Agreement including the confidentiality provisions of Article 13 and any rights granted to such subcontractor are restricted to only those rights necessary for performance by such subcontractor of the portions of work on behalf of the sub-contracting Party.  The sub-contracting Party will remain fully responsible (at its cost) for all acts or omissions of any subcontractor it appoints (including any acts or omissions which result in a breach of the terms of this Agreement) and shall ensure that each subcontractor complies with the terms and conditions of this Agreement.  Each Party shall notify the other Party in writing of any sub-contractor appointments other than Affiliates.  In addition, either Party may audit any sub-contractor appointed by the other Party prior to such sub-contractor being appointed to perform any part of any Co-Development Plan, and on provision of written notice within ***                    of a Party becoming aware of such sub-contractor appointment.  Such audit will occur as soon as reasonably practicable and in any event in accordance with any timelines set out in the applicable Co-Development Plan.  The Party appointing such sub-contractor will provide reasonable assistance to enable the conduct of such audits (including interacting with such sub-contractors to substantiate the need and right to conduct such audits).  To the extent any audit identifies any non-compliance with Applicable Laws (including non-compliance with GMP), the Party appointing such sub-contractor shall use reasonable efforts to procure correction of such non-compliance by sub-contractor or shall use an alternative sub-contractor where correction of such non-compliance is not possible or practicable.  Each Party will put in place written Quality Agreements with any subcontractor performing GMP activities prior to them supplying materials or services supporting any relevant GMP activities under any Co-Development Plan.  The other Party may request copies of such Quality Agreement to the extent necessary to satisfy its internal standard operating procedures or to satisfy obligations to any Regulatory Authority or under Applicable Laws.

 

5.3                              Completion of any Co-Development Plan.  The term for a particular Co-Development Plan shall commence on Acceptance, and shall continue, unless earlier terminated in accordance with Article 17, until the completion or waiver of all the tasks set out in the Co-Development Plan (on a Selected Target-by-Selected Target basis, the “Co-Development Term”).  During the Co-Development Term and subject to reimbursement by the other Party under Clause 10.2, each Party shall be responsible for its own costs associated with the activities it conducts under the Co-Development Plan.  The final report for each Co-Development Plan shall (i) identify all relevant data necessary for assessment by the JSC of whether the Candidate criteria have been met by any Joint Selected Candidate and (ii) include such data and research records that have been compiled and which may be required to support an IND filing for any Joint Selected Candidate.

 

5.4                              Reports; Records; and Inspections.

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 24

 

Execution Copy

 

5.4.1                                      Progress Reports.  Each Party shall keep the other Party regularly informed of its activities (if any) under each Co-Development Plan and shall provide to the other Party’s representatives on the JDC regular written summary updates at each JDC meeting.  If reasonably necessary for a Party to perform its work under a Co-Development Plan, that Party may request that the other Party provide more detailed information and data regarding the updates it earlier provided, and the other Party shall promptly provide the requesting Party with information and data as is reasonably available and reasonably necessary to conduct a Co-Development Plan, and such other information as the Parties agree.  All such reports, information and data provided by a Party shall be considered the providing Party’s Confidential Information.

 

5.4.2                                      Development Records.  Each Party shall maintain records of its performance of each, if any, Co-Development Plan (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of such Co-Development Plan.  All laboratory notebooks shall be maintained for no less than ***                after creation of the relevant notebook entry.  All other records shall be maintained by each Party during the applicable Co-Development Term and for a minimum of ***            thereafter.  All such records of a Party shall be considered such Party’s Confidential Information.  The Party responsible for any Clinical Trial shall also procure that any Third Parties involved in any Clinical Trial or Party itself maintain all records relevant to the Clinical Trial for a minimum of         ***             from completion of relevant Clinical Trial or such longer period required under Applicable Laws and that the other Party is given access to such records as may be reasonably necessary for such other Party to comply with Applicable Laws or perform its obligations hereunder.  Records shall not be destroyed by either Party without prior written notification of such destruction being provided to other Party, and other Party being given the opportunity to take over the storage and responsibility for such records.

 

5.4.3                                      Quality.  Each Co-Development Plan shall be performed at all times in accordance with all Applicable Laws including as applicable requirements of GxP.  Each Party shall ensure that any manufacture and supply of Joint Selected Candidate for any Clinical Trials is carried out in accordance with cGMPs and applicable Quality Agreements.

 

5.4.4                                      Inspections.  The Parties shall notify each other of any inspections carried out or requested by any Regulatory Authority that relates, and in each case to the extent such inspection or request relates, to any Joint Selected Candidate under any Co-Development Plan or to the facility at which any Joint Selected Candidate is being manufactured or stored or any Clinical Trial site or other Third Party site or facility relevant to any Joint Selected Candidate (including where such sites are managed by a CRO or other Third Party).  From and after the initiation of the first Phase III Clinical Trial with respect to a given Therapy that is the subject of such Co-Development Plan, both Parties shall be entitled to be present at such inspections to the extent such inspections relate solely to such Therapy and to the extent reasonably practicable; provided, that the Party who is not in control of the relevant facility (either directly or through a subcontract) shall only be permitted to attend such inspections as a silent observer.  Where any inspection identifies any non-compliance with Applicable Laws, then the Party responsible for the facility shall correct any such non-compliance and shall keep the other Party informed of the steps being taken to correct any non-compliance.

 

5.5         Research Efforts.  Each Party shall assign such scientific and technical personnel and allocate such other resources as are reasonably necessary for performing the activities as are assigned to it in each Co-Development Plan and shall perform such activities in accordance with all Applicable Laws (including GxPs) in each case to the extent applicable to performance of the relevant Co-Development Plan activities by such Party, the terms and conditions of this Agreement, and within generally accepted professional standards.  Each Party shall be solely responsible for the safety and health of its employees, consultants and visitors, and for compliance with all Applicable Laws related to health, safety and the

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 25

 

Execution Copy

 

environment, including providing its employees, consultants and visitors with all required information and training concerning any potential hazards involved in performing such activities and any precautionary measures to protect its employees from any such hazards at its own facilities and as regards its or its subcontractors performance of the Co-Development Plan.  Each Party shall use Commercially Reasonable Efforts to train its personnel assigned to perform activities under this Agreement and ensure that any personnel so assigned shall be capable of professionally and competently performing the activities assigned to it in each Co-Development Plan.  Each Party may request an on-site visit to the other Party and/or its Affiliates for the purpose of conducting a quality assessment and/or quality audit for any GMP activities, which visit the other Party will promptly accommodate.  Each Party shall be entitled to request such on-site visit no more than ***    in any ***                      (except in the case of any subsequent “for cause” audits) and any visit will be conducted to reasonably minimize interference to the other Party’s business.

 

5.6                              Reserved Activities.  The following activities shall be reserved to Adaptimmune under any Co-Development Plan (“Adaptimmune Reserved Activities”):

 

(a)              ***

 

;

 

(b)             ***                                                  ;

 

(c)              ***

 

     ;

 

(d)             ***                                                                    .

 

The following activities shall be reserved to Bellicum under any Co-Development Plan (“Bellicum Reserved Activities”); and as used herein, the term “Reserved Activities” means Adaptimmune Reserved Activities and/or Bellicum Reserved Activities, as the context may require:

 

(a)              ***

 

;

 

(b)             ***

 

.

 

For avoidance of doubt, each of the Parties may ***

 

 

 

 

 

 

.

 

5.7          Changes to Co-Development Plan.  The Parties acknowledge and agree that each Co-Development Plan will change and develop as the applicable Joint Selected Candidate progresses through development, Clinical Trials and to Regulatory Approval.  The JPT will be responsible for amending the Co-Development Plan in relation to any non-material changes.  Subject to Clause 2.3.2(b) and Clause 2.3.3 (which references the limitations set forth in Clause 2.2.4), the JDC shall be responsible for reviewing and amending operational aspects and activities under each Co-Development Plan as necessary in relation to any material changes; provided that material changes to a Party’s personnel, funding and/or resources necessary for performance of such Co-Development Plan must be mutually agreed by the Parties in writing (i.e., the JDC cannot make such decisions).  Material changes will include

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 26

 

Execution Copy

 

any changes which significantly increase the resource requirement, significantly change the timescales for performance or increase the cost of the performance of the Co-Development Plan (as against budgeted costs) or any change of any Joint Selected Candidate.  Each Party shall update its part of the budget for any Co-Development Plan on a regular basis and provide an update to such budget at each JDC meeting.  Such budget will be discussed at the JDC and approved at the JDC.  Any changes to a Co-Development Plan (including to the budget set out in such Co-Development Plan) will be made in good faith and with a bona fide intention that such changes are required for the successful development and commercialisation of any Joint Selected Candidate or Therapy utilising such Joint Selected Candidate.  The Parties will also negotiate in good faith any amendments or additional terms required to this Agreement to address changes in scope of the Co-Development Plan as the applicable Joint Selected Candidate or Therapy utilising such Joint Selected Candidate progresses through to Regulatory Approval.

 

5.8                              Additional HLA Candidates.  Each Co-Development Plan shall initially focus on Candidates for only one HLA Type.  Following completion of any Phase II Clinical Trial in relation to any Co-Development Plan, the Parties will discuss and agree whether development of any further Additional HLA Candidates is desirable and if so the terms on which such Additional HLA Candidates will be developed.  Any Additional HLA Candidates will be mutually agreed between the Parties, and will require a related Co-Development Plan.

 

ARTICLE 6                                                REGULATORY

 

6.1                              Regulatory Matters.

 

6.1.1                                      As between the Parties, (a) Bellicum shall be responsible for holding and applying for any Regulatory Approvals or MAAs in relation to the Bellicum Candidate and any Therapy comprising the Bellicum Candidate; and (b) Adaptimmune shall be responsible for holding and applying for any Regulatory Approvals or MAAs in relation to the Adaptimmune Candidate and any Therapy comprising the Adaptimmune Candidate.

 

6.1.2           The Party holding the relevant Regulatory Approval in relation to a Therapy shall be primarily responsible, and act as the sole point of contact, for communications with Regulatory Authorities in connection with the development, commercialisation, and manufacturing of such Therapy.  To the extent the other Party is required to provide any information or response to a Regulatory Authority, such response will be discussed with the responsible Party to the extent practicable and responding Party shall provide only such information as is necessary to comply with its legal obligations unless otherwise mutually agreed.  The Parties shall copy each other on any material correspondence in relation to a Therapy (or anything which is likely to affect the safety or regulatory approval of any Therapy) received from a Regulatory Authority and where reasonably possible provide the other Party an opportunity to comment on such correspondence.  Both Parties shall be entitled to be present at any scheduled meeting, interview or discussion with any Regulatory Authority relating to any Joint Selected Candidate or Therapy utilising such Joint Selected Candidate.

 

6.1.3           Notwithstanding the foregoing, each Party shall provide such assistance as may reasonably be requested by the other Party relating to regulatory matters (including preparation and filing for any INDs and MAAs and obtaining and maintaining Regulatory Approvals).  Such assistance will include, without limitation, a right to ***

 

 

 

 

 

 

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 27

 

Execution Copy

 

 

 

.

 

6.1.4                                      Nothing in this Clause 6.1 shall require any Party to breach its obligations to any Regulatory Authority under Applicable Law.

 

ARTICLE 7                                                COMMERCIALISATION

 

7.1          Commercialisation Generally.  Each of the Parties shall use its Commercially Reasonable Efforts to commercialise and promote any Therapy in accordance with its mutually agreed Co-Commercialisation Agreement and/or a subsequent detailing agreement (as outlined in Exhibit 3 and to be further described in a Co-Commercialization Agreement).  Bellicum shall be primarily responsible for commercialisation, manufacture and promotion of the Therapy comprising the Bellicum Candidate, and Adaptimmune shall be primarily responsible for commercialisation, manufacture and promotion of the Therapy comprising the Adaptimmune Candidate.

 

7.2          Co-Commercialisation Agreement.  Not later than ***                 after ***                                                          

for any Therapy, the Parties shall negotiate in good faith and agree to commercially reasonable terms of an agreement, or an appropriate amending and restating of this Agreement, covering any co-commercialisation activities (if any) and the profit/loss sharing and governance that will apply to Therapies (such agreement or amended and restated iteration of this Agreement, “Co-Commercialisation Agreement”).  Such Co-Commercialisation Agreement shall include the principles set out in Exhibit 3, unless otherwise mutually agreed in writing.  Activities described in such Co-Commercialization Agreement will not be initiated unless and until the Parties agree regarding the terms and conditions of such Co-Commercialisation Agreement.  Where any of the terms of such Co-Commercialization Agreement have not been agreed by the Parties following ***

 

 

, then for a Bellicum Therapy, Bellicum shall be entitled to refer resolution of any non-resolved terms and conditions to arbitration  in accordance with Clause 18.2, and for an Adaptimmune Therapy, Adaptimmune shall be entitled to refer resolution of any non-resolved terms and conditions to arbitration in accordance with Clause 18.2.

 

7.3          Commercialisation Updates.  Each Party shall continue to keep the other Party informed of its commercialisation of any relevant Therapy and will provide regular updates to the JCC.  Each Party shall also provide to the other Party, on or about ***

 

 

.  Each Party may address questions on the annual reports to the Alliance Managers or JCC following receipt of such written reports.

 

7.4                              Safety Event Reporting.  Additionally, each Party shall provide to the other Party prompt written notice of any material safety events pertaining to Therapies of which it becomes aware including any SUSARs or other material events which might have general applicability to the use of Candidates, TCRs or Therapies to treat patients. The Parties shall enter into a pharmacovigilance agreement on commercially reasonable terms to facilitate the reporting of such events.

 

ARTICLE 8                                                LICENSES

 

8.1                              Development License.  Commencing on the Effective Date and continuing in full force and effect until completion or termination of all Co-Development Plans, each Party hereby grants

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 28

 

Execution Copy

 

to the other Party a royalty-free, non-transferable (except to such other Party’s agents performing the POC Plan or Co-Development Plan), non-exclusive license in the Field under such Party’s Licensed Intellectual Property solely for the purposes of and to the extent necessary for (a) performing the POC Plan; and (b) performing each Co-Development Plan, including CMC activities (collectively, the “Development License”).  The Development License shall be specific to the research and development activities and responsibilities of the licensee Party under the Co-Development Plan and directed to the applicable Selected Target, including any associated diagnostic assays and companion diagnostics developed for a Party’s Joint Selected Candidate.

 

For clarity, the Development License does not include the right for Bellicum to conduct any Adaptimmune Reserved Activities, and does not include the right for Adaptimmune to conduct any Bellicum Reserved Activities.

 

8.2                              Exclusive License.

 

8.2.1                                      Exclusive License Grant.  As from the Acceptance Date, each Party grants to the other Party an exclusive license under such Party’s Licensed Intellectual Property in each case to (i) make, have made, use, import and have imported Joint Selected Candidates and Therapies, and (ii) sell, have sold and offer for sale Therapies, in each case of sub-Clauses (i) and (ii), in the Field and directed to the corresponding Selected Target (each, an “Exclusive License”).  Each such Exclusive License shall be subject to the following:

 

(a)     The Exclusive License shall include a grant back to the licensor Party, to the extent applicable, of a right to perform co-development and co-commercialisation activities regarding any Therapy or Joint Selected Candidate as part of any POC Plan, Co-Development Plan or Co-Commercialisation Agreement;

 

(b)    The Exclusive License shall not include the right for Bellicum to conduct any Adaptimmune Reserved Activity or for Adaptimmune to conduct any Bellicum Reserved Activity; and

 

(c)     The Exclusive License shall not include:

 

(i)      any right to modify, improve or otherwise materially alter any Candidate, Joint Selected Candidate or Therapy (save as reasonably necessary to address any requirement from any Regulatory Authority or to address any safety concern).  For clarity, modification of any complementarity determining region of any TCR included within any Therapy or the sequence encoding such complementarity determining region shall constitute a material alteration; or

 

(ii)     any right to generate any new TCR or new Candidate to any Selected Target or to any other Target under the Exclusive License; provided that the licensee Party retains the right to use its own technology (obtained independently of this Agreement) to modify, improve or alter its own Candidates, Joint Selected Candidate and Therapies.

 

8.2.2             Sublicenses.  Each Party shall have the right to sublicense the licenses and rights granted under Clauses 8.1 and 8.2.1 to its Affiliates and permitted sub-contractors acting on its behalf; provided that in each case such sublicense:

 

(a)              is consistent with the terms and conditions of this Agreement; and

 

(b)             is in writing.

 

Each Party shall be responsible for all actions and omissions of any Sublicensee including where such actions and omissions result in a breach of the terms of this Agreement.  Any other sub-licensing must be prior approved in writing by the licensor Party.

 

Page 29

 

Execution Copy

 

8.3                              ***                                                                                        .  During the term of this Agreement, and subject to the limitations set forth in this Clause 8.3, ***

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

.

 

8.4                              No Additional Licenses.  Except as expressly provided in this Agreement, nothing in this Agreement shall grant either Party any right, title or interest in and to the know-how, Patents or other Intellectual Property Rights of the other Party (either expressly or by implication or estoppel).

 

ARTICLE 9                                                TECHNOLOGY TRANSFER

 

9.1                              In addition to any technology transfer contemplated by any Co-Development Plan, following completion of any Co-Development Plan and as part of any Co-Commercialisation Plan, Adaptimmune will:

 

(a)              reasonably assist Bellicum in establishing a ***                        for any Therapy comprising a Bellicum Candidate, and will allow and enable Bellicum to work with ***                                   (to the extent relevant).  Such assistance will include ***

 

                                                                                                                                         ; 

 and

 

(b)             provide ongoing technical assistance in relation to Bellicum’s development and manufacturing of the Bellicum Candidates and Therapies comprising a Bellicum Candidate as reasonably requested from time to time and during the Term.

 

The details of what technical assistance and transfer of technology will be required from Adaptimmune will be agreed upon by the Parties as part of a technology transfer plan to be initially prepared by Bellicum and approved by the JDC.  The costs of such technical assistance and transfer shall be considered to be a Development Cost and subject to reimbursement in accordance with Article 10.  Any technology transfer obligations and provision of confidential information will be subject to any Third Party restrictions relevant to such technology transfer and provision of confidential information.

 

9.2                              In addition to any technology transfer contemplated by any Co-Development Plan, following completion of any Co-Development Plan and as part of any Co-Commercialisation Plan, Bellicum will:

 

(a)              reasonably assist Adaptimmune in establishing a ***                for any Therapy comprising an Adaptimmune Candidate, and will allow and enable Adaptimmune to work with ***           (to the extent relevant).  Such assistance will include ***

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 30

 

Execution Copy

 

; and

 

(b)    provide ongoing technical assistance in relation to Adaptimmune’s development and manufacturing of the Adaptimmune Candidates and Therapies comprising an Adaptimmune Candidate as reasonably requested from time to time and during the Term.

 

The details of what technical assistance and transfer of technology will be required from Bellicum will be agreed upon by the Parties as part of a technology transfer plan to be initially prepared by Adaptimmune and approved by the JDC.  The costs of such technical assistance and transfer shall be considered to be a Development Cost and subject to reimbursement in accordance with Article 10.  Any technology transfer obligations and provision of confidential information will be subject to any Third Party restrictions relevant to such technology transfer and provision of confidential information

 

ARTICLE 10                                         FINANCIAL TERMS

 

10.1      Co-commercialisation Profit/Loss Sharing.  If a Co-Commercialisation Agreement is agreed upon by the Parties, the costs of Co-Commercialisation, manufacture and promotion of any Therapy shall be shared equally between the Parties as set forth in such Co-Commercialisation Agreement.  The mechanism for such payments and the calculation of cost, profit and loss share shall be agreed as part of the Co-Commercialisation Agreement and in accordance with Exhibit 3.

 

10.2                       Reimbursement of Co-Development Costs under any Co-Development Plan.

 

10.2.1                               The budget established for each Co-Development Plan will control the reimbursable costs incurred by each Party in performing under such Co-Development Plan.  The budget and/or the Co-Development Plan may allow for a certain percentage of excess spending over the budgeted amount, and/or may establish a cap on spending that may not be exceeded without amendment of such budget and/or the Co-Development Plan (as applicable).  The Parties shall each pay 50% of the costs incurred in accordance with the relevant budget by each of the Parties in performance of the Co-Development Plan, including the costs of Clinical Trials, costs of CMC, costs of manufacture and any sub-contractor costs necessarily incurred in the performance of any Co-Development Plan.  Agreed FTE Rates applicable to various levels of employees and agents utilized by a Party in connection with its performance under a Co-Development Plan are set forth in Exhibit B, and such Agreed FTE Rates may be further described in each Co-Development Plan.

 

10.2.2         The estimated costs and budget for any Co-Development Plan shall be set out in the initial Co-Development Plan prepared in accordance with Clause 5.1.1, and such Co-Development Plan and its budget shall be reviewed, updated and amended as required, in accordance with Clause 5.7.  The Co-Development Plan expenses subject to reimbursement by a Party under this Clause 10.2 shall not exceed ***% of the expenses set forth in the then-current budget for the other Party’s Co-Development Plan, unless the Parties otherwise mutually agree in writing.

 

10.2.3                               No later than the ***                           after the end of each ***                        during the performance of any Co-Development Plan, each Party shall provide to the other Party a list of all costs and expenses reasonably incurred in accordance with the corresponding budget in the performance of the relevant Co-Development Plan (“Development Costs”).  In addition to the following, each Co-Development Plan may describe in greater detail certain types of expenses, and a calculation of certain expenses, that are permitted within (or excluded from) Development Costs.  Such Development Costs shall include ***

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 31

 

Execution Copy

 

 

 

 

 

.  Development Costs shall not include, for example only, ***

 

 

 

 

 

 

 

 

.  Each Party shall provide reasonable evidence supporting any claimed Development Costs on reasonable request from the other Party.  Development Costs may be subject to annual increases to account for inflation, but such increases shall be based on a mutually agreed, objective, relevant inflation index (as set forth in the Co-Development Plan or its related budget).

 

10.2.4                               Where Bellicum is owed reimbursement of Development Costs, Bellicum shall invoice Adaptimmune for such sums and Adaptimmune shall pay such invoice within ***                       of receipt of invoice.  Where Adaptimmune is owed reimbursement of Development Costs, Adaptimmune shall invoice Bellicum for such sums and Bellicum shall pay such invoice within ***                        of receipt of invoice.  Where any part of Development Costs is disputed, reimbursement of the non-disputed part of such Development Costs shall occur in accordance with this Clause 10.2.4 and the Parties shall resolve the dispute as expeditiously as possible in accordance with Clause 10.2.6.

 

10.2.5                               In calculating any Development Costs the following principles will apply:

 

(a)              ***

 

;

 

(b)             ***

 

;

 

(c)              ***

 

;

 

(d)             ***

 

;

 

(e)              ***

 

;

 

(f)                ***

 

;

 

(g)             ***

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 32

 

Execution Copy

 

 

 

; and

 

(h)              ***

 

 

 

.

 

10.2.6         Audit Right.  Where either Party disputes that any costs are not necessarily incurred in the performance of any Co-Development Plan, the dispute shall first be referred to senior managers in accordance with Clause 18.1.  Where the dispute is not resolved within ***                of such referral, either Party may request that such report be verified by the Party’s then-current independent, certified and internationally recognized public accounting firm.  Such right to request a verified report shall (i) be limited to the period covered by the disputed Development Costs being claimed; and (ii) not more frequently than once with respect to records covering any specific period of time.  Each Party shall, upon timely written request and on at least ***                advance written notice from Adaptimmune or Bellicum, as applicable, and at a mutually agreeable time during its regular business hours, make its records available for inspection by the relevant accounting firm at such place or places where such records are customarily kept, solely to verify the accuracy of the disputed Development Costs being requested under this Agreement.  The accounting firm shall only state factual findings in its audit reports.  The draft audit report shall be shared with both Parties at the same time.  Following review and approval by all Parties of the draft audit, the final audit report shall be shared with Bellicum and Adaptimmune.

 

10.2.7                               Underpayment; Overpayment.  After reviewing the audit report delivered under Clause 10.2.6, any discrepancy in Development Costs and reimbursement of such costs shall be corrected by the relevant Party or Parties within ***            of delivery of audit report under Clause 10.2.6.  Any audit shall be at the requesting Party’s expense unless such audit shows more than the greater of (a) a *** percent and (b) $***     , discrepancy in the Development Costs being claimed.

 

10.2.8                               Payment and Related Matters.  All payments in connection with Development Costs will be handled in accordance with Clauses 11.1 – 11.4 inclusive.

 

ARTICLE 11                                         PAYMENTS

 

11.1                       Mode of Payment.

 

11.1.1                               All payments hereunder shall be made by wire transfer in immediately available funds to the account listed below (or such other account as the receiving Party shall designate before such payment is due):

 

If to Adaptimmune:

 

Payee: Adaptimmune Limited

Bank Name: ***

Bank address: ***

IBAN: ***

SWIFT/BIC: ***

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 33

 

Execution Copy

 

If to Bellicum:

 

Beneficiary’s Bank: ***

Bank Address: ***

Bank Phone: ***

 

Beneficiary Name: Bellicum Pharmaceuticals, Inc.

Beneficiary Account Number: ***

Swift Code: ***

ABA Routing Number: ***

 

11.1.2         The Party paying any sum under this Agreement will be responsible for any bank costs or charges associated with any transfer of sums or reimbursement of costs including any currency conversion costs or transfer costs.

 

11.2       Currency of Payments.  All payments under this Agreement shall be made in US dollars, unless otherwise expressly provided in this Agreement.

 

11.3       Taxes.  Each Party shall comply with Applicable Laws regarding filing and reporting for tax purposes.  Neither Party shall treat their relationship under this Agreement as a pass through entity for tax purposes.  If any payments made by the Parties under this Agreement are subject to withholding taxes under Applicable Laws of any state, federal, provincial or foreign government, each Party shall be authorised to withhold such taxes as are required under such Applicable Laws, pay such taxes to the appropriate government authority, and remit the balance due to the other Party net of such taxes.  The Party paying the taxes to the government authority shall secure and deliver to the other Party an official receipt for taxes paid.  The Parties will fully cooperate with each other to enable each Party to more accurately determine its own tax liability and to minimize such liability to the extent legally permissible and administratively reasonable.  Each Party shall provide and make available to the other Party any exemption certificates, resale certificates, information regarding out of state or out of country sales or use of equipment, materials or services, and any other information reasonably requested by the other Party to support the provisions of this Clause 11.3, including the appropriate organization of invoice formats and supporting documents to allow maximization of reclamation of VAT and other transaction taxes.

 

11.4       Late Payment.  In relation to any undisputed amount required to be paid by a Party hereunder which is not paid by the payment date due, the other Party may charge interest at a monthly rate equal to *** percent (***%); provided, however, that in no event will such rate exceed the maximum legal interest rate then in effect.  Such interest shall be computed on the basis of a month of 30 days for the actual number of days such payment is overdue.

 

ARTICLE 12                                         INTELLECTUAL PROPERTY; OWNERSHIP

 

12.1                       Disclosure; Ownership; Inventorship; Assignment and Cooperation.

 

12.1.1          Disclosure.  During the Term, each Party shall promptly disclose to the other Party in writing any registerable or potentially registerable Foreground IP (whether or not patentable) conceived or reduced to practice by or for the disclosing Party in the course of performance of this Agreement.  Disclosure will be made via designated patent representatives for each Party.

 

12.1.2                               Ownership.  As between the Parties:

 

(a)              Adaptimmune shall solely own any Foreground IP which primarily relates to the Adaptimmune Technology including any Foreground IP which claims or Covers any improvement to the Adaptimmune Technology (“Adaptimmune Foreground IP”);

 

(b)             Bellicum shall solely own any Foreground IP which primarily relates to the Bellicum Technology including any Foreground IP which claims or Covers

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 34

 

Execution Copy

 

any improvement to the Bellicum Technology (“Bellicum Foreground IP”); and

 

(c)              The Parties shall jointly own any Foreground IP other than that set out in clause 12.1.2 (a) and (b) (“Joint IP”).

 

In relation to any inventions, existence and ownership of inventions shall be determined in accordance with the laws of the United States.  Without limiting the foregoing, each Party retains an undivided one-half interest in and to the Joint IP (including Patents therein).  Subject to the licenses granted in Article 8, (i) each Party may exploit fully the Joint IP, in any field, and may grant licenses under the Joint IP, without obtaining consent from the other Party, and (ii) may transfer or encumber its ownership interest in any of the Joint IP, subject to obtaining the prior written consent of the other Party (which consent will not be unreasonably withheld, conditioned or delayed), in each case of sub-clauses (i) and (ii), without accounting to the other Party.

 

In the event of any dispute as to whether any Foreground IP primarily relates to either the Adaptimmune Technology or Bellicum Technology under Clauses 12.1.2(a) or 12.1.2(b) and where such dispute is not resolved by reference to senior executives in accordance with Clause 18.1, an independent patent expert (“Patent Expert”) shall be appointed by the Parties to resolve such dispute.  The decision of the Patent Expert shall be binding on the Parties in the absence of manifest error or fraud.  The Patent Expert shall be mutually agreed between the Parties in writing within ***                      of expiry of the ***         resolution period in Clause 18.1.  Where the Parties cannot agree such Patent Expert, the Patent Expert shall be appointed by the American Arbitration Association under its Supplementary Rules for the Resolution of Patent Disputes.  Any Patent Expert shall be a patent attorney and have at least 20 years’ experience in relation to pharmaceutical or biotechnology patent matters.  The fees of the Patent Expert shall be shared equally between the Parties and the Parties shall use reasonable efforts to ensure resolution occurs as quickly as possible after referral to such Patent Expert.  The Parties shall reasonably cooperate with the Patent Expert, including providing such information as may reasonably be required by the Patent Expert to reach a decision.

 

Nothing in this clause shall affect or impact any ownership of either Party in relation to such Party’s Background IP.

 

12.1.3          Assignment; Cooperation.  Each Party shall execute such further documentation as may be necessary or appropriate, and provide reasonable assistance and cooperation, to implement the provisions of this Article 12.  Each Party shall to the extent legally practicable and possible under relevant national or local laws use Commercially Reasonable Efforts to cause all of its employees, Affiliates and any Third Parties working pursuant to this Agreement on its behalf, to assign (or otherwise convey rights) to such Party any Patents and Know-How or other Foreground IP discovered, conceived or reduced to practice by such employee, Affiliate or Third Party, and to cooperate with such Party in connection with obtaining patent protection therefore.

 

12.2                       Patent Prosecution.

 

12.2.1                               Adaptimmune Controlled Prosecution and Maintenance.

 

(a)              Adaptimmune shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the Adaptimmune Background IP.

 

(b)             Adaptimmune shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the Adaptimmune Foreground IP, to the extent such Patents do not include any claim Covering

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 35

 

Execution Copy

 

(i) a Selected Target, or (ii) the composition of matter of a Candidate or Therapy.  Without limiting the foregoing, in the event that Adaptimmune elects not to Prosecute and Maintain any Patents under this Clause 12.2.1(b), Adaptimmune shall not grant any Third Party the right to do so.

 

(c)              Adaptimmune shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the Foreground IP, to the extent such Patents include any claim Covering (i) an Adaptimmune Selected Target; or (ii) the composition of matter of an Adaptimmune Candidate or Therapy comprising such Adaptimmune Candidate.  Without limiting the foregoing, in the event that Adaptimmune elects not to Prosecute and Maintain any Patents under this Clause 12.2.1(c), Adaptimmune shall not grant any Third Party the right to do so.

 

12.2.2                               Bellicum Controlled Prosecution and Maintenance.

 

(a)    Bellicum shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the Bellicum Background IP.

 

(b)    Bellicum shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the Bellicum Foreground IP, to the extent such Patents do not include any claim Covering (i) a Selected Target, or (ii) the composition of matter of a Candidate or Therapy.  Without limiting the foregoing, in the event that Bellicum elects not to Prosecute and Maintain any Patents under this Clause 12.2.2(b), Bellicum shall not grant any Third Party the right to do so.

 

(c)    Bellicum shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the Foreground IP to the extent such Patents include any claim Covering (i) a Bellicum Selected Target, or (ii) the composition of matter of a Bellicum Candidate or Therapy comprising a Bellicum Candidate.  Without limiting the foregoing, in the event that Bellicum elects not to Prosecute and Maintain any Patents under this Clause 12.2.2(c), Bellicum shall not grant any Third Party the right to do so.

 

12.3                       Jointly Controlled Prosecution and Maintenance:

 

12.3.1                               In relation to any Joint IP not Prosecuted and Maintained by either Adaptimmune or Bellicum under Clauses 12.2.1 and 12.2.2, the Parties shall mutually agree upon which Party shall have the right to Prosecute and Maintain such Patents.

 

12.4                       Failure to Prosecute.  If the Prosecuting Party elects not to Prosecute and Maintain any Patents under Clauses 12.2.1, 12.2.2 or 12.3.1, the Prosecuting Party shall provide at least ***                   written notice to Non-Prosecuting Party describing with specificity such election.  Thereafter, Non-Prosecuting Party shall have the right, but not the obligation, to Prosecute and Maintain any such notified Patents, at ***                     and in its sole discretion.  Prosecuting Party will provide reasonable cooperation and assistance to Non-Prosecuting Party in relation to transferring such Prosecution and Maintenance.  Clause 12.4 shall continue to apply in relation to ongoing Prosecution and Maintenance of any transferred Patents.

 

12.5                       Comments from Non-Prosecuting Party.  The Prosecuting Party will provide the Non-Prosecuting Party with copies of any filed patent application, filings and other material correspondence with applicable governmental authorities relating to any Foreground IP, and will keep the Non-Prosecuting Party reasonably informed of the status of such Prosecution and Maintenance, including providing Non-Prosecuting Party with copies of all communications received from or filed in patent offices within a reasonable period of time after receipt by Prosecuting Party.  Prosecuting Party shall also consult with Non-Prosecuting Party regarding such activities and shall reasonably consider Non Prosecuting Party’s input

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 36

 

Execution Copy

 

with respect thereto.  The Prosecuting Party shall be responsible for the fees of Prosecution and Maintenance of the Foreground IP for which it is responsible.

 

12.6                       Enforcement Rights for Infringement by Third Parties.

 

12.6.1                               Notice.  Each Party shall promptly notify, in writing, the other Party upon learning of any actual or suspected infringement of the Patents within the Background IP or Foreground IP to the extent such actual or suspected infringement is relevant to any Selected Target, Candidate or a Therapy, or, of any claim of invalidity, unenforceability, or non-infringement of any Patents within the Background IP (to the extent relevant to any Selected Target, Candidate or Therapy) or Foreground IP (each an “Infringement”).

 

12.6.2                               Enforcement Actions.

 

(a)       The Parties shall consult in good faith as to potential strategies to terminate suspected or potential Infringement, and shall mutually agree on which Party shall have primary responsibility for any enforcement action, provided, that where the Parties cannot reach agreement within ***           of the date of notification of any actual or suspect Infringement (or any applicable shorter period of time before enforcement rights lapse), the Prosecuting Party in relation to the relevant Patent or Party owning or Controlling the relevant intellectual property right in the case of other Foreground IP or Background IP shall have the first right, but not the obligation, to seek to abate any actual or suspected Infringement by a Third Party, or to file suit against any Third Party for Infringement.  If the Prosecuting Party or owning or Controlling Party does not, within ***

of receipt of a notice under Clause 12.4.1, take steps to abate the Infringement, or to file suit to enforce against such Infringement, then Non-Prosecuting Party shall have the right, but not the obligation, to take action to enforce against such Infringement; provided that if Prosecuting Party is diligently pursuing ongoing settlement discussions at the end of such ***           period then Non-Prosecuting Party shall not be permitted to exercise such right unless such settlement discussions cease without reaching settlement or Prosecuting Party ceases to pursue such discussions diligently.

 

(b)             The non-controlling Party shall reasonably cooperate with the Party controlling any such action to abate or enforce pursuant to this Clause 12.6.2 (as may be reasonably requested by the controlling Party and at the controlling Party’s expense), including, if necessary, by being joined as a party; provided that the non-controlling Party shall be reimbursed by the controlling Party as to any costs or expenses incurred, and shall have the right to be represented by its own counsel at its own expense.  The Party controlling any such action shall keep the other non-controlling Party updated with respect to any such action, including providing copies of all documents received or filed in connection with any such action.

 

12.6.3                               Settlement.  The Party controlling any such enforcement action described in Clause 12.6.2 (a “Enforcement”), at its sole discretion, may take reasonable actions to terminate any alleged infringement without litigation; provided, that if any such arrangement would adversely affect the non-controlling Party’s rights under this Agreement or impose any obligation or requirement on the non-controlling Party, then that arrangement is subject to the non-controlling Party’s prior written consent, which consent shall not to be unreasonably withheld, conditioned or delayed.

 

12.6.4                               Costs and expenses.  The Party controlling any Enforcement shall bear all of its costs and expenses, including litigation expenses, related to such Enforcement actions, except to the extent agreed otherwise in the Co-Commercialisation Agreement.

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 37

 

Execution Copy

 

12.6.5                               Damages.  Unless otherwise mutually agreed by the Parties in writing, and subject to the respective indemnity obligations of the Parties set forth in Article 16, all damages, amounts received in settlement (including royalty, milestone or other payments), judgment or other monetary awards recovered in Enforcement with respect to activities of the Third Party that occurred prior to the effective date of such award shall be shared as follows:

 

(a)              first, to reimburse the controlling Party for costs and expenses incurred under Clause 12.4.4; and

 

(b)             second, shall be apportioned ***% to the controlling Party and ***% to the other (non-controlling) Party.

 

12.7                       Third Party Infringement Claims.

 

12.7.1         Notice.  In the event that a Third Party shall make any claim, give notice, or bring any suit or other inter parties proceeding against Bellicum or Adaptimmune, or any of their respective Affiliates, subcontractors or customers, for infringement or misappropriation of any Intellectual Property Rights with respect to the research, development, making, using, selling, offering for sale, import or export of any Candidate or Therapy or with respect to any Selected Target (“Third Party Infringement Claim”), in each case, the Party receiving notice of a Third Party Infringement Claim shall promptly notify the other Party in writing and provide all evidence in its possession pertaining to the claim or suit that it is entitled to disclose.

 

12.7.2         Defense.  The Parties shall consult as to potential strategies to defend against any Third Party Infringement Claim, consistent with the overall goals of this Agreement, including by being joined as a party.  The Parties shall cooperate with each other in all reasonable respects in the defense of any Third Party Infringement Claim or raising of any counterclaim related thereto.  Subject to the respective indemnity obligations of the Parties set forth in Article 16, (a) Bellicum shall be primarily responsible for defending such Third Party Infringement Claim including selection of counsel, venue, and directing all aspects, stages, motions, and proceedings of litigation to the extent such Third Party Infringement Claim relates to a Bellicum Candidate, Therapy comprising a Bellicum Candidate or the Bellicum Target; and (b) Adaptimmune shall be primarily responsible for defending such Third Party Infringement Claim including selection of counsel, venue, and directing all aspects, stages, motions, and proceedings of litigation to the extent such Third Party Infringement Claim relates to an Adaptimmune Candidate, Therapy comprising an Adaptimmune Candidate or the Adaptimmune Target.  If the Party with primary responsibility does not, within ***                                                  of receipt of a notice under Clause 12.5.2, take steps to defend the Third Party Infringement Claim, then to the extent that such Third Party Infringement Claim is brought against the other Party, the other Party shall have the right, but not the obligation, to take action to enforce or defend against such Third Party Infringement Claim; provided that if the Party with primary responsibility is diligently pursuing ongoing settlement discussions at the end of such ***                                                                                                                          period, then other Party shall not be permitted to exercise such right unless such settlement discussions cease without reaching settlement or such responsible Party ceases to pursue such settlement discussions diligently.  At the controlling Party’s request and expense, the non-controlling Party shall cooperate with the controlling Party in connection with any such defense and counterclaim, provided that the non-controlling Party shall be reimbursed by the controlling Party as to any reasonable and documented costs or expenses, and shall have the right to be represented by its own counsel at its own expense.  Any counterclaim or other similar action by a Party, to the extent such action involves any enforcement of rights under the Licensed Intellectual Property, Foreground IP or Joint IP, will be treated as an Enforcement subject to Clause 12.6.  Nothing in this Clause 12.7 shall prevent any Party from complying with the terms of any court order relating to or arising out of any Third Party Infringement Claim.

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 38

 

Execution Copy

 

12.7.3        Settlement.  If any such defense under Clause 12.7.2 would adversely affect the other Party’s rights under this Agreement or impose a financial obligation upon the other Party or grant rights in respect, or affect the validity or enforceability, of the other Party’s Patents or any Foreground IP, then any settlement, consent judgment or other voluntary final disposition of such Third Party Infringement Claim shall not be entered into without the consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed).

 

12.7.4       Costs and Expenses.  The Party controlling the defense of any Third Party Infringement Claim shall bear all costs and expenses, including litigation expenses, to defend against any Third Party Infringement Claim.

 

ARTICLE 13    CONFIDENTIALITY

 

13.1      Non-use and Non-disclosure of Confidential Information.  During the Term, and for the longer of (a) a period of ***               from the Effective Date, or (b) ***                   after the date of expiration or termination of this Agreement, a Party shall (i) except to the extent permitted by this Agreement or otherwise agreed to by the Parties in writing, keep confidential and not disclose to any Third Party any Confidential Information of the other Party; (ii) except in connection with activities contemplated by, the exercise of rights permitted by  or in order to further the purposes of, this Agreement or otherwise agreed to by the Parties in writing, not use for any purpose any Confidential Information of the other Party; and (iii) take all reasonable precautions to protect the Confidential Information of the other Party (including all precautions a Party employs with respect to its own confidential information of a similar nature).

 

13.2      Exclusions Regarding Confidential Information.  Notwithstanding anything set forth in this Article 13 to the contrary, the obligations of Clause 13.1 above shall not apply to the extent that the Party seeking the benefit of the exclusion from the obligations set forth in Clause 13.1 (the receiving Party) can demonstrate that the Confidential Information of the other Party:

 

(a)   was already known to the receiving Party, other than under an obligation of confidentiality, at the time of receipt by the receiving Party;

 

(b)   was generally available to the public or otherwise part of the public domain at the time of its receipt by the receiving Party;

 

(c)   became generally available to the public or otherwise part of the public domain after its receipt by the receiving Party other than through any act or omission of the receiving Party or those to whom the receiving Party discloses in breach of this Agreement;

 

(d)    was received by the receiving Party without an obligation of confidentiality from a Third Party having the right (to the knowledge of the receiving Party) to disclose such information without restriction;

 

(e)  was independently developed by or for the receiving Party without use of or reference to the Confidential Information of the other Party; or

 

(f)    was released from the restrictions set forth in this Agreement and imposed on the receiving Party by express prior written consent of the other Party.

 

13.3      Authorised Disclosures of Confidential Information.  Notwithstanding the foregoing, a receiving Party may use and disclose the Confidential Information of the other Party as follows:

 

(a)    if required by law, rule or governmental regulation or by judicial order, including as may be required in connection with any filings made with, or by the disclosure policies of, a major stock exchange; provided that the receiving Party seeking to disclose the Confidential Information of the other Party (i)

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 39

 

Execution Copy

 

uses all reasonable efforts to inform the other Party of such requirement in writing prior to making any such disclosures and cooperates with the other Party’s efforts to avoid or limit disclosure, or to seek a protective order, confidential treatment or other appropriate remedy (including redaction) and (ii) whenever possible, requests confidential treatment of such information that is disclosed;

 

(b)   to the extent such use and disclosure is reasonably required in the Prosecution and Maintenance of a Patent within the Foreground IP in accordance with this Agreement; provided that such proposed disclosure is provided to the other Party in writing in advance and the other Party approves such disclosure;

 

(c)  as reasonably necessary to obtain or maintain any Regulatory Approval, including to conduct preclinical studies and Clinical Trials and for pricing approvals, for any Therapies, provided, that, the disclosing Party shall take all reasonable steps to limit disclosure of the Confidential Information outside such Regulatory Agency and to otherwise maintain the confidentiality of the Confidential Information;

 

(d)  to take any lawful action that it deems necessary to protect its interest under, or to enforce compliance with the terms and conditions of, this Agreement; or

 

(e)  to the extent necessary, to permitted Sublicensees, collaborators (including collaborators, and potential collaborators, relating to use of Therapies in combination with other Therapies), vendors, consultants, agents, attorneys, contractors and clinicians under written agreements of confidentiality at least as restrictive as those set forth in this Agreement (or as restrictive as reasonably possible), who have a need to know such information in connection with such Party performing its obligations or exercising its rights under this Agreement.  Further the receiving Party may disclose Confidential Information to existing or potential acquirers, merger partners, permitted sub-contractors and professional advisors only to the extent strictly necessary for the relevant transaction with such Third Parties, and provided in each case that such Third Parties agree to maintain the Confidential Information under written agreements of confidentiality at least as restrictive as those set forth in this Agreement.

 

13.4     Terms of this Agreement.  The Parties agree that this Agreement and the terms hereof will be considered Confidential Information of both Parties.

 

13.5       No License.  As between the Parties, Confidential Information disclosed hereunder shall remain the property of the disclosing Party.  Disclosure of Confidential Information to the other Party shall not constitute any grant, option or license to the other Party, beyond those licenses expressly granted under Articles 8 and 17, under any patent, trade secret or other rights now or hereinafter held by the disclosing Party.

 

13.6      Change of Control.  In the event of a Change of Control of a Party, and prior to any termination of the Agreement in accordance with Clause 17.5.4, the Party undergoing such Change of Control will adopt reasonable procedures to (i) prevent use of the other Party’s Confidential Information by Acquiring Third Party or in any clinical or commercial program of such Acquiring Third Party; (ii) otherwise ensure compliance with the confidentiality obligations set out in this Clause 13; and (iii) keep the other Party’s Confidential Information separate from any information relating to Acquiring Third Party’s ***

 

.  The Party undergoing such Change of Control shall require Acquiring Third Party to agree to terms of non-disclosure and non-use that are at least as restrictive as those set out in this Article 13, prior to disclosure of any of the other Party’s Confidential Information to such Acquiring Third Party.  Any right to disclose such Confidential Information of the other Party (excluding terms of this Agreement) to the Acquiring Third Party shall only apply after expiry

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 40

 

Execution Copy

 

of a period of ***      from the date of such Change of Control or, if earlier, confirmation in writing from the other Party that it will not terminate the Agreement under Clause 17.5.4.

 

ARTICLE 14    PUBLICITY; PUBLICATIONS; USE OF NAME

 

14.1       Publicity.  The Parties shall agree and issue a joint press release, as set out in Exhibit 5, concerning the execution of this Agreement on or within fourteen (14) days of the Effective Date.  The text of any other press releases, public announcements or PowerPoint presentations concerning this Agreement, the subject matter hereof, or the research, development or commercial results of Therapies hereunder (a “Release”) shall be addressed pursuant to Clauses 14.2 - 14.5, inclusive, as applicable.

 

14.2      Releases during any Co-Development Plan.  Subject to Clause 14.3, and during the Co-Development Term, neither Party may issue a Release without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed, and any consent or refusal shall be provided within ***                  of request for such consent.  In the absence of any reply to a request for consent (where delivery of such request has been confirmed) within such ***                               period, consent shall be deemed given.  Releases related to any activities under the Co-Commercialisation Agreement will be addressed in the Co-Commercialisation Agreement.

 

14.3      Releases required by Law or Regulation.  Each Party may issue any Release it is required to issue by Applicable Law (including requirements of any law or rule imposed by the US Securities and Exchange Commission or any securities exchange).  For clarification, where any Party reasonably believes, after consultation with outside legal counsel or General Counsel, that any Release is required in order for it to comply with any securities exchange requirement, including a required release of any material information or an obligation to correct any market misstatement, such Party shall be entitled to issue such Release in accordance with such reasonable belief, without providing the other Party with any prior notification of such Release.

 

14.4      Publications.  Notwithstanding Clauses 14.2 and 14.3, both Parties recognise that the publication or disclosure of papers, presentations, abstracts or any other written or oral presentations regarding results of and other information regarding the Candidates and Therapies may be beneficial to both Parties, provided that such publications or presentations are subject to reasonable controls to protect Confidential Information, the patentability of inventions and other commercial considerations.  Accordingly, the following shall apply:

 

14.4.1        Any proposed paper, presentation, or other public disclosure regarding any Candidate or Therapy (“Publication”) by either Party (“Publishing Party”) shall be provided to the other Party (“Non-Publishing Party”) for review.  The Non-Publishing Party shall review such proposed Publication within ***       of receipt and may comment on and/or object to any content of the proposed Publication.

 

14.4.2        The Parties shall work together to resolve any comments and objections of the Non-Publishing Party on a timely basis and neither Party shall unreasonably withhold its consent to any proposed Publication, save that a Non-Publishing Party may request deletion of any of its Confidential Information from any such proposed Publication.

 

14.4.3        No Publication shall be made unless the contents of such Publication are mutually agreed between the Parties.

 

14.5      No Use of Names.  Except as expressly provided herein, no right, express or implied, is granted by the Agreement to use in any manner the name of “Adaptimmune” or “Bellicum” or any of their Affiliates, or any other trade name, symbol, logo or trademark of the other Party or its Affiliates, in connection with the performance of this Agreement.

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 41

 

Execution Copy

 

ARTICLE 15    REPRESENTATIONS

 

15.1     Mutual Representations and Warranties.  Each Party represents and warrants to the other Party that as of the Effective Date:

 

15.1.1        it is validly organized under the laws of its jurisdiction of incorporation;

 

15.1.2                          it has obtained all necessary consents, approvals and authorizations of all governmental authorities and other persons or entities required to be obtained by it in connection with this Agreement;

 

15.1.3        the execution, delivery and performance of this Agreement have been duly authorised by all necessary corporate action on its part;

 

15.1.4          it has the legal right and power to enter into this Agreement and to fully perform its obligations hereunder;

 

15.1.5        the performance of its obligations under this Agreement will not conflict with such Party’s charter or incorporation documents or any Third Party agreement, contract or other arrangement to which such Party is a party;

 

15.1.6        it will comply with all Applicable Laws in the performance of this Agreement;

 

15.1.7        it has not received any written letter threatening infringement or alleging any infringement in relation to any Background IP which to its actual knowledge will be required for performance of the POC Plan or any Co-Development Plan;

 

15.1.8          it will not use in the performance of this Agreement any person or personnel (whether directly or through a subcontractor) that has been debarred or otherwise prevented or restricted from performing any clinical research or has been convicted of any offence related to any Clinical Trial in any jurisdiction or otherwise prevented from performing any Clinical Trial by any Regulatory Authority; and

 

15.1.9         it has the legal right and power to extend the rights and licenses granted to the other Party hereunder.

 

15.2        Disclaimers.  EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO PATENTS, KNOW-HOW, MATERIALS OR CONFIDENTIAL INFORMATION SUPPLIED BY IT TO THE OTHER PARTY HEREUNDER, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT.  IN PARTICULAR BOTH PARTIES ACCEPT THAT, GIVEN THE NATURE OF THE CANDIDATES AND THERAPIES BEING GENERATED UNDER THIS AGREEMENT, THERE CAN BE NO GUARANTEE THAT ANY CANDIDATE CAN BE SUCCESSFULLY GENERATED OR THAT IF GENERATED, THE CANDIDATE OR ASSOCIATED THERAPY WILL BE CAPABLE OF OBTAINING REGULATORY APPROVAL.

 

ARTICLE 16    INDEMNIFICATION

 

16.1    Indemnification by Adaptimmune.  Subject to Clause 16.3, Adaptimmune shall indemnify, defend and hold Bellicum, its Affiliates, their Sublicensees and their respective directors, officers, and employees and the successors and assigns of any of the foregoing harmless from and against any and all liabilities, damages, settlements, penalties, fines, costs or expenses (including reasonable attorneys’ fees and other reasonable expenses of litigation) (collectively, “Loss” or “Losses”) to the extent arising out of or in connection with any Third Party claims, suits, actions, demands or judgments (“Third Party Claims”) relating to (a) the negligence or willful misconduct of Adaptimmune or its Affiliates, Sublicensees or any of its or

 

Page 42

 

Execution Copy

 

their sub-contractors; and (b) any breach of Applicable Laws by Adaptimmune or its Affiliates, Sublicensees or any of its or their sub-contractors except, in each case, to the extent caused by the negligence or willful misconduct of Bellicum or its Affiliates or breach of this Agreement by Bellicum or its Affiliates.

 

16.2     Indemnification by Bellicum.  Subject to Clause 16.3, Bellicum shall indemnify, defend and hold Adaptimmune, its Affiliates and their respective directors, officers, and employees and the successors and assigns of any of the foregoing harmless from and against any and all Losses to the extent arising out of or in connection with any Third Party Claims relating to (a) the negligence or willful misconduct of Bellicum, its Sublicensees or any sub-contractor of Bellicum (including its Affiliates); and (b) any breach of Applicable Laws by Bellicum, its Affiliates, Sublicensees or sub-contractors except, in each case, to the extent caused by the negligence or willful misconduct of Adaptimmune or its Affiliates or breach of this Agreement by Adaptimmune or its Affiliates.

 

16.3      Procedure.  If a Party intends to claim indemnification under this Agreement (the “Indemnitee”), it shall promptly notify the other Party (the “Indemnitor”) in writing of such alleged Loss and the Third Party Claim.  The Indemnitor shall have the right to control the defense thereof with counsel of its choice as long as such counsel is reasonably acceptable to Indemnitee.  Any Indemnitee shall have the right to retain its own counsel at its own expense for any reason in connection with such Third Party Claim, provided, however, that if the Indemnitee shall have reasonably concluded, based upon a written opinion from outside legal counsel, that there is a conflict of interest between the Indemnitor and the Indemnitee in the defense of such action, the Indemnitor shall pay the fees and expenses of one law firm serving as counsel for the Indemnitee in relation to such Third Party Claim.  The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any Third Party Claims covered by this Agreement.  The obligations of this Article 16 shall not apply to any settlement of any Third Party Claims if such settlement is effected without the consent of both Parties, which shall not be unreasonably withheld or delayed.  The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, to the extent prejudicial to its ability to defend such action, shall relieve the Indemnitor of any obligation to the Indemnitee under this Clause 16.3.  It is understood that only Bellicum and Adaptimmune may claim indemnity under this Agreement (on its own behalf or on behalf of its Indemnitees), and other Indemnitees may not directly claim indemnity hereunder.

 

16.4      Insurance.

 

16.4.1        Insurance Coverage.  Each Party shall obtain and maintain comprehensive general liability insurance customary in the industry for companies of similar size conducting similar business.

 

16.4.2       Evidence of Insurance.  No earlier than ***                 after signing this Agreement, each Party shall provide, upon request therefor, the other Party with its certificate of insurance evidencing the insurance coverage set forth Clause 16.4.1.

 

16.4.3       Therapy / Clinical Trial Liability Insurance.  Commencing not later than first patient enrolment in a Clinical Trial using the first Therapy comprising the Bellicum Candidate, Bellicum shall have and maintain such type and amounts of Therapies / clinical trial liability insurance covering the development of Therapies as is normal and customary in the industry generally for parties similarly situated, but, in any event, with a minimum combined single limit per occurrence for clinical trials liability as follows: a minimum limit of ***                US dollars ($***              ) for any period during which Bellicum or any of its Sublicensees is conducting a clinical trial(s) with any Therapy(s) or as otherwise required in order to comply with Applicable Laws.  Commencing not later than first patient enrolment in a Clinical Trial using the first Therapy comprising the Adaptimmune Candidate, Adaptimmune shall have and maintain such type and amounts of Therapies / clinical trial liability insurance covering the development of Therapies as is normal and customary in the industry generally for parties similarly situated, but, in any

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 43

 

Execution Copy

 

event, with a minimum combined single limit per occurrence for clinical trials liability as follows: a minimum limit of ***                US dollars ($***              ) for any period during which Adaptimmune or any of its Sublicensees is conducting a clinical trial(s) with any Therapy(s) or as otherwise required in order to comply with Applicable Laws.  Such insurance policies of each Party shall be primary insurance.

 

16.5     Limitation of Damages.  NEITHER PARTY HERETO WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT IN RESPECT OF ANY BREACH OF (1) A PARTY’S OBLIGATIONS UNDER ARTICLE 12 OR 13, OR (2) INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 16 FOR THIRD PARTY CLAIMS.  FOR THE AVOIDANCE OF DOUBT, NOTHING IN THIS CLAUSE SHALL LIMIT OR EXCLUDE ANY LIABILITY TO A THIRD PARTY FOR FRAUD BY ANY PARTY OR ANY LIABILITY ARISING AS A RESULT OF PERSONAL INJURY OR DEATH CAUSED BY NEGLIGENCE OF ANY PARTY.  NOTHING IN THIS CLAUSE 16.5 SHALL LIMIT EITHER PARTY’S RIGHT TO PURSUE AND OBTAIN EQUITABLE RELIEF.

 

16.6     Therapy Recall.  Bellicum shall be responsible for investigating any SUSAR or other complaint in relation to any Therapy comprising a Bellicum Candidate.  Adaptimmune shall be responsible for investigating any SUSAR or other complaint in relation to any Therapy comprising an Adaptimmune Candidate.  The responsible Party shall report its finding to the JDC or JCC, as relevant, once it has identified the reason for such complaint, SUSAR or has identified any requirement to recall any Therapy or any batch of Therapy.  The responsible Party shall be responsible for carrying out any Therapy recall but shall keep the JDC or JCC, as relevant, informed of the status and process for such recall including any material correspondence with any Regulatory Authority.  Where such recall is during the performance of any POC Plan or Co-development Plan, the costs associated with such recall will be shared between the Parties in the same way as other Co-Development Plan costs unless (a) such recall is due to any failure of responsible Party arising out of the manufacture or supply of Therapy or any part of the Therapy; or (b) any such costs are covered by applicable insurance policies.  The costs associated with any recall during commercialisation of any Therapy and after Completion of the relevant Co-Development Plan shall be shared in accordance with the terms of the Co-Commercialisation Agreement or if none, Exhibit 3.

 

ARTICLE 17    TERM AND TERMINATION

 

17.1        Term.  The term of this Agreement (the “Term”) shall commence on the Effective Date and, unless sooner terminated as provided in this Article 17, shall continue in full force and effect, on a country-by-country and Therapy-by-Therapy basis until such Therapy ceases being commercialized by either Party, at which time this Agreement shall expire with respect to such Therapy in such country (except for such provisions of this Agreement as continue beyond its natural expiration).  The Term shall expire on the date this Agreement has expired in its entirety with respect to all Therapies in all countries in the world.

 

17.2      Opt-out Rights.  Following the start date of any Co-Development Plan of the other Party or the start date of any Co-Commercialisation Agreement, and without prejudice to the termination rights set out in Clauses 17.3 - 17.5 below, a Party (“Notifying Party”) may notify the other Party (“Non-notifying Party”) in writing that it wishes to opt-out of its funding obligation under any such Co-Development Plan or Co-Commercialisation Agreement, as appropriate (“Opt-out Notice”).  Any Opt-out Notice shall be subject to the following:

 

17.2.1         Any Opt-out Notice may only be provided by the Notifying Party in relation to, in the case of Adaptimmune, any Bellicum Candidate or Bellicum Therapy, and in the case of Bellicum, any Adaptimmune Candidate or Adaptimmune Therapy (such Candidate or Therapy in relation to which the Opt-out Notice has been provided, the “Opt-Out Candidate/ Therapy”).

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 44

 

Execution Copy

 

17.2.2       The Opt-out Notice shall take effect on the date notified by the Notifying Party in the Opt-out Notice, such date to be no earlier than ***                          from date of receipt of Opt-out Notice by Non-notifying Party (“Opt-out Date”).  During such period between delivery of the Opt-out Notice and the Opt-out Date, the Non-notifying Party may only incur expenses in accordance with the then-current budget for such Opt-Out Candidate/ Therapy, and the Notifying Party shall continue to bear its share of expenses for such Opt-Out Candidate/ Therapy in accordance with Article 10.

 

17.2.3          From and after the Opt-out Date:

 

(a)     The Notifying Party (including its Affiliates) shall have no further obligation to reimburse the costs arising under the Co-Development Plan for such Opt-Out Candidate/ Therapy, save that the obligation to reimburse under Section 10.2 shall continue in relation to any costs and expenses incurred prior to the Opt-out Date.

 

(b)    The Notifying Party shall have no further license under the Non-notifying Party’s intellectual property rights in such Opt-Out Candidate/ Therapy, save as required for any remaining performance under Section 17.2.3(g) below.

 

(c)     The Notifying Party shall have no further right to commercialize or develop (including conducting any clinical trials) such Opt-Out Candidate/ Therapy.

 

(d)    The Notifying Party shall have no right or obligation to share in any profit or loss, respectively, arising from sale of such Opt-Out Candidate/ Therapy, save that any right or obligation to share in any profit or loss arising from the sale of such Opt-Out Candidate/ Therapy prior to the Opt-out Date shall continue as provided under this Agreement or under the Co-Commercialisation Agreement (if separate).

 

(e)     The Non-notifying Party shall continue to be licensed and entitled to proceed with the development or commercialisation of such Opt-Out Candidate/ Therapy in accordance with Article 8 of this Agreement.

 

(f)     The continuing Non-notifying Party shall be fully responsible for the remaining development and commercialization of such Opt-Out Candidate/ Therapy, save as provided in Section 17.2.3(g) below;

 

(g)    The Non-notifying Party may request that the Notifying Party continue to perform certain of its obligations under the Co-Development Plan for such Opt-Out Candidate/ Therapy, particularly to the extent such obligations relate to any Reserved Activity of the Notifying Party, or to the Adaptimmune Technology or Bellicum Technology, as applicable to the Notifying Party, or to any safety reporting by the Notifying Party that has relevance to such Opt-Out Candidate/ Therapy.  At the Non-notifying Party’s sole expense (for resources expended by the Notifying Party, including payments for personnel on an FTE basis, at the FTE rates set forth in Exhibit 2), the Notifying Party shall perform its obligations under the Co-Development Plan, including with respect to such Reserved Activities and/or to the Adaptimmune Technology or Bellicum Technology, as applicable to the Notifying Party, as reasonably and specifically requested by the Non-notifying Party in writing, and in each case as reasonably necessary for the further development and commercialization of such Opt-Out Candidate/ Therapy.  The Notifying Party shall ensure that it transfers to the Non-notifying Party, at the Non-notifying Party’s expense, any items and rights controlled by the Notifying Party that are necessary for the Non-notifying Party to advance such Opt-Out Candidate/ Therapy on its own

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 45

 

Execution Copy

 

through development and commercialization; provided that (a) this obligation does not include ***

 

                                         ; and (b) this obligation does not include ***

 

                                  .  Performance of activities (excluding co-funding activities) by the Notifying Party pursuant to this Clause 17.2.3(g) shall continue to be made in accordance with the provisions of this Agreement and the applicable Co-Development Plan.

 

(h)     Provisions of this Agreement as are applicable to the continuing rights and activities of either Party following the Opt-out Date, for any Candidate or Therapy of a Party in relation to which no Opt-out Notice has been provided, shall continue in full force and effect, including in relation to any Opt-Out Candidate/ Therapy, and shall include Article 5, Article 6, Article 8 (as amended in this Clause 17.2.3), Article 9, Article 11 (in relation to any payments which remain due and owing or are payable under Clause 17.2.4 below), Article 12, Article 13, and Article 16.  The provisions of Article 2, to the extent they relate to an Opt-Out Candidate/ Therapy, shall cease to apply, save that Clause 2.9 shall continue and survive.

 

17.2.4          Non-notifying Party will pay to Notifying Party ***                                                         
  for its use of the Notifying Party’s Licensed Intellectual Property in relation to an Opt-Out Candidate/ Therapy.  The ***           shall be ***

until ***

 

                                                     .  For clarity, such

 

***      shall be payable ***

 

.

 

If the Parties enter into a related agreement that includes non-financial terms and conditions regarding use of the Notifying Party’s Licensed Intellectual Property (which shall be consistent with the terms and conditions of this Agreement), the***                 set forth above (but no other financial terms) shall be incorporated into such agreement.

 

17.3        Termination by Either Party for Material Breach.  Either Party may terminate this Agreement (i) in its entirety, (ii) with respect to any Exclusive License granted by such Party, (iii) with respect to a given Selected Target (and Candidates directed to such Selected Target), or (iv) on a country-by-country basis, by written notice delivered to the other Party for any material breach of this Agreement by the other Party if, in the case of remediable breach, such material breach is not cured within sixty (60) days (thirty (30) days for payment defaults) after the breaching Party receives written notice of such breach from the non-breaching Party describing such breach and demanding its cure; provided, that if such breach is not capable of being cured within such 90-day (or 30-day) period, the cure period shall be extended for such amount of time that the Parties may agree in writing is reasonably necessary to cure such breach, so long as (1) the breaching Party is making Commercially Reasonable Efforts to do so, and (2) the Parties agree on an extension within such 90-day (or 30-day) period.  For clarity, this Agreement may be terminated in its entirety under this Clause 17.3 only if the material breach affects the fundamental purpose of this Agreement.  Notwithstanding anything to the contrary herein, if the allegedly breaching Party in good faith either disputes (a) whether a breach is material or has occurred or (b) the alleged failure to cure or remedy such material breach, and provides written notice of that dispute to the other Party within the above time periods, then the matter will be addressed under the dispute resolution provisions in Article 18, and the notifying Party may not so terminate this Agreement until it has been determined under Article 18 that the allegedly breaching Party is in material breach of this

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 46

 

Execution Copy

 

Agreement, and such breaching Party further fails to cure such breach within 90-days (or such longer period as determined by the arbiter of such dispute resolution) after the conclusion of that dispute resolution procedure.

 

17.4        Termination by Either Party for Insolvency or Bankruptcy.  Either Party may terminate this Agreement effective ten (10) business days after delivery of written notice to the other Party upon the liquidation, dissolution, winding-up, insolvency, bankruptcy, or filing of any petition therefor, appointment of a receiver, custodian or trustee, or any other similar proceeding, by or of the other Party where such petition, appointment or similar proceeding is not dismissed or vacated within ninety (90) calendar days.  All rights and licenses granted pursuant to this Agreement are, for purposes of Clause 365(n) of Title 11 of the United States Code or any foreign equivalents thereof (as used in this Clause 20.3, “Title 11”), licenses of rights to “intellectual property” as defined in Title 11.  Each Party in its capacity as a licensor hereunder agrees that, in the event of the commencement of bankruptcy proceedings by or against such bankrupt Party under Title 11, (a) the other Party, in its capacity as a licensee of rights under this Agreement, shall retain and may fully exercise all of such licensed rights under this Agreement (including as provided in this Clause 17.4) and all of its rights and elections under Title 11, and (b) the other (licensee) Party shall be entitled to a complete duplicate of all embodiments of such intellectual property, and such embodiments, if not already in its possession, shall be promptly delivered to the other (licensee) Party (i) upon any such commencement of a bankruptcy proceeding, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under (i), immediately upon the rejection of this Agreement by or on behalf of the bankrupt Party.

 

17.5        Termination by Either Party, or Automatically Under Clause 3.5

 

17.5.1          Bellicum may terminate:

 

(a)     the Exclusive License granted by Adaptimmune relating to any Bellicum Candidate at any time by providing written notice to Adaptimmune, such termination to be effective ninety (90) days after provision of such notice; and

 

(b)    the Exclusive License relating to any particular Adaptimmune Candidate at any time after start of Phase II Clinical Trials for such Adaptimmune Candidate by providing written notice to Adaptimmune, where Adaptimmiune has materially ceased the commercialisation or development of such Adaptimmune Candidate or Adaptimmune Therapy comprising such Adaptimmune Candidate, and such cessation is not due to significant safety or efficacy concerns with the relevant Adaptimmune Therapy, such termination to be effective ninety (90) days after provision of such notice.

 

17.5.2          Adaptimmune may terminate

 

(a)     the Exclusive License granted by Bellicum relating to any Adaptimmune Candidate at any time by providing written notice to Bellicum; such termination to be effective ninety (90) days after provision of such notice; and

 

(b)    the Exclusive License relating to any particular Bellicum Candidate at any time after start of Phase II Clinical Trials for such Bellicum Candidate by providing written notice to Bellicum, where Bellicum has materially ceased the commercialisation or development of such Bellicum Candidate or Bellicum Therapy comprising such Bellicum Candidate, and such cessation is not due to significant safety or efficacy concerns with the relevant Bellicum Therapy, such termination to be effective ninety (90) days after provision of such notice.

 

Page 47

 

Execution Copy

 

17.5.3          Either Party (in the case of the following clauses (a) and (b)), and the licence-granting Party (in the case of the following clause (c)) may terminate

 

(a)     Any Exclusive License granted to it, and such Party’s associated Co-Development Plan, where it believes that continuing with the applicable Candidate and Therapy comprising such Candidate causes or is likely to cause significant safety or efficacy concerns, and following written notification of such concerns to the other Party.  Any termination under this Clause 17.5.3(a) shall be effective ninety (90) days after the other Party’s receipt of such notice;

 

(b)    The Agreement in accordance with Clause 3.4, on provision of 30 days written notice to the other Party; and

 

(c)     The Exclusive Licence under which a licence has been granted to the other Party to use any of such Party’s Licensed Intellectual Property, if the other Party or its Affiliates or Sublicensees commences proceedings (whether before a regulatory or administrative body or a court) anywhere in the world, or voluntarily assists any Third Party in commencing or participating in such proceedings (whether before a regulatory or administrative body or a court) alleging that any claim in any Patent within such Licensed Intellectual Property that is licensed to the other Party by such Party (including the Adaptimmune Background IP or Bellicum Background IP, as applicable) is invalid, unenforceable or otherwise not patentable, and such proceedings are not withdrawn within thirty (30) days after receipt of a written notice to withdraw.  Notwithstanding the foregoing, a licence-granting Party shall have no right to terminate any Exclusive License pursuant to this Clause 17.5.3(c) if any proceedings are brought as a defense (including an affirmative defense) in relation to a claim of infringement brought against the other Party or its Affiliates or Sublicensees.

 

17.5.4          A Party may terminate the Exclusive License(s) granted to the Party undergoing a Change of Control (the “CoC Party”), such termination being subject to the following: (a) provision of written notice to such Party by the CoC Party within fourteen (14) days after the Change of Control is consummated; and (b) provision by such Party to the CoC Party of written notice of termination of such Exclusive License(s) granted by such Party within thirty (30) days of becoming notified of the Change of Control of the CoC Party; provided that such termination right will apply only with respect to any Candidate(s) that has not been designated as a Joint Selected Candidate of the CoC Party (i.e., a Candidate that has not been selected by the JDC for advancement to pre-clinical and clinical development) at the date of consummation of the Change of Control.  For clarity, and with respect to Joint Selected Candidates of the CoC Party that exist at the date of consummation of the Change of Control, any Exclusive Licenses granted to the CoC Party for its existing Joint Selected Candidates shall remain in full force and effect after such Change of Control.  To the extent the Party that is not the CoC Party determines earlier than expiry of the period of thirty (30) days from being notified of such Change of Control that it will not terminate the Exclusive License(s) granted by it, it will notify the CoC Party accordingly in writing, and such right to terminate the Exclusive License(s) granted to the CoC Party for such Change of Control shall cease on receipt of such written notice by the CoC Party.

 

17.5.5          Termination of the Agreement will also occur automatically in accordance with Clause 3.5.

 

17.6        Accrued Rights and Obligations.  Expiration or termination of this Agreement in its entirety, or with respect to a particular Exclusive License, a given Therapy or Candidate, or a given country for any reason, shall not release either Party hereto from any liability which, as of the effective date of such expiration or termination, had already accrued to the other Party or which is attributable to a period prior to such termination, nor preclude either Party from

 

Page 48

 

Execution Copy

 

pursuing any rights and remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior to the effective date of such expiration or termination.

 

17.7        Effects of Termination.  The effects of termination set forth in this Clause 17.7 shall apply either with respect to this Agreement in its entirety, if the Agreement is terminated in its entirety, or only with respect to a specific Therapy, Candidate or Exclusive License or country, if this Agreement is only terminated with respect to a specific Therapy, Candidate or Exclusive License or country, in all cases as applicable.  For clarity, this Clause 17.7 shall not apply to any given Therapy and country with respect to which the Term naturally expires.

 

17.7.1          Termination of Licenses.

 

(a)     Upon termination of a particular Exclusive License granted by Adaptimmune pursuant to Clause 17.3, Clause 17.5, such Exclusive License and the related Development License to any Selected Target, Therapy or Candidate covered by such Exclusive License shall terminate as of the effective date of such termination.  Bellicum shall ensure that it transfers to Adaptimmune all items and rights necessary for Adaptimmune to advance on its own, through development and commercialization, the Candidate/ Therapy that was the subject of the terminated Exclusive License.  The exclusivity to the relevant Target under Clause 4.1.2 shall also cease as of the effective date of such termination;

 

(b)    Upon termination of a particular Exclusive License granted by Bellicum pursuant to Clause 17.3, Clause 17.5, such Exclusive License and the related Development License to any Selected Target, Therapy or Candidate covered by such Exclusive License shall terminate as of the effective date of such termination.  Adaptimmune shall ensure that it transfers to Bellicum all items and rights necessary for Bellicum to advance on its own through development and commercialization the Candidate/ Therapy that was the subject of the terminated Exclusive License.  The exclusivity to the relevant Target under Clause 4.1.2 shall also cease as of the effective date of such termination; and

 

(c)     Upon termination of the Agreement in its entirety by either Party pursuant to Clause 17.3, Clause 17.4, Clause 17.5.4 or Clause 17.5.3(b), or an automatic termination of the Agreement as described in Clause 17.5.5, all licenses and options granted under this Agreement shall terminate as of the effective date of such termination.

 

17.7.2          Clinical Trials.  The Parties shall ensure that where termination of any Exclusive License or this Agreement occurs during any Clinical Trial, that any such Clinical Trial shall be wound down in accordance with the protocol for such Clinical Trial and in such a way as to minimize any patient harm and at all times in accordance with all Applicable Laws.

 

17.7.3          Return of Confidential Information.  Following expiry or any early termination of this Agreement, the Party that has Confidential Information of the other Party shall to the extent reasonably possible destroy (at such Party’s written request) or put beyond use all such Confidential Information in its possession as of the effective date of expiration or termination (with the exception of one copy of such Confidential Information, which may be retained by the legal department of the Party that received such Confidential Information solely for purposes of ensuring compliance with confidentiality obligations), provided that each Party may retain and continue to use such Confidential Information of the other Party to the extent necessary to exercise any surviving rights, licenses or obligations under this Agreement or any obligation under Applicable Laws.  This clause shall not require return or destruction of any Confidential Information which is held on back-up servers or archive systems, provided such back-ups have been made as part of the routine business of a Party and such back-ups are not accessible other than

 

Page 49

 

Execution Copy

 

by members of the IT team at such Party.  Any retained Confidential Information will continue to be subject to the confidentiality provisions of this Agreement.

 

17.7.4          Inventory at Termination.  Subject to Clause 17.7.5, upon termination of this Agreement or any Exclusive License under Clause 17.3, Clause 17.4, Clause 17.5.1(b) or Clause 17.5.2(b), and for a period of ***               months following such termination, any non-breaching Party and its permitted Affiliates and Sublicensee/s shall have the right to sell or otherwise dispose of all inventory of Therapies in all countries then in its stock, subject to payment of its share of co-commercialisation receipts due under this Agreement, and any other applicable provisions of this Agreement, and the other Party covenants not to sue such non-breaching Party or its permitted Sublicensee/s for infringement under, or misappropriation of, any of the Licensed Intellectual Property that were licensed by other Party to non-breaching Party immediately prior to such termination with respect to such activities conducted by non-breaching Party or its permitted Sublicensee/s pursuant to this Clause 17.7.4.  To the extent any continuing requirement to supply exists after such termination, the Parties may mutually agree that the non-breaching Party can continue to supply to the breaching Party to fulfill any such continuing supply requirement.

 

17.7.5          Right to take over Manufacture, Sell and Supply.  On termination of any Exclusive License where such termination is for a material breach by the other Party under Clause 17.3 or in the event of insolvency under Clause 17.4 or under Clause 17.5.1(b) or Clause 17.5.2(b) or under Clause 17.5.3(c), and upon the Parties’ negotiation and execution of a corresponding written agreement containing mutually agreed, commercially reasonable terms and conditions pursuant to Clause 17.7.6, the terminating Party shall be entitled to take over the manufacture, supply and development of the relevant Joint Selected Candidate and any Therapy utilising the Joint Selected Candidate that are the subject of the terminated Exclusive License. The other (terminated) Party shall provide to the terminating Party reasonable assistance, documentation (including manufacturing process information) as may be reasonably required by the terminating Party for the ongoing manufacture and supply of the relevant (terminated) Joint Selected Candidate or Therapy (to the extent that the terminated Party can do so without violating its obligations to Third Parties), at terminating Party’s sole cost and expenses (subject to ***                 as set out below).  Such assistance shall include, to the extent relevant and depending on the stage of research and development of the relevant (terminated) Therapy or Joint Selected Candidate:

 

(a)     transfer of any INDs and Regulatory Approvals regarding the terminated Therapy or Joint Selected Candidate held by other (terminated) Party to the terminating Party (which terminating Party shall promptly accept);

 

(b)    provision of all CMO and CRO details and other sub-contractor details regarding the terminated Therapy or Joint Selected Candidate, where not already known to terminating Party, and where reasonably possible transfer of all related sub-contractor agreements (to the extent such transfer is requested by terminating Party), subject where relevant to the consent of any relevant Third Party;

 

(c)     provision of all master drug files and records or documentation regarding the terminated Therapy or Joint Selected Candidate and required by terminating Party to continue with any Clinical Trials or Regulatory Approvals of such terminated Therapy or Joint Selected Candidate or as may otherwise be required in order to comply with Applicable Laws in this regard;

 

(d)    transfer of sponsorship for any Clinical Trials and transfer of any Third Party agreements associated with such Clinical Trials regarding the terminated Therapy or Joint Selected Candidate, subject where relevant to the consent of any relevant Third Party;

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 50

 

Execution Copy

 

(e)     provision of all reasonable assistance and technical training as may be reasonably required by terminating Party to enable transfer of manufacture, ongoing Clinical Trials and supply of the terminated Therapy or Joint Selected Candidate to the terminating Party as soon as reasonably possible; and

 

(f)     provision of any documentation relating to any associated diagnostics and diagnostic assays regarding the terminated Therapy or Joint Selected Candidate, to the extent not covered by any transfer of a Third Party agreement to terminating Party.

 

17.7.6          On termination of any Exclusive License and transfer of the terminated Therapy or Joint Selected Candidate under Clause 17.7.5 pursuant to a written agreement containing commercially reasonable terms and conditions that are negotiated and executed by the Parties on a timely basis, and where such termination occurs after completion of the Co-Development Phase, the Parties shall negotiate and agree, in good faith, upon appropriate ***

 

 

              .  The terminating Party shall have no rights to take over the manufacture, sale and supply of any Joint Selected Candidate or Therapy utilizing such Joint Selected Candidate under Clause 17.7.5 unless and until such agreement is executed by the Parties.  Such agreement between the Parties shall also include terms relating to the transfer of manufacture, supply and development of such terminated Joint Selected Candidate or Therapy.  Neither Party shall unreasonably delay negotiation of such agreement, and any negotiations shall be in good faith at all times.  Where any agreement terms have not been finalised within ninety (90) days of the effective date of termination, such unresolved terms may be forwarded to the respective officers of the Parties set out in Clause 18.1 for resolution.  Where such respective officers remain unable to resolve any unresolved terms within a further sixty (60) days of the date of referral to such respective officers, then (i) in relation to any unresolved terms that relate to the compensation which breaching Party should receive under such agreement, then such unresolved terms shall be determined by arbitration in accordance with Clause 18.2.  The Parties shall incorporate the ***                      terms, once agreed upon by the Parties or determined through arbitration, in such agreement.

 

17.8        Survival.  In addition to any provisions specified in this Agreement as surviving under the applicable circumstances, the following provisions shall survive: Articles 6, 10 (to the extent any reimbursement of any shared costs remains outstanding), 11, 12, 13, 14, 15, 16, 18, 19, 20, 21 and Clauses 5.4.2, 7.4, 10.2.6, 10.2.7, 17.6, 17.7, and 17.8.  In addition to those provisions specifically referenced in this Clause 17.8, those provisions which by their nature are intended to survive, as well as any other provisions necessary to interpret or implement any other surviving provisions (including, to the extent applicable, the definitions in Article 1), shall survive.

 

ARTICLE 18    DISPUTE RESOLUTION

 

18.1        Disputes.  Adaptimmune and Bellicum recognize that a dispute, controversy or claim of any nature whatsoever arising out of or relating to this Agreement, or the breach, termination or invalidity thereof (each, a “Dispute”), may from time to time arise during the Term.  Unless otherwise specifically recited in this Agreement, such Disputes between Adaptimmune and Bellicum will be resolved as recited in this Article 18.  In the event of the occurrence of such a Dispute, the Parties shall first refer such Dispute to their respective Alliance Managers for attempted resolution by such Alliance Managers within ***                after such referral.  If such Dispute is not resolved within such ***                   period, either Adaptimmune or Bellicum may, by written notice to the other, have such Dispute referred to their respective officers designated below, or their respective designees, for attempted resolution within ***

 

after such notice is received.  Such designated officers are as follows:

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 51

 

Execution Copy

 

For Bellicum —   Chief Executive Officer

 

For Adaptimmune — Chief Executive Officer

 

In the event the designated officers, or their respective designees, are not able to resolve such Dispute, and if resolution of such Dispute is not explicitly provided for herein through any other means, then within ***                     of such other Party’s receipt of such written notice, either Party may initiate the dispute resolution procedures set forth in Clause 18.2.

 

18.2        Arbitration.

 

18.2.1          Rules.  Except as otherwise expressly provided in this Agreement (including under Clause 18.3 with respect to Patent-related matters), the Parties agree that any Dispute not resolved internally by the Parties pursuant to Clause 18.1 shall be resolved through binding arbitration conducted by the International Chamber of Commerce in accordance with the then prevailing Rules of Arbitration of the International Chamber of Commerce (for purposes of this Article 18, the “Rules”), except as specifically modified in this Agreement, applying the substantive law specified in Clause 21.1.

 

18.2.2          Arbitrators; Location.  Each Party shall select one (1) arbitrator, and the two (2) arbitrators so selected shall choose a third arbitrator.  All three (3) arbitrators shall serve as independent arbitrators and have at least ten (10) years of (a) dispute resolution experience (including judicial experience) and/or (b) legal or business experience in the biotech or pharmaceutical industry.  In any event, at least one (1) arbitrator shall satisfy the foregoing experience requirement under Clause (b).  If a Party fails to nominate its arbitrator, or if the Parties’ arbitrators cannot agree on the third, the necessary appointments shall be made in accordance with the Rules.  Once appointed by a Party, such Party shall have no ex parte communication with its appointed arbitrator.  The arbitration proceedings shall be conducted in New York, New York.  The arbitration proceedings and all pleadings and written evidence shall be in the English language.  Any written evidence originally in another language shall be translated into English and accompanied by the original or a true copy thereof.

 

18.2.3          Procedures; Awards.  Each Party agrees to use reasonable efforts to make all of its current employees available to the arbitrators, if reasonably needed, and agrees that the arbitrators may determine any person as necessary.  The arbitrators shall be instructed and required to render a written, binding, non-appealable resolution and award on each issue that clearly states the basis upon which such resolution and award is made.  The written resolution and award shall be delivered to the Parties as expeditiously as possible, but in no event more than ***               after conclusion of the hearing, unless otherwise agreed by the Parties.  Judgment upon such award may be entered in any competent court or application may be made to any competent court for judicial acceptance of such an award and order for enforcement.  Each Party agrees that, notwithstanding any provision of Applicable Law or of this Agreement, it will not request, and the arbitrators shall have no authority to award, punitive or exemplary damages against any Party.  All information disclosed and generated in the course of such arbitration proceeding shall be treated as confidential information by each of the Parties.

 

18.2.4          Costs.  The prevailing Party, as determined by the arbitrators, shall be entitled to (a) its share of fees and expenses of the arbitrators and (b) its reasonable attorneys’ fees and associated costs and expenses.  In determining which Party “prevailed,” the arbitrators shall consider (i) the significance, including the financial impact, of the claims prevailed upon and (ii) the scope of claims prevailed upon, in comparison to the total scope of the claims at issue.  If the arbitrators determine that, given the scope of the arbitration, neither Party “prevailed,” the arbitrators shall order that the Parties (1) share equally the fees and expenses of the arbitrators and (2) bear their own attorneys’ fees and associated costs and

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 52

 

Execution Copy

 

expenses.

 

18.2.5          Interim Equitable Relief.  Notwithstanding anything to the contrary in this Clause 18.2, in the event that a Party reasonably requires relief on a more expedited basis than would be possible pursuant to the procedure set forth in this Article 18, such Party may seek a temporary injunction or other interim equitable relief in a court of competent jurisdiction pending the ability of the arbitrators to review the decision under this Clause 18.2.  Such court shall have no jurisdiction or ability to resolve Disputes beyond the specific issue of temporary injunction or other interim equitable relief.

 

18.2.6          Protective Orders; Arbitrability.  At the request of either Party, the arbitrators shall enter an appropriate protective order to maintain the confidentiality of information produced or exchanged in the course of the arbitration proceedings.  The arbitrators shall have the power to decide all questions of arbitrability.

 

18.3        Subject Matter Exclusions.  Notwithstanding the provisions of Clause 18.2, any Dispute not resolved internally by the Parties pursuant to Clause 18.1 that involves the validity or infringement of a Patent Covering a Therapy or Candidate shall be brought before an appropriate regulatory or administrative body in the country in which such Patent is granted or applied for, and the Parties hereby consent to the jurisdiction and venue of such courts and bodies.

 

18.4        Continued Performance.  Provided that this Agreement has not terminated, the Parties agree to continue performing under this Agreement in accordance with its provisions, pending the final resolution of any Dispute.

 

ARTICLE 19    ANTI-BRIBERY

 

19.1       Anti-Bribery.

 

19.1.1          “Anti-Corruption Laws” means all anti-corruption and anti-bribery laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the United Kingdom Bribery Act 2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism.

 

19.1.2          “Government Official” means any person employed by or acting on behalf of a government, government-controlled entity or public international organization; any political party, party official or candidate; any person who holds or performs the duties of an appointment, office or position created by custom or convention; and any person who holds himself out to be the authorised intermediary of any of the foregoing.

 

19.1.3          The Parties agree, on behalf of themselves and their respective officers, directors and employees, that in connection with this Agreement, it shall not directly or indirectly pay, offer or promise to pay, or authorise the payment of any money, or give, offer or promise to give, or authorise the giving of anything else of value, to (i) any Government Official in order to influence official action; (ii) any person (whether or not a Government Official) (a) to influence such person to act in breach of a duty of good faith, impartiality or trust, (b) to reward such person for acting improperly, or (c) where such person would be acting improperly by receiving the money or other thing of value; (iii) any other person while knowing or having reason to know that all or any portion of the money or other thing of value will be paid, offered, promised or given to, or will otherwise benefit a Government Official in order to influence official action for or against any party in connection with the matters that are the subject of this agreement; or (iv) any person to reward that person for acting improperly or to induce that person to act improperly.

 

Page 53

 

Execution Copy

 

19.1.4          The Parties agree, on behalf of themselves and their respective officers, directors and employees that work in connection with this Agreement that they shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation of the Anti-Corruption Laws.  In connection with the performance of the services hereunder, the Parties undertake to comply with the Anti-Corruption Laws and shall not take any action that will, or would reasonably be expected to, cause it to be in violation of any such laws to the extent applicable to either Party.

 

19.1.5          Each Party shall promptly provide the other Party with written notice of (i) becoming aware of any breach or violation by the relevant Party or its sub-contractors or its or their respective officers, directors, employees, of any of the representation, warranty or undertaking set forth in this Clause 22.1 or (ii) upon receiving a formal notification that it is the target of a formal investigation by any governmental authority for any breach of Anti-Corruption Laws in connection with the performance of this Agreement.

 

ARTICLE 20    DATA PROTECTION

 

For the purposes of this Article, Personal Data shall have the meaning given to it in the Data Protection Act 1998.

 

a)           To the extent applicable, the Parties will comply with all applicable national and international laws, regulations and guidelines relating to protection of the personal information of study subjects, including the European Commission Directive 95/46/IC as it relates to the protection of the personal information of EU/EEA persons, and the Standards for Privacy of Individually Identifiable Health Information (Privacy Rule) under the Health Insurance Portability and Accountability Act of 1996 (HIPAA).

 

b)           The Parties shall process the Personal Data only to the extent, and in such a manner, as is necessary for the purposes of performing their respective obligations under this Agreement and for other lawful purposes. In addition any Personal Data shall only be processed in accordance with any informed consents.

 

c)           The Parties shall not disclose the Personal Data to any person except as required or permitted by this Agreement or with the written consent of the other Party.

 

d)           The Parties shall implement appropriate technical and organisational measures to protect the Personal Data against accidental or unlawful destruction or accidental loss, unauthorised disclosure, access, use, modification, alteration, copying and all other unlawful forms of Processing.

 

ARTICLE 21    MISCELLANEOUS

 

21.1        Applicable Law.  This Agreement (including the arbitration provisions of Article 21.2) shall be governed by and interpreted in accordance with the laws of England and Wales, without reference to the principles of conflicts of laws.  The United Nations Convention on Contracts for the International Sale of Goods shall not apply to the transactions contemplated by this Agreement.

 

21.2        Notices.  Except as otherwise expressly provided in the Agreement, any notice required under this Agreement shall be in writing and shall specifically refer to this Agreement.  Notices shall be sent via one of the following means and will be effective (a) on the date of delivery, if delivered in person; or (b) on the date of receipt, if sent by private express courier or by first class certified mail, return receipt requested.  Notices shall be sent to the other Party at the addresses set forth below.  Either Party may change its addresses for purposes of this Clause

 

Page 54

 

Execution Copy

 

21.2 by sending written notice to the other Party.

 

	
If to Bellicum:
    	
Bellicum Pharmaceuticals, Inc.
    
	
 
    	
Attn: General Counsel
    
	
 
    	
2130 W. Holcombe Blvd., Suite 800
    
	
 
    	
Houston, Texas USA
    
	
 
    	
77030
    
	
 
    	
 
    
	
If to Adaptimmune:
    	
Adaptimmune Limited
    
	
 
    	
Attn: COO and General Counsel
    
	
 
    	
101 Park Drive
    
	
 
    	
Abingdon, Oxfordshire, UK
    
	
 
    	
OX14 4RX
    

 

21.3        Assignment.  Neither Party may assign or otherwise transfer, in whole or in part, this Agreement without the prior written consent of the non-assigning Party, such approval not to be unreasonably withheld, conditioned or delayed.  Notwithstanding the foregoing, either Party may assign this Agreement to (i) an Affiliate or (ii) any purchaser of all or substantially all of the assets of such Party that relate to the performance of this Agreement, or of all of its capital stock, or to any successor corporation or entity resulting from any merger or consolidation or re-organization of such party with or into such corporation or entity, provided that the Party to which this Agreement is assigned expressly agrees in writing to assume and be bound by all obligations of the assigning Party under this Agreement.  Subject to the foregoing, this Agreement will benefit and bind the Parties’ successors and permitted assigns. Any assignment not in accordance with Clause 21.3 shall be null and void.

 

21.4        Non-solicit.  Neither Party shall (except with the prior written consent of the other Party) knowingly solicit for employment or entice away (or attempt to solicit or entice away) from the employment of the other Party any person employed in the provision of such other Party’s obligations under any POC Plan or Co-Development Plan during the course of any Co-Development Plan or POC Plan and for a further period of ***                from expiry, termination or completion of such Co-Development Plan or POC Plan; provided that this Clause 21.4 shall not apply to advertisements of a general nature placed in newspapers, trade publications or online or if such employee initiates the contact.

 

21.5        Independent Contractors.  The Parties hereto are independent contractors and nothing contained in this Agreement shall be deemed or construed to create a partnership, joint venture, employment, franchise, agency or fiduciary relationship between the Parties.

 

21.6        Entire Agreement.  Except to the extent expressly provided herein, this Agreement constitutes the entire agreement between the Parties relating to the subject matter of this Agreement and supersedes all previous oral and written communications between the Parties with respect to the subject matter of this Agreement.  Both Parties confirm that in entering into this Agreement that have not relied on any representation or statement from the other Party that is not explicitly stated as a warranty or representation under this Agreement. Nothing in this Clause 21.6 shall exclude any liability for fraud or fraudulent misrepresentation or exclude any remedy for such.

 

21.7        Amendment; Waiver.  Except as otherwise expressly provided herein, no alteration of or modification to this Agreement shall be effective unless made in writing and executed by an authorised representative of both Parties.  No course of dealing or failing of either Party to strictly enforce any term, right or condition of this Agreement in any instance shall be construed as a general waiver or relinquishment of such term, right or condition.  The observance of any provision of this Agreement may be waived (either generally or any given instance and either retroactively or prospectively) only with the written consent of the Party granting such waiver.

 

21.8        Further Assurance.  Each Party shall and shall use all Commercially Reasonable Efforts to procure that any necessary Third Party shall promptly execute and deliver such further

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.

 

Page 55

 

Execution Copy

 

documents and do such further acts as may be required for the purpose of giving full effect to this Agreement.

 

21.9        Severability.  The Parties do not intend to violate any public policy or statutory or common law.  However, if any sentence, paragraph, section, clause or combination or part thereof of this Agreement is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph, section, clause or combination or part of the same shall be deleted and the remainder of this Agreement shall remain binding, provided that such deletion does not alter the basic purpose and structure of this Agreement.

 

21.10     No Third Party Rights.  The Parties do not intend that any term of this Agreement should be enforceable by any person who is not a Party.

 

21.11     Interpretation.  The captions and headings to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement.  Unless context otherwise clearly requires, whenever used in this Agreement: (a) the words “include” or “including” shall be construed as incorporating “but not limited to” or “without limitation”; (b) the words “hereof,” “herein,” “hereby” and derivative or similar words refer to this Agreement, including the Exhibits; (c) the word “law” or “laws” means any applicable, legally binding statute, ordinance, resolution, regulation, code, guideline, rule, order, decree, judgment, injunction, mandate or other legally binding requirement of a governmental authority (including a court, tribunal, agency, legislative body or other instrumentality of any (i) government or country or territory, (ii) any state, province, county, city or other political subdivision thereof, or (iii) any supranational body); (d) all references to the word “will” are interchangeable with the word “shall” and shall be understood to be imperative or mandatory in nature; (f) the singular shall include the plural and vice versa; and (g) the word “or” has the inclusive meaning represented by the phrase “and/or”.  All references to days, months, quarters or years are references to calendar days, calendar months, calendar quarters, or calendar years.

 

21.12     Other Activities.  The Parties acknowledge that each of them may now or in the future engage in research, manufacturing, development or commercialisation activities that utilize technologies similar to or involve therapies or pharmaceutical products competitive with those contemplated by this Agreement.  Except as may be expressly provided in this Agreement, nothing in this Agreement, including any obligation to use Commercially Reasonable Efforts to promote Therapies or any restriction on the use of Confidential Information, shall create any obligation not to research, manufacture, develop or commercialize any Therapy or any obligation to utilize a separate sales force for Therapies.  Neither Party shall be prevented from using any publicly available research results or other information (including any publicly available information of the other Party) to the same extent as Third Parties generally are legally permitted to do so.  Each Party agrees to inform its key personnel assigned to perform activities hereunder of the limitations on use of Confidential Information contained in this Agreement, instruct such personnel to comply with such restrictions, and where appropriate, impose firewalls or other appropriate measures to minimize the potential for misuse of information.  However, each Party has limited resources, and as a result it is anticipated that personnel assigned to activities hereunder may also participate in other activities that may utilize technologies similar to or involve therapies or pharmaceutical products competitive with those contemplated by this Agreement.  In particular, it is anticipated that personnel in sales, marketing, clinical and regulatory functions, regardless of level, will participate in multiple programs and that management personnel will by nature of their leadership positions participate in multiple programs.

 

21.13     Counterparts.  This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.  For purposes hereof, a facsimile copy, or email with attached pdf copy, of this Agreement, including the signature pages hereto, will be deemed to be an original.

 

[Signature page follows — the rest of this page intentionally left blank.]

 

Page 56

 

Execution Copy

 

IN WITNESS WHEREOF, duly authorised representatives of the Parties have executed this Agreement as of the Effective Date.

 

	
ADAPTIMMUNE LIMITED
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/ Helen Tayton-Martin
    	
 
    
	
 
    	
 
    
	
Name: Helen Tayton-Martin
    	
 
    
	
 
    	
 
    
	
Title: Chief Operating Officer
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
BELLICUM   PHARMACEUTICALS, INC.
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/ Thomas J. Farrell
    	
 
    
	
 
    	
 
    
	
Name: Thomas J. Farrell
    	
 
    
	
 
    	
 
    
	
Title: President and CEO
    	
 
    

 

Page 57

 

Execution Copy

 

EXHIBIT 1 – POC Plan

 

Background:

 

***

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 58

 

Execution Copy

 

 

 

 

***

 

	
***

 
    	
***
    	
***
    
	
***

 

 

 

 

 

 

 
    	
***
    	
***
    
	
***

 

 
    	
***
    	
***
    
	
***

 

 

 
    	
***
    	
***
    
	
***

 

 
    	
***
    	
***
    
	
***

 

 
    	
***
    	
***
    
	
***

 

 
    	
***
    	
***
    
	
***

 

 

 

 

 

 

 
    	
***
    	
***
    

 

***

 

***

 

 

 

 

 

 

 

 

 

 

 

 

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 59

 

Execution Copy

 

 

 

***

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	
***

 
    	
***
    	
***
    
	
***

 
    	
***
    	
***
    
	
***

 
    	
***
    	
***
    
	
***

 
    	
***
    	
***
    
	
***

 
    	
***
    	
***
    
	
***

 
    	
***
    	
***
    

 

 

 

 

 

 

 

 

 

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 60

 

Execution Copy

 

***

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 61

 

Execution Copy

 

 

EXHIBIT 2- FTE RATES

 

 

 

A weighted average FTE hourly rate will be calculated prior to the start of a Co-Development Plan taking into account the following standard internal costs:

 

a.             ***

 

.

b.            ***                                           :

i.                                  ***

ii.                               ***

iii.                            ***

iv.                           ***

c.             ***                                          :

i.                                  ***

ii.                               ***

iii.                            ***

 

The FTE hourly rates below will be agreed as part of agreement of the Co-Development Plan under clause 5.1 of this Agreement.

 

The FTE Rate will be inflated on an annual basis in accordance with the index agreed at the same time as Co-Development Plan is agreed.

 

 

 

	
 
    	
job level
    	
Example of Titles
    	
Agreed FTE Rate
    
	
Level   1
    	
 
    	
 
    	
 
    
	
Level   2
    	
 
    	
 
    	
 
    
	
Level   3
    	
 
    	
 
    	
 
    

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 62

 

Execution Copy

 

 

EXHIBIT 3 – CO-COMMERCIALISATION AGREEMENT PRINCIPLES

 

	
Co-commercialisation Therapy
    	
 
    	
Therapies containing a Bellicum Candidate or Adaptimmune   Candidate, the “Bellicum Therapy” and “Adaptimmune Therapy” respectively

 
    
	
Co-promotion Territory
    	
 
    	
Any of the *** or ***
    or other territories mutually agreed between the Parties.

 
    
	
***
    	
 
    	
***

 

 

    .

 

    ***

 

 

 

 

 

 

    

    
    
    
    .
    
	
Responsibility for manufacture
    	
 
    	
***

 

 

 

 

    
    .
    
	
Promotion rights
    	
 
    	
Bellicum will have sole promotion rights in relation to   the Bellicum Therapy. Adaptimmune will have sole promotion rights in relation   to the Adaptimmune Therapy.

 
    
	
Booking of sales
    	
 
    	
Bellicum shall book all sales for the Bellicum Therapy and   shall be responsible for all contracts of sale. Adaptimmune shall book all   sales for the Adaptimmune Therapy and shall be responsible for all contracts   of sale.

 
    
	
Marketing Plan
    	
 
    	
The JCC will be responsible for overseeing the marketing   plan for each Therapy and its performance. Bellicum shall be primarily   responsible for the Marketing Plan for the Bellicum Therapy and Adaptimmune   shall be primarily responsible for the Marketing Plan for the Adaptimmune

 
    

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 63

 

Execution Copy

 

 

	
 
    	
 
    	
Therapy.

 
    
	
Marketing materials
    	
 
    	
The JCC shall approve all marketing and advertising   materials, which shall also be subject to each Party’s internal review   process, if any.

 
    
	
Distribution Channel
    	
 
    	
Each Therapy will be distributed through distribution   channels of the Party responsible for booking of sales of such Therapy.

 
    
	
Compliance requirements
    	
 
    	
Co-Commercialisation Agreement, as and to the extent   necessary and appropriate, will set out the compliance responsibilities for   both Parties, including standard provisions relating to compliance.

 
    
	
Reporting Obligations
    	
 
    	
Parties to report regularly to JCC on their respective   Therapy sales and progress of commercialisation.

 
    
	
Adverse events
    	
 
    	
The Co-Commercialisation Agreement, as and to the extent   necessary and appropriate, will set out a notification process related to   adverse events and reporting of other safety information and will refer such   matter to a safety/regulatory agreement to be negotiated by the Parties   contemporaneously with execution of the Co-Commercialisation Agreement.

 
    
	
***
    	
 
    	
***
    
    

 

 

 

 

 

 

 

    

 

    

 

    
    
    
    .
    ***

 

 

 

 

    .

 
    

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 64

 

Execution Copy

 

 

EXHIBIT 4 – TECHNOLOGY DESCRIPTIONS

 

Adaptimmune Technology

 

 

The Adaptimmune Technology for the purposes of this Agreement comprises the following:

 

·                  ***

 

 

 

;

 

·                  ***

 

 

 

 

;

 

·                  ***

 

 

 

;

 

·                  ***

 

 

 

 

;

 

·                  ***

 

;

 

·                  ***

 

 

 

;

 

·                  ***

 

.

 

Bellicum Technology

 

The Bellicum Technology for the purposes of the Agreement comprises the following:

 

·                  the iCasp9 Technology; and

 

·                  the iMC Technology

 

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 65

 

Execution Copy

 

 

EXHIBIT 5 – PRESS RELEASE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Page 66

 

	

    	

    

 

Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation

 

T-Cell Therapies

 

PHILADELPHIA, PA, OXFORD, UK, and HOUSTON, TX – December XX, 2016 – Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, and Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that they have entered into a staged collaboration to evaluate, develop, and commercialize next-generation T-cell therapies.

 

Under the agreement, the companies will evaluate Bellicum’s GoTCR technology (inducible MyD88/CD40 co-stimulation, or iMC) with Adaptimmune’s affinity-optimized SPEARTM T-cells for the potential to create enhanced TCR product candidates. Depending on results from the preclinical proof-of-concept phase, the companies expect to progress to a two-target co-development and co-commercialization phase.

 

“We are committed to advancing our clinical pipeline of proprietary cell therapies and to entering strategic collaborations that can further leverage the unique potential of our controllable T-cell technologies,” commented Tom Farrell, President and Chief Executive Officer of Bellicum. “We’re looking forward to working with the Adaptimmune team to create and advance potentially best-in-class TCR therapies.”

 

“As we advance our deep pipeline of second- and third-generation SPEAR T-cell therapies, we are excited by the potential of Bellicum’s iMC switch to complement the activity of our affinity enhanced T-cell therapies, as part of our continuing initiative to assess novel cell therapy enhancement technologies,” said James Noble, Adaptimmune’s Chief Executive Officer. “This is an innovative field that requires broad, industry-wide collaborations, such as our relationship with Bellicum and its strong leadership position in switch technology.”

 

About Bellicum’s iMC Technology

 

Bellicum’s Chemical Induction of Dimerization (CID) technology platform was designed to address the challenges of current cellular immunotherapies by enabling control over cellular activities and functions, such as growth, activation, proliferation, persistence and survival. Bellicum’s CID platform consists of molecular switches—modified forms of signaling proteins—which are triggered inside the patient by infusion of small molecule rimiducid, instead of by natural upstream signals. Current product candidates incorporate either the CaspaCIDeâ safety switch, or iMC activation switch. After rimiducid is administered, CaspaCIDe is designed to trigger programmed cell death, or apoptosis, and iMC is designed to drive proliferation, activation and/or persistence of T cells.

 

About Adaptimmune’s TCR Technology

 

Adaptimmune’s proprietary SPEARTM (Specific Peptide Enhanced Affinity Receptor) T-cell receptor (TCR) technology enables the Company to genetically optimize TCRs in an effort to equip them to recognize and bind cancer antigens that are presented in small quantities on the surface of a cancer cell, whether of intracellular or extracellular origin, thus initiating cell death. The Company’s differentiated, proprietary

 

 

technology allows it to reliably generate parental TCRs to naturally presented targets, affinity optimize its TCRs to bind cancer proteins from solid and hematologic cancers that are generally unavailable to naturally occurring TCRs, and to significantly reduce the risk of side effects resulting from off-target binding of healthy tissues.

 

About Bellicum Pharmaceuticals

 

Bellicum is a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com

 

About Adaptimmune

 

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform. Established in 2008, the Company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. These include SPEAR T-cell therapies targeting the MAGE-A10 and AFP cancer antigens, which both have open INDs, and a further SPEAR T-cell therapy targeting the MAGE-A4 cancer antigen that is in pre-clinical phase with IND acceptance targeted for 2017. The Company has identified over 25 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 250 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com

 

Forward-Looking Statements

 

Bellicum and Adaptimmune may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our intentions regarding our collaboration and the development and commercialization of products pursuant to the collaboration; and the timing and success of our collaboration. Various factors may cause differences between our expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s and Adaptimmune’s filings with the Securities and Exchange Commission, including without limitation, Bellicum’s annual report on Form 10-K for the year ended December 31, 2015; and Adaptimmune’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2016. Any forward-looking statements that we make in this press release speak only as of

 

 

the date of this press release. Neither Bellicum nor Adaptimmune assume any obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 

 

Bellicum Contacts

 

 

Alan Musso

Chief Financial Officer

T: 832-384-1116

E: amusso@bellicum.com

 

Brad Miles

BMC Communications

T: 646-513-3125

E: bmiles@bmccommunications.com

 

Adaptimmune Contacts

 

Will Roberts

Vice President, Investor Relations

T:  (215) 825-9306

E: will.roberts@adaptimmune.com

 

Juli P. Miller, Ph.D.

Associate Director, Investor Relations

T:  (215) 825-9310

E: juli.miller@adaptimmune.com

 

Margaret Henry

Head of PR

T: +44 (0)1235 430036

Mob: +44 (0)7710 304249

E: margaret.henry@adaptimmune.com

 

 

Execution Copy

 

 

EXHIBIT 6 – CO-DEVELOPMENT RESPONSIBILITIES

 

 

The responsibilities for performance of any Co-Development Plan will be agreed prior to the start of such Co-Development Plan. The following is intended as an illustrative guide as to which Party may have which responsibility – exact responsibilities will depend on activities required for any program.

 

	
Co-development activity
    	
Adaptimmune

Responsibility

 
    	
Bellicum Responsibility
    
	
***

 

 
    	
***
    	
 
    
	
***

 
    	
***
    	
 
    
	
***

 

 
    	
***
    	
 
    
	
***

 

 
    	
***
    	
 
    
	
***

 

 

 
    	
 
    	
***
    
	
***

 

 
    	
 
    	
***
    
	
***

 

 
    	
***
    	
***
    
	
***

 

 
    	
 
    	
***
    
	
***

 

 
    	
***
    	
***
    
	
***

 

 
    	
***
    	
***
    
	
***

 

 
    	
***
    	
***
    
	
***

 

 
    	
***
    	
***
    
	
***

 

 
    	
***
    	
***
    
	
***

 

 
    	
***
    	
***
    
	
***

 

 
    	
***
    	
***
    
	
***

 

 
    	
***
    	
***
    

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 66

 

Execution Copy

 

 

	
***
    	
***
    	
***
    

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 66

 

EXHIBIT 7 – DESIGNATION CRITERIA

 

Designation criteria will be agreed between the Parties dependent on the Co-Development Plan. Initial designation criteria for progression of a candidate into pre-clinical development are set out below. These criteria will be amended and refined as part of the progression of the Co-Development Plan.

 

	
Criteria
     	
Suggested    metrics
     
	
***

 
    	
·                  ***                                                              .

·                  ***

 

 

.

·                  ***

 

 

 

.

·                  ***

 

.

 
    
	
***

 
    	
·                  ***

.

·                  ***

 

 

 

.

·                  ***

 

 

 

.

 
    
	
***

 
    	
·                  ***

 

 

 

.

·                  ***

 

 

.

·                  ***

 

 

 

 

.

·                  ***

 

 

 

 

 

.

 
    

 

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

 

Page 67

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]